citalopram has been researched along with Depressive Disorder in 529 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy." | 9.41 | [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021) |
| " This study investigated the efficacy and safety of escitalopram in treating depressive disorders identified 2-14 weeks after a confirmed ACS episode." | 9.20 | Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Jung, BO; Kang, G; Kang, HJ; Kim, JH; Kim, JK; Kim, JM; Kim, SW; Shin, HY; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| " Of 446 baseline participants with co-morbid depressive disorders, 300 were randomized to a 24-week double blind trial of escitalopram or placebo, while the remaining 146 received medical treatment only (MTO)." | 9.20 | Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "To investigate the correlates of sleep disturbance and to assess escitalopram treatment effects of depression on sleep disturbance in patients with acute coronary syndrome (ACS)." | 9.20 | Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 9.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders." | 9.14 | Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2010) |
| "Patients with severe depression together with comorbid anxiety symptoms responded significantly better to treatment with escitalopram 20 mg compared with paroxetine 40 mg." | 9.14 | Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. ( Boulenger, JP; Hermes, A; Huusom, AK; Weiller, E, 2010) |
| "Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included." | 9.13 | Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008) |
| "To determine whether treatment with escitalopram or problem-solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication." | 9.13 | Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. ( Acion, L; Arndt, S; Fonzetti, P; Hegel, M; Jorge, RE; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2008) |
| "This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder." | 9.12 | Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007) |
| "This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks." | 9.12 | Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007) |
| "This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder." | 9.11 | A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. ( Bothmer, J; Huusom, AK; Montgomery, SA, 2004) |
| "In this randomized trial, patients (diagnosis of DSM-IV-defined major depressive disorder; baseline Hamilton Rating Scale for Depression score of >/= 20) received 1 week of single-blind placebo treatment, followed by 8 weeks of double-blind, fixed-dose treatment with either escitalopram or venlafaxine XR (rapidly titrated to 20 mg/day and 225 mg/day, respectively, in accordance with prescribing information)." | 9.11 | A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. ( Bielski, RJ; Chang, CC; Ventura, D, 2004) |
| " Citalopram and venlafaxine are similarly efficient in treatment of depressive disorders and are well tolerated by elderly patients." | 9.11 | [Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients]. ( Florkowski, A; Gałecki, P; Kołodziejska, I; Nowakowski, T; Pawełczyk, A; Pietras, T; Zboralski, K, 2004) |
| " Enhanced cortisol synthesis, impaired leptin production and diminished insulin sensitivity have been reported in some depressed populations." | 9.11 | Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. ( Baldock, SD; Castracane, VD; Kauffman, RP; Owens, R; White, DL, 2005) |
| "This study evaluated the effectiveness of citalopram in the treatment of pathological gambling." | 9.10 | An open-label study of citalopram in the treatment of pathological gambling. ( Breen, RB; Posternak, MA; Zimmerman, M, 2002) |
| " This randomised, double-blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia." | 9.09 | A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. ( Augusto De Mendonça Lima, C; Eglin, M; Godderis, J; Karlsson, I; Nygaard, H; Simányi, M; Taal, M, 2000) |
| "The aim of the study was to investigate the efficacy and safety of the selective serotonin reuptake inhibitor citalopram in treating poststroke depression, since available treatments are usually poorly tolerated." | 9.07 | Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. ( Andersen, G; Lauritzen, L; Vestergaard, K, 1994) |
| "A total of 149 patients in 7 centers in Denmark, Norway and Sweden entered a 6-week double-blind trial intended to assess the antidepressant effect and safety of citalopram vs placebo in depressed elderly patients (65 years of age or older) who might also suffer from somatic disorders and/or senile dementia." | 9.07 | A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. ( Eriksson, S; Gottfries, CG; Gylding-Sabroe, J; Kristensen, M; Lyby, K; Nyth, AL; Ofsti, E; Refsum, HE; Smedegaard-Andersen, L; Syversen, S, 1992) |
| "Glutamatergic modulators may have therapeutic potential in the treatment of depressive disorder (DD), riluzole, as a modulating drug of the glutamatergic system, its antidepressant efficacy and safety of riluzole for DD are inconsistent." | 9.05 | Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. ( Wang, G; Wang, H; Wu, C; Yao, R; Yuan, M, 2020) |
| "The study aimed to summarize clinical data for escitalopram in the treatment of major depressive disorder in primary care." | 8.82 | Evidence based review of escitalopram in treating major depressive disorder in primary care. ( Einarson, TR, 2004) |
| "to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 7.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
| "The study revealed that patients treated with escitalopram had a reduction of psycho-diagnostic test scores that measure depression and anxiety levels as well as the values of pruritus." | 7.80 | Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. ( Agnoletti, AF; Betti, S; Campolmi, E; Cossidente, A; D'Erme, AM; Lotti, T; Santosuosso, U; Zanieri, F, 2014) |
| "The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to citalopram among children and adolescents with depression and/or anxiety disorders." | 7.79 | Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Kronenberg, S; Rotberg, B; Weizman, A; Zalsman, G, 2013) |
| "In this 16-week post-marketing surveillance (PMS) study, antidepressant effects and tolerability of escitalopram was examined in 2 911 patients with comorbid depression and anxiety." | 7.79 | Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study. ( Friede, M; Laux, G; Müller, WE, 2013) |
| "To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders." | 7.74 | Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH, 2007) |
| "To determine if escitalopram is cost-effective in the UK when compared with venlafaxine and generic citalopram in primary care treatment of Major Depressive Disorder (MDD)." | 7.73 | A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. ( Hemels, ME; Toumi, I; Wade, AG, 2005) |
| "A 74-year-old man was admitted with rhabdomyolysis after undergoing initial treatment for gastrointestinal cancer with irinotecan." | 7.72 | Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. ( Fanucchi, MP; Giblin, J; Khuri, F; Richards, S; Umbreit, JN, 2003) |
| "Citalopram appears to be effective and well tolerated in this group of children and adolescents with depressive or anxiety disorders and a high degree of comorbidity." | 7.71 | Citalopram in children and adolescents with depression or anxiety. ( Baumgartner, JL; Crismon, ML; Emslie, GJ, 2002) |
| "All citalopram patients were able to complete interferon therapy as planned." | 6.73 | Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. ( Hofbauer, I; Keicher, C; Kraus, MR; Schäfer, A; Scheurlen, M; Schöttker, K; Weissbrich, B, 2008) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 6.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose." | 6.43 | Managing depressive and anxiety disorders with escitalopram. ( Thase, ME, 2006) |
| "The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported." | 6.42 | [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003) |
| "The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy." | 5.41 | [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021) |
| "Priapism is documented to occur in association with treatment with a variety of psychotropic agents." | 5.30 | Citalopram-associated clitoral priapism: a case series. ( Acton, M; Berk, M, 1997) |
| "136 elderly patients with depression were divided into EGb + citalopram (Cit) group and Cit group equally." | 5.27 | Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B. ( Dai, CX; Hu, CC; Shang, YS; Xie, J, 2018) |
| " This study investigated the efficacy and safety of escitalopram in treating depressive disorders identified 2-14 weeks after a confirmed ACS episode." | 5.20 | Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Jung, BO; Kang, G; Kang, HJ; Kim, JH; Kim, JK; Kim, JM; Kim, SW; Shin, HY; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| " Of 446 baseline participants with co-morbid depressive disorders, 300 were randomized to a 24-week double blind trial of escitalopram or placebo, while the remaining 146 received medical treatment only (MTO)." | 5.20 | Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "To investigate the correlates of sleep disturbance and to assess escitalopram treatment effects of depression on sleep disturbance in patients with acute coronary syndrome (ACS)." | 5.20 | Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "Participants 18-65 years of age (N=1,008) who met criteria for major depressive disorder were randomly assigned to 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine." | 5.20 | Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. ( Arnow, BA; Blasey, C; Etkin, A; Kulkarni, J; Luther, JF; Palmer, DM; Rekshan, W; Rush, AJ; Schatzberg, AF; Williams, LM, 2015) |
| "To study the effect of Escitalopram (SSRI) in patients with diabetes mellitus with comorbid depression and the relationship of treatment response for depression and glycemic control." | 5.17 | Diabetes with comorbid depression: role of SSRI in better glycemic control. ( Gahlan, D; Gehlawat, P; Gehlawat, VK; Gupta, R; Rajput, R, 2013) |
| " Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine)." | 5.16 | Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. ( Davis, LL; Fava, M; Friedman, ES; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "In genome-based drugs for depression (GENDEP), 811 patients with major depressive disorder treated with escitalopram or nortriptyline were assessed with the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Rating Scale for Depression (HRSD), and the self-report Beck Depression Inventory (BDI)." | 5.16 | Self-report and clinician-rated measures of depression severity: can one replace the other? ( Dernovšek, MZ; Farmer, A; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Perlis, RH; Placentino, A; Uher, R, 2012) |
| "6 years), predominantly female with non-metastatic breast, lung and colon cancer and depressive disorder (DSM-IV-TR) were randomized to receive treatment with NT plus escitalopram (n=39) or escitalopram (10-20 mg QD) plus usual care (n=33)." | 5.15 | Combined therapy versus usual care for the treatment of depression in oncologic patients: a randomized controlled trial. ( Bayón, C; Benito, G; Castelo, B; Dieguez, M; Hospital, A; Palao, A; Pérez, E; Rodríguez Vega, B; Torres, G, 2011) |
| " To compare changes in body weight during treatment with different antidepressants, body weight and height were measured at baseline and after 6, 8, 12 and 26 wk treatment with escitalopram or nortriptyline in 630 adults with moderate-to-severe unipolar depression participating in GENDEP, a part-randomized open-label study." | 5.15 | Changes in body weight during pharmacological treatment of depression. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Gray, JM; Hauser, J; Henigsberg, N; Kalember, P; Keers, R; Kozel, D; Larsen, ER; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Szczepankiewicz, A; Uher, R; Zobel, A, 2011) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 5.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "Outpatients with nonpsychotic major depressive disorder treated for up to 14 weeks with citalopram in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were divided by household incomes of <$20,000, $20,000-<$40,000, and >or=$40,000." | 5.14 | Income and attrition in the treatment of depression: a STAR*D report. ( Balasubramani, GK; Lesser, IM; Nierenberg, AA; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2009) |
| "Citalopram augmentation of antipsychotic treatment in middle aged and older patients with schizophrenia and subsyndromal depression appears to improve social and mental health functioning as well as quality of life." | 5.14 | Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning. ( Fellows, I; Golshan, S; Kasckow, J; Lanouette, N; Patterson, T; Solorzano, E; Zisook, S, 2010) |
| "Relatively treatment-naive depressed outpatients (with DSM-IV diagnoses of major depressive disorder, dysthymic disorder, or depression not otherwise specified) were initially treated with a combination of escitalopram (ESC) plus bupropion (BUP), using rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15 in an open-label, 8-week study." | 5.14 | Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? ( Deliyannides, RA; McGrath, PJ; Quitkin, FM; Stewart, JW, 2009) |
| "To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders." | 5.14 | Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2010) |
| "Patients with severe depression together with comorbid anxiety symptoms responded significantly better to treatment with escitalopram 20 mg compared with paroxetine 40 mg." | 5.14 | Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. ( Boulenger, JP; Hermes, A; Huusom, AK; Weiller, E, 2010) |
| "Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included." | 5.13 | Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008) |
| "Patients aged > or =60 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition major depressive disorder were randomized to 12 weeks of double-blind, flexible-dose treatment with escitalopram (10-20 mg/day; N = 130) or placebo (N = 134)." | 5.13 | Escitalopram in the acute treatment of depressed patients aged 60 years or older. ( Bose, A; Gandhi, C; Li, D, 2008) |
| "To determine whether treatment with escitalopram or problem-solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication." | 5.13 | Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. ( Acion, L; Arndt, S; Fonzetti, P; Hegel, M; Jorge, RE; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2008) |
| "This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder." | 5.12 | Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007) |
| "This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks." | 5.12 | Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007) |
| "Outpatients diagnosed with DSM-IV major depressive disorder (male or female, aged 18 to 81 years) who had completed 8 weeks of randomized double-blind treatment with escitalopram, citalopram, or placebo entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day)." | 5.11 | Escitalopram continuation treatment prevents relapse of depressive episodes. ( Bose, A; Rapaport, MH; Zheng, H, 2004) |
| "An 8-week, randomized, double-blind, placebo-controlled study compared the safety and efficacy of citalopram with placebo in the treatment of children (ages 7-11) and adolescents (ages 12-17) with major depressive disorder." | 5.11 | A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. ( Findling, RL; Gutierrez, MM; Heydorn, WE; Jin, J; Robb, AS; Wagner, KD, 2004) |
| "This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder." | 5.11 | A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. ( Bothmer, J; Huusom, AK; Montgomery, SA, 2004) |
| "In this randomized trial, patients (diagnosis of DSM-IV-defined major depressive disorder; baseline Hamilton Rating Scale for Depression score of >/= 20) received 1 week of single-blind placebo treatment, followed by 8 weeks of double-blind, fixed-dose treatment with either escitalopram or venlafaxine XR (rapidly titrated to 20 mg/day and 225 mg/day, respectively, in accordance with prescribing information)." | 5.11 | A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. ( Bielski, RJ; Chang, CC; Ventura, D, 2004) |
| "The aim of this study was to compare over 1 year the effect of sertraline and citalopram on depressive symptoms and cognitive functions of nondemented elderly patients with minor depressive disorder and subsyndromal depressive symptomatology." | 5.11 | Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. ( Bogetto, F; Calvarese, P; Faggiano, F; Marchiaro, L; Mathis, F; Rivoira, E; Rocca, P; Taricco, B, 2005) |
| " Citalopram and venlafaxine are similarly efficient in treatment of depressive disorders and are well tolerated by elderly patients." | 5.11 | [Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients]. ( Florkowski, A; Gałecki, P; Kołodziejska, I; Nowakowski, T; Pawełczyk, A; Pietras, T; Zboralski, K, 2004) |
| " Enhanced cortisol synthesis, impaired leptin production and diminished insulin sensitivity have been reported in some depressed populations." | 5.11 | Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. ( Baldock, SD; Castracane, VD; Kauffman, RP; Owens, R; White, DL, 2005) |
| "Fifty-five outpatients with DSM-IV major depressive disorder and a confirmed history of intolerance to fluoxetine (mean final dose = 24." | 5.10 | Citalopram treatment of fluoxetine-intolerant depressed patients. ( Calabrese, JR; Londborg, PD; Shelton, MD; Thase, ME, 2003) |
| " In the present work we studied for the first time the dose-dependent changes of ECG, body surface potential maps (BSPM - parameter DIAM 30, 40) in 43 TCA dosulepine, 40 SSRI citalopram and 30 Li outpatients (Hamilton scale: HAMDŁ10; age 40+/-5 years; treated for depressive disorders or bipolar disorders)." | 5.10 | Electrocardiographic dose-dependent changes in prophylactic doses of dosulepine, lithium and citalopram. ( Dohnalová, A; Kitzlerová, E; Paclt, I; Pisvejcová, K; Slavícek, J, 2003) |
| "Thirty inpatients (DSM-IV major depressive disorder [N = 21] and bipolar disorder [N = 9]) were treated with citalopram, 40 mg, and randomized in a 3:2 manner to receive 30 minutes of 400 lux green light treatment in the morning or placebo (exposure to a deactivated negative ion generator) during the first 2 weeks of drug treatment." | 5.10 | Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. ( Benedetti, F; Bernasconi, A; Colombo, C; Florita, M; Pontiggia, A; Smeraldi, E, 2003) |
| "This study evaluated the effectiveness of citalopram in the treatment of pathological gambling." | 5.10 | An open-label study of citalopram in the treatment of pathological gambling. ( Breen, RB; Posternak, MA; Zimmerman, M, 2002) |
"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), was compared to placebo in a study of patients with major depressive disorder (DSM-IV) who had baseline Montgomery-Asberg Depression Rating Scale (MADRS) total scores >or=22 and | 5.10 | Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. ( Bang Hedegaard, K; Michael Lemming, O; Wade, A, 2002) | |
| "Fifty inpatients with recurrent major depressive disorder (DSM-IV criteria) who had had at least one depressive episode during the 18 months preceding the index episode were openly treated with citalopram, 40 mg/day." | 5.09 | Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. ( Franchini, L; Gasperini, M; Smeraldi, E; Zanardi, R, 1999) |
| " This randomised, double-blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia." | 5.09 | A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. ( Augusto De Mendonça Lima, C; Eglin, M; Godderis, J; Karlsson, I; Nygaard, H; Simányi, M; Taal, M, 2000) |
| "Three hundred twenty-three patients with DSM-IV-defined major depressive disorder were randomized to 24 weeks of double-blind treatment with citalopram (20-60 mg/day), sertraline (50-150 mg/day), or a placebo." | 5.09 | Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. ( Stahl, SM, 2000) |
| " In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the most selective SSRI available, on the length of electrically induced seizures and on hormone secretion during ECT." | 5.09 | Administration of citalopram before ECT: seizure duration and hormone responses. ( Daras, M; Markianos, M; Papakostas, YG; Theodoropoulou, M; Vaidakis, N; Zervas, IM, 2000) |
| "The aim of the study was to investigate the efficacy and safety of the selective serotonin reuptake inhibitor citalopram in treating poststroke depression, since available treatments are usually poorly tolerated." | 5.07 | Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. ( Andersen, G; Lauritzen, L; Vestergaard, K, 1994) |
| "A total of 149 patients in 7 centers in Denmark, Norway and Sweden entered a 6-week double-blind trial intended to assess the antidepressant effect and safety of citalopram vs placebo in depressed elderly patients (65 years of age or older) who might also suffer from somatic disorders and/or senile dementia." | 5.07 | A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. ( Eriksson, S; Gottfries, CG; Gylding-Sabroe, J; Kristensen, M; Lyby, K; Nyth, AL; Ofsti, E; Refsum, HE; Smedegaard-Andersen, L; Syversen, S, 1992) |
| "Glutamatergic modulators may have therapeutic potential in the treatment of depressive disorder (DD), riluzole, as a modulating drug of the glutamatergic system, its antidepressant efficacy and safety of riluzole for DD are inconsistent." | 5.05 | Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. ( Wang, G; Wang, H; Wu, C; Yao, R; Yuan, M, 2020) |
| "We used pooled datasets from 1-year follow-up data from a 24-week randomized double-blind placebo-controlled trial (RCT) of escitalopram for treatment of depressive disorder and data from a naturalistic, prospective, observational cohort study in patients with ACS." | 4.98 | Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. ( Ahn, YK; Bae, KY; Berk, M; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Yoon, JS, 2018) |
| "Tramadol is widely prescribed for treating acute and chronic forms of pain." | 4.95 | Use of tramadol in psychiatric care: A comprehensive review and report of two cases. ( Gamma, F; Panksepp, J; Rougemont-Bücking, A, 2017) |
| "Randomized controlled trials have demonstrated the efficacy of sertraline, citalopram and nortriptyline to treat post-stroke depression." | 4.84 | Antidepressant therapy in post-stroke depression. ( Mizrahi, R; Power, BD; Starkstein, SE, 2008) |
| " To study the onset of effect of escitalopram, a selective serotonin reuptake inhibitor (SSRI), data were pooled from controlled randomized clinical double-blind trials comparing this drug with other antidepressant drugs (SSRIs and venlafaxine XR) in major depressive disorder (MDD), with assessments of the primary efficacy parameter [mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline, using last observation carried forward]." | 4.83 | Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. ( Angst, J; Kasper, S; Spadone, C; Verpillat, P, 2006) |
| "Data from the three available placebo-controlled trials with fixed doses of escitalopram in the acute therapy of DSM-IV major depressive disorder (MDD) were pooled." | 4.83 | Effective dose of escitalopram in moderate versus severe DSM-IV major depression. ( Andersen, HF; Bech, P; Wade, A, 2006) |
| "Two antidepressants with different mechanisms of action, escitalopram and duloxetine, have recently been developed for the treatment of major depressive disorder." | 4.82 | Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. ( Hirschfeld, RM; Vornik, LA, 2004) |
| "The study aimed to summarize clinical data for escitalopram in the treatment of major depressive disorder in primary care." | 4.82 | Evidence based review of escitalopram in treating major depressive disorder in primary care. ( Einarson, TR, 2004) |
| "The escitalopram clinical trial database, consisting of all placebo-controlled and relapse prevention trials within major depressive disorder (MDD) and anxiety disorders, was analysed for specific adverse events indicative of suicidal behaviour (fatal suicide, non-fatal self-harm or suicidal thoughts) in relation to treatment." | 4.82 | Escitalopram and suicidality in adult depression and anxiety. ( Pedersen, AG, 2005) |
| "Escitalopram is an effective, well-tolerated treatment for major depressive disorder in both primary and specialist settings." | 4.82 | Efficacy of escitalopram in patients with severe depression: a pooled analysis. ( Azorin, JM; Despiegel, N; Llorca, PM; Verpillat, P, 2005) |
| " Alleviation of anhedonia was assessed in chronic mild stress model using sucrose preference test." | 4.12 | Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization. ( Abraham, R; Gagginapally, SR; Goura, V; Goyal, VK; Jasti, V; Jayarajan, P; Kallepalli, R; Medapati, RB; Mohammed, AR; Nirogi, R; Palacharla, VRC; Pandey, SK; Petlu, S; Subramanian, R; Tadiparthi, J; Thentu, JB, 2022) |
| "Escitalopram is commonly prescribed to patients with recurrent depressive disorder." | 4.12 | Influence of ( Bryun, EA; Horyaev, DS; Ivanchenko, VA; Noskov, VV; Pankratenko, EP; Petukhov, AE; Pozdniakov, SA; Rwere, F; Skryabin, V; Sychev, DA; Vinokurova, NV; Vlasovskih, RV; Zastrozhin, MS; Zaytsev, IA, 2022) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "For paroxetine and fluvoxamine the pronounced decline in maternal drug serum concentrations in pregnancy may necessitate a dose increase of about 100% during the third trimester in order to maintain stable concentrations." | 3.85 | Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. ( Brekke, M; Molden, E; Skogvoll, E; Spigset, O; Westin, AA, 2017) |
| "Depression and substance cocaine abuse are disorders with a high frequency of comorbidity." | 3.85 | Effects of escitalopram and imipramine on cocaine reinforcement and drug-seeking behaviors in a rat model of depression. ( Filip, M; Frankowska, M; Jastrzębska, J; Nowak, E; Przegaliński, E; Suder, A; Wydra, K, 2017) |
| " Emerging data has identified certain drugs such as ketamine as rapidly-acting antidepressants for major depressive disorder and TRD." | 3.85 | Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. ( Anderson, WH; Catlow, JT; Felder, CC; Higgs, RE; Kuo, MS; Laksmanan, A; Li, X; Martin, AE; Nikolayev, A; Schober, DA; Tolstikov, VV; Witkin, JM, 2017) |
| "In response to recent documentation of symptom and subtype heterogeneity in major depressive disorder, we report on exploratory analyses of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical-trial data to further describe heterogeneity in depression and test the hypothesis that citalopram treatment-outcome patterns differ as a function of depression symptom combinations." | 3.83 | Treatment outcome variation between depression symptom combinations in the STAR*D study. ( Gala, GJ; Olbert, CM; Rasmussen, A; Tupler, LA, 2016) |
| "to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia." | 3.81 | [Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015) |
| "The Css values and concentration-dose ratios (CDRs) of citalopram or escitalopram, administered orally or intravenously, were determined in patients with short bowel syndrome." | 3.80 | Antidepressant agents in short bowel syndrome. ( Bergmann, JF; Corcos, O; Declèves, X; Faye, E; Joly, F; Lancelin, F; Lloret-Linares, C, 2014) |
| "The study revealed that patients treated with escitalopram had a reduction of psycho-diagnostic test scores that measure depression and anxiety levels as well as the values of pruritus." | 3.80 | Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. ( Agnoletti, AF; Betti, S; Campolmi, E; Cossidente, A; D'Erme, AM; Lotti, T; Santosuosso, U; Zanieri, F, 2014) |
| "The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to citalopram among children and adolescents with depression and/or anxiety disorders." | 3.79 | Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Kronenberg, S; Rotberg, B; Weizman, A; Zalsman, G, 2013) |
| "Citalopram daily doses >40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0." | 3.79 | Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. ( Blow, FC; Bohnert, AS; Ganoczy, D; Kales, HC; Nallamothu, BK; Pfeiffer, PN; Zivin, K, 2013) |
| "In this 16-week post-marketing surveillance (PMS) study, antidepressant effects and tolerability of escitalopram was examined in 2 911 patients with comorbid depression and anxiety." | 3.79 | Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study. ( Friede, M; Laux, G; Müller, WE, 2013) |
| "An open, multi-centre study was designed to address the effectiveness and tolerability profile of treatment with escitalopram under naturalistic conditions, in elderly outpatients (above 65 years of age) with depression." | 3.76 | Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany. ( Flürenbrock, W; Möller, HJ; Schnitker, J, 2010) |
| "To test the hypothesis that the selective serotonin reuptake inhibitor (SSRI) citalopram would down-regulate human immunodeficiency virus (HIV) infectivity and that the greatest effects would be seen in people with depression." | 3.76 | Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. ( Benton, T; Blume, J; Douglas, SD; Dubé, B; Evans, DL; Gettes, DR; Lynch, K; Metzger, DS; Ping Lai, J; Tustin, NB, 2010) |
| "Two cases, one of recurrent depression and another of major depressive disorder with hypertension switched to hypomania while on escitalopram." | 3.75 | Hypomania induced by escitalopram: 2 case reports. ( Sharma, RC, 2009) |
| "To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders." | 3.74 | Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH, 2007) |
| "This secondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared rates of remission and response for blacks (n = 495), whites (n = 1853), and Hispanics (n = 327) with nonpsychotic major depressive disorder who were treated with citalopram." | 3.74 | Ethnicity/race and outcome in the treatment of depression: results from STAR*D. ( Alpert, JE; Castro, DB; Gaynes, BN; Gonzalez, J; Lesser, IM; Luther, JF; Rush, AJ; Trivedi, M; Wisniewski, SR, 2007) |
| "To determine if escitalopram is cost-effective in the UK when compared with venlafaxine and generic citalopram in primary care treatment of Major Depressive Disorder (MDD)." | 3.73 | A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. ( Hemels, ME; Toumi, I; Wade, AG, 2005) |
| "Depression, a common condition in MS patients, was precipitated in this patient by the spontaneous discontinuation of citalopram and not influenced by IFN beta-1a therapy, which the patient resumed at 44 mug 3 times per week." | 3.73 | Interferon beta-1a overdose in a multiple sclerosis patient. ( Falcone, NP; Nappo, A; Neuteboom, B, 2005) |
| "Fluoxetine seems to be a better cost-utility SSRI option for treating depressive disorders in PC." | 3.73 | Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. ( Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D, 2006) |
| "Perimenopausal and postmenopausal women with depressive disorders (DSM-IV criteria) and menopause-related symptoms received treatment with 20 to 60 mg/day of citalopram alone (N = 22) or adjunctive to estrogen therapy (N = 13)." | 3.72 | Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. ( Alexander, AB; Cohen, LS; Poitras, JR; Prouty, J; Shifren, JL; Soares, CN, 2003) |
| "A 74-year-old man was admitted with rhabdomyolysis after undergoing initial treatment for gastrointestinal cancer with irinotecan." | 3.72 | Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. ( Fanucchi, MP; Giblin, J; Khuri, F; Richards, S; Umbreit, JN, 2003) |
| "Citalopram appears to be effective and well tolerated in this group of children and adolescents with depressive or anxiety disorders and a high degree of comorbidity." | 3.71 | Citalopram in children and adolescents with depression or anxiety. ( Baumgartner, JL; Crismon, ML; Emslie, GJ, 2002) |
| "The effect of citalopram was investigated in 20 mentally retarded patients suffering from a depressive disorder characterized by alterations in the domains of affectivity, motivation, motor activity and vital signs." | 3.71 | Citalopram in mentally retarded patients with depression: a long-term clinical investigation. ( Jacobs, GA; Tuinier, S; van den Berg, YW; Veendrik-Meekes, MJ; Verhoeven, WM, 2001) |
| "Triiodothyronine (T3) has been shown to accelerate and potentiate the clinical response to tricyclic antidepressant (TCA) treatment in depressive disorders." | 3.71 | Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain. ( Jeanningros, R; Mazzola-Pomietto, P; Moreau, X, 2001) |
| " In this paper we describe two patients with comorbid epilepsy, major depression, and panic disorder, whose serum citalopram levels increased and antidepressant response changed when concurrent carbamazepine treatment was substituted with oxcarbazepine." | 3.69 | Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. ( Koponen, H; Leinonen, E; Lepola, U, 1996) |
| "Depressive disorder was diagnosed according to DSM-IV criteria and included prevalent depressive disorder at baseline and incident or persistent depressive disorder at follow-up based on depression status at the two examinations." | 2.90 | Methylation of the glucocorticoid receptor gene associated with depression in patients with acute coronary syndrome. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, HR; Kim, JM; Kim, SW; Shin, IS; Shin, MG; Yoon, JS, 2019) |
| "Major depressive disorder is a serious mental disorder in which treatment with antidepressant medication is associated with incidence of adverse events, such as constipation, diarrhea, dry mouth, headache, insomnia, and sexual dysfunction (SDys)." | 2.90 | Pycnogenol supplementation as an adjunct treatment for antidepressant-induced sexual dysfunction. ( Farsky, I; Ondrejka, I; Smetanka, A; Stara, V; Tonhajzerova, I, 2019) |
| "Depression is a mental disorder, affecting the quality of life." | 2.87 | Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial. ( Anil Kumar, MN; Jois, SN; Mallikarjuna Majgi, S; Rajagopal, R; Shashidhar, HB, 2018) |
| "Melatonin suppression was calculated by comparing placebo and citalopram light exposure conditions to a dim light baseline." | 2.87 | The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose. ( Cain, SW; Mansfield, DR; McGlashan, EM; Nandam, LS; Rajaratnam, SMW; Vidafar, P, 2018) |
| "Appropriate detection and treatment of depressive disorder are clearly important in ACS patients." | 2.80 | Predictors of depressive disorder following acute coronary syndrome: Results from K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "Escitalopram treatment was associated with beneficial effects compared to placebo and MTO on one-year outcomes on HAMD, MADRS and SOFAS (p-values<0." | 2.80 | Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| " Adverse effects are common, occur early on in treatment and are reported to be one of the main reasons for discontinuation of antidepressant treatment." | 2.79 | Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. ( Cowen, P; Crawford, AA; Lewis, G; Lewis, S; Nutt, D; O'Donovan, MC; Peters, TJ; Wiles, N, 2014) |
| "Escitalopram was started at 10 mg/d with a dosage increase to 20 mg/d after 4 weeks; placebo dosing was identical." | 2.77 | Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. ( Gadde, KM; Gang, CH; Griffing, GT; Vander Wal, JS, 2012) |
| "Among 811 adults with moderate-to-severe depression, melancholic, atypical, anxious and anxious-somatizing depression subtypes established at baseline were evaluated as predictors of outcome of treatment with flexible dosage of the SSRI escitalopram or the tricyclic antidepressant nortriptyline." | 2.76 | Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Kalember, P; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2011) |
| "Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI." | 2.75 | Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression. ( Culang, ME; Devanand, DP; Keilp, JG; Roose, SP; Rutherford, BR; Sneed, JR, 2010) |
| "In a multicentre part-randomised open-label design (the Genome Based Therapeutic Drugs for Depression (GENDEP) study) 811 adults with moderate to severe unipolar depression were allocated to flexible dosage escitalopram or nortriptyline for 12 weeks." | 2.74 | Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. ( Aitchison, KJ; Barreto, M; Dmitrzak-Weglarz, M; Elkin, A; Farmer, A; Giovannini, C; Hauser, J; Henigsberg, N; Jorgensen, L; Kalember, P; Landau, S; Maier, W; Marusic, A; McGuffin, P; Mors, O; Petrovic, A; Placentino, A; Rietschel, M; Schmael, C; Souery, D; Uher, R; Zobel, A, 2009) |
| "In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks." | 2.74 | Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. ( Aitchison, KJ; Campbell, D; Elkin, A; Farmer, AE; Giovannini, C; Gray, J; Gunasinghe, C; Gupta, B; Hauser, J; Henigsberg, N; Jorgensen, L; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Szczepankiewicz, A; Uher, R; Zobel, A, 2009) |
| "Citalopram nonresponders were the only group to decline on verbal learning and psychomotor speed." | 2.74 | Change in cognitive functioning following acute antidepressant treatment in late-life depression. ( Culang, ME; Devanand, DP; Keilp, JG; Pelton, GH; Roose, SP; Rutherford, BR; Sneed, JR, 2009) |
| "Escitalopram was effective and well tolerated in the treatment of depression over a 16-week period in a semi-naturalistic setting, and an additional effect of educational information could not be shown, possibly due to the high response to treatment." | 2.73 | The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study. ( Leinonen, E; Niemi, H, 2007) |
| "All citalopram patients were able to complete interferon therapy as planned." | 2.73 | Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. ( Hofbauer, I; Keicher, C; Kraus, MR; Schäfer, A; Scheurlen, M; Schöttker, K; Weissbrich, B, 2008) |
| "Escitalopram was efficacious and safe for the treatment of dAD in this study." | 2.72 | An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD). ( Lee, HB; Lyketsos, CG; Rao, V; Rosenberg, PB; Rosenblatt, A; Spiro, JR, 2006) |
| "Escitalopram was compared to placebo in moderately to severely depressed patients in primary care with citalopram as the active reference." | 2.71 | Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. ( Lepola, UM; Loft, H; Reines, EH, 2003) |
| "Citalopram is a highly selective serotonin reuptake inhibitor antidepressant." | 2.71 | Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. ( Hudson, JI; Keck, PE; Malhotra, S; McElroy, SL; Nelson, EB; Welge, JA, 2003) |
| "Depression is the strongest risk factor for late-life suicide and for suicide's precursor, suicidal ideation." | 2.71 | Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. ( Alexopoulos, GS; Brown, GK; Bruce, ML; Katz, II; McAvay, GJ; Mulsant, BH; Pearson, JL; Reynolds, CF; Schulberg, HC; Ten Have, TR, 2004) |
| "In view of the good tolerability of escitalopram, the pharmacokinetic changes observed on co-administration with cimetidine or omeprazole are unlikely to be of clinical concern." | 2.71 | The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ( Malling, D; Poulsen, MN; Søgaard, B, 2005) |
| "All of the patients with primary conversion disorder had a current or previous depressive or anxiety disorder compared with 40% (N = 2) of the patients with additional somatoform diagnoses." | 2.71 | Antidepressant treatment outcomes of psychogenic movement disorder. ( Lang, AE; Voon, V, 2005) |
| "Among the many problems in interpreting dose-response studies with antidepressants are the psychometric problems in the identification of true antidepressive effect versus true adverse drug effect." | 2.70 | Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. ( Andersen, HF; Bech, P; Overø, K; Tanghøj, P, 2002) |
| "The citalopram group was significantly older than the sertraline group and had more severe SH (72% vs." | 2.70 | MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. ( Boyle, P; Correia, S; Krishnan, KR; Lavretsky, H; Malloy, P; Roose, S; Sackheim, H; Salloway, S; Schneider, L, 2002) |
| "Time to recurrence was longer in patients taking citalopram than in patients taking placebo (P:<0." | 2.70 | Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. ( Andersen, M; Hochstrasser, B; Isaksen, PM; Koponen, H; Lauritzen, L; Mahnert, FA; Nil, R; Pedersen, SF; Rouillon, F; Swart, JC; Wade, AG, 2001) |
| "Citalopram treatment also significantly improved depressive symptomatology compared with placebo; however, escitalopram, 10 mg/day, was at least as effective as citalopram, 40 mg/day, at endpoint." | 2.70 | Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. ( Bose, A; Burke, WJ; Gergel, I, 2002) |
| "41 of the 61 patients using placebo had recurrence." | 2.70 | Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. ( Andersen, M; Bent-Hansen, J; Hansen, HL; Klysner, R; Lunde, M; Petersen, HE; Pleidrup, E; Poulsen, DL, 2002) |
| "Citalopram (40 mg/day) was administered double-blindly as tablets or slow-drop infusion during the first 10 days and then open, orally, up to treatment Day 42." | 2.69 | A double-blind double-dummy study of citalopram comparing infusion versus oral administration. ( Baumann, P; Bertschy, G; Brändli, H; Jecker, A; Kasas, A; Morand, J; Nil, R; Ramseier, F; Vuagniaux, O, 1998) |
| "When the personality disorders were analysed as continuous, dimensional personality traits significant reductions were seen for most personality categories." | 2.69 | Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. ( Ekselius, L; von Knorring, L, 1998) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 2.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Citalopram was well tolerated, with only 15% of patients discontinuing for adverse events." | 2.69 | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. ( Feighner, JP; Overø, K, 1999) |
| "Citalopram was equally well tolerated in both treatment groups." | 2.69 | Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. ( Guelfi, JD; Loft, H; Strub, N, 2000) |
| "The citalopram-treated patients in whom AAM developed were significantly older than those in whom it did not (about 10 years, P < 0." | 2.69 | Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients? ( Barak, Y; Kimhi, R; Weizman, R, 2000) |
| "Relapse was defined as a total score of 25 or more on the MADRS scale." | 2.68 | Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. ( Montgomery, SA; Robert, P, 1995) |
| " No evidence was seen of a pharmacokinetic interaction between CIT and Li, and this combination was well tolerated." | 2.68 | A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. ( Amey, M; Baettig, D; Baumann, P; Jonzier-Perey, M; Kasas, A; Lambert, S; Montaldi, S; Nil, R; Souche, A; Uehlinger, C, 1996) |
| " According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine." | 2.68 | Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. ( Baumann, P; Bertschy, G; Bondolfi, G; Chautems, C; Rochat, B, 1996) |
| "The imipramine-treated patients showed a higher frequency of adverse events, especially the anticholinergic type, than citalopram-treated patients." | 2.67 | Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. ( Damsbo, N; Fuglum, E; Horsgård, S; Jacobsen, LV; Rosenberg, C, 1994) |
| "Orthostatic hypotension, the clinically most important side effect in treatment with tricyclic antidepressants, was investigated in a double-blind study with clomipramine and the selective serotonin reuptake inhibitor citalopram given for 5 weeks." | 2.66 | Orthostatic side effects of clomipramine and citalopram during treatment for depression. ( Christensen, P; Gram, LF; Kragh-Sørensen, P; Pedersen, OL; Thomsen, HY, 1985) |
| "Citalopram is a bicyclic phtalane derivative." | 2.66 | Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients. ( Bjerkenstedt, L; Edman, G; Flyckt, L; Hagenfeldt, L; Sedvall, G; Wiesel, FA, 1985) |
| "Somatic anxiety, psychic anxiety and psychomotor agitation as assessed using the Hamilton Depression Rating Scale (HDRS) were analysed in all trials (n = 8262); anxiety-related adverse events were analysed in trials investigating paroxetine and citalopram (n = 5712)." | 2.55 | Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. ( Emilsson, JF; Eriksson, E; Hieronymus, F; Lisinski, A; Näslund, J; Nilsson, S, 2017) |
| "Escitalopram is a widely used antidepressant for the treatment of patients with major depression." | 2.48 | Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. ( Haddjeri, N; Sánchez, C; Zhong, H, 2012) |
| "Depressive disorders are common in young people and are associated with significant negative impacts." | 2.48 | Newer generation antidepressants for depressive disorders in children and adolescents. ( Cox, GR; Hetrick, SE; McKenzie, JE; Merry, SN; Simmons, MB, 2012) |
| "Fluoxetine was the only SSRI where there was consistent evidence from three trials that it was effective in reducing depression symptoms in both children and adolescents (CDRS-R treatment effect -5." | 2.44 | Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. ( Hetrick, S; McKenzie, J; Merry, S; Proctor, M; Sindahl, P, 2007) |
| "Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose." | 2.43 | Managing depressive and anxiety disorders with escitalopram. ( Thase, ME, 2006) |
| "The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported." | 2.42 | [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003) |
| "Escitalopram is a new antidepressant drug, available for clinical use in many countries." | 2.41 | Escitalopram: efficacy and tolerability in the treatment of depression. ( Baldwin, DS, 2002) |
| "Citalopram does not cause anticholinergic or cardiovascular adverse effects associated with the TCAs." | 2.41 | Citalopram in the treatment of depression. ( Brown, CS; Parker, NG, 2000) |
| "Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment." | 2.40 | Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999) |
| " From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme." | 2.39 | Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. ( Baumann, P; Rochat, B, 1995) |
| " Metanalysis of the placebo controlled results with citalopram demonstrated that the dose-response curves based on log odds ratios showed a very flat curve across the 20-60 mg range and that 20 mg appeared therefore to be the minimum effective dose." | 2.39 | Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. ( Montgomery, SA, 1995) |
| "Optimal dosing schedules for an antidepressant drug can only be established during clinical studies in depressed patients." | 2.39 | The optimal dosing regimen for citalopram--a meta-analysis of nine placebo-controlled studies. ( Montgomery, SA; Pedersen, V; Rasmussen, C; Rioux, P; Tanghøj, P, 1994) |
| "Citalopram has been well tolerated in both short- and long-term use, and the profile seen in trials has been confirmed in the clinic." | 2.39 | The safety and tolerability of citalopram. ( Muldoon, C, 1996) |
| "Citalopram is an SSRI drug with an attractive pharmacokinetic profile, i." | 2.39 | Scandinavian experience with citalopram in the elderly. ( Gottfries, CG, 1996) |
| "Major depressive disorder is a very common and a very serious illness that not only disrupts the lives of the people with the condition but also the lives of their families." | 2.38 | A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. ( Luo, H; Richardson, JS, 1993) |
| "The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen." | 1.51 | Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. ( Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Eap, CB; Glatard, A; Guidi, M; Marzolini, C, 2019) |
| "The condition has been referred to as Morgellons disease." | 1.48 | Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes. ( Bewley, A; Mohandas, P; Taylor, R, 2018) |
| " Application of new drugs which could enhance the effectiveness of antidepressants drug and reduce side effects of their long-term use seems necessary." | 1.48 | Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. ( Akhondzadeh, S; Nejatisafa, AA; Roohi-Azizi, M; Sadat-Shirazi, MS; Torkaman-Boutorabi, A; Zarrindast, MR, 2018) |
| "Depressive disorders are involved as a background factor in over 50% of suicide cases." | 1.46 | Serotonergic 5HTTLPR/rs25531 s-allele homozygosity associates with violent suicides in male citalopram users. ( Haukka, J; Majaharju, S; Palo, JU; Rahikainen, AL; Sajantila, A, 2017) |
| " Chronic administration of amitriptyline reversed the despaired behavior induced by exposure to UCMS paradigm and, fully recovered pNF-H labeling to control values." | 1.46 | Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression. ( Galeotti, N; Ghelardini, C; Sanna, MD, 2017) |
| "In the amnestic mild cognitive impairment subsample (n = 22), the conversion rate was 4." | 1.43 | Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study. ( D'Antonio, K; Devanand, DP; Harper, OL; Marder, K; Pelton, GH; Roose, SP, 2016) |
| " However, a long term use of ketamine tends to elicit its adverse reactions." | 1.42 | Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. ( Guo, J; Liu, WX; Qiu, LL; Sun, HL; Wang, XM; Yang, JJ; Zhang, GF; Zhou, ZQ, 2015) |
| "As a result, SSRIinduced akathisia is very frequently under-recognized." | 1.40 | A case of akathisia induced by escitalopram: case report & review of literature. ( Basu, B; De, S; Dutta, N; Gangopadhyay, T; Mandal, B; Mondal, S, 2014) |
| "We therefore believe that "melancholia" thus defined could be a valuable construct under the Research Domain Criteria (RDoC), which specifically aims at identifying the neurobiology underlying mental disorders and providing drugable targets." | 1.40 | Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). ( Bech, P; Fava, M; Ostergaard, SD; Rush, AJ; Trivedi, MH; Wisniewski, SR, 2014) |
| "Discontinuation or withdrawal symptoms have been documented for all major classes of antide- pressants, especially the selective serotonin reuptake inhibitors (SSRIs)." | 1.40 | Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction. ( DE Berardis, D; DI Giannantonio, M; Fornaro, M; Kahn, DA; Marini, S; Martinotti, G; Serroni, N; Valchera, A, 2014) |
| "Escitalopram treatment decreased anxiety-related behaviours in stressed animals, by increasing the time spent in the central part of the arena with respect to saline treated stressed animals, without affecting exploratory related behaviours." | 1.40 | Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. ( Alboni, S; Benatti, C; Blom, JM; Brunello, N; Gandolfi, F; Mendlewicz, J; Tascedda, F, 2014) |
| " This hypermethylated pattern was reversed to normal, as indicated by the control line, after chronic administration of escitalopram (a selective serotonin reuptake inhibitor; SSRI)." | 1.38 | Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. ( Björk, K; Lavebratt, C; Lennartsson, A; Mathé, AA; Melas, PA; Qi, H; Rogdaki, M; Svenningsson, P; Wegener, G; Werme, M; Witasp, A, 2012) |
| " Excellent bioavailability and brain penetration are associated with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4." | 1.36 | 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. ( Andreotti, D; Arban, R; Benedetti, R; Bertani, B; Bettati, M; Bettelini, L; Bonanomi, G; Braggio, S; Carletti, R; Cavanni, P; Checchia, A; Corsi, M; Di Fabio, R; Fazzolari, E; Fontana, S; Marchioro, C; Merlo-Pich, E; Micheli, F; Negri, M; Oliosi, B; Ratti, E; Read, KD; Roscic, M; Sartori, I; Spada, S; Tarsi, L; Tedesco, G; Terreni, S; Visentini, F; Zocchi, A; Zonzini, L, 2010) |
| "For patients with unipolar depression, discharge rates were higher when they were prescribed one of 'the four' and highest when prescribed escitalopram." | 1.36 | An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| "Sertraline was the antidepressant most likely to reduce suicidality in our sample." | 1.36 | An audit to compare discharge rates and suicidality between antidepressant monotherapies prescribed for unipolar depression. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| "Sertraline was the antidepressant most likely to reduce suicidality in our sample." | 1.36 | Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| "Escitalopram was discontinued and the patient did not have any further seizure activity." | 1.35 | Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. ( Canepa, EA; Lorenz, RA; Vandenberg, AM, 2008) |
| "The citalopram treatment produced unexpected results in the FRL rats: 5-HT synthesis was elevated not only in most of the terminal areas, but also in the cell body areas, the DR and MR." | 1.35 | Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation. ( Diksic, M; Hasegawa, S; Kanemaru, K; Nishi, K, 2008) |
| "Mecamylamine was effective on its own in some tests, but did not augment the effects of citalopram or reboxetine at the doses tested." | 1.35 | Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. ( Andreasen, JT; Redrobe, JP, 2009) |
| "High blood pressure is a risk factor for cerebrovascular disease and white matter changes." | 1.35 | Blood pressure and white matter integrity in geriatric depression. ( Alexopoulos, GS; Ardekani, BA; Etwaroo, GR; Gunning-Dixon, FM; Hoptman, MJ; Hrabe, J; Kanellopoulos, D; Lim, KO; Murphy, CF, 2009) |
| "Treatment with desipramine or imipramine, however, was not effective at reducing immobility in the 21-day-old rats." | 1.35 | Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression. ( Bylund, DB; Happe, HK; Petty, F; Reed, AL, 2008) |
| "In the group with major depressive disorder, treatment with antidepressants showed an increase from 15% to 30%." | 1.35 | Trends in antidepressant use in the older population: results from the LASA-study over a period of 10 years. ( Beekman, AT; Comijs, HC; Deeg, DJ; Sonnenberg, CM; van Tilburg, W, 2008) |
| " In 9% of patients, RLS was recorded as a side effect related to the administration of AD." | 1.35 | Restless legs syndrome as side effect of second generation antidepressants. ( Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ, 2008) |
| "Hysterical paralysis is an uncommon type of conversion disorder." | 1.34 | Hysterical paralysis. ( Atan, C; Bodur, H; Seçkin, U, 2007) |
| " The dosage was reduced and yawning disappeared some hours later." | 1.34 | Do your patients suffer from excessive yawning? ( Gutiérrez-Alvarez, AM, 2007) |
| "Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients." | 1.34 | Citalopram to treat depression in pediatric oncology. ( DeJong, M; Fombonne, E, 2007) |
| "Imipramine promotes the non-amyloidogenic route of APP processing via stimulatory effects on PKC." | 1.33 | Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. ( Bjelik, A; Hugyecz, M; Janka, Z; Kálmán, J; Kása, P; Pákáski, M, 2005) |
| "To report the onset of bilateral angle closure glaucoma resulting from ciliochoroidal effusions noted after taking escitalopram." | 1.33 | Escitalopram-induced uveal effusions and bilateral angle closure glaucoma. ( Fine, HF; Finger, PT; Hsu, IS; Rubinstein, VJ; Zelefsky, JR, 2006) |
| "One hundred sixty-five patients with cancer, consecutively admitted to the Oncology Division of San Camillo-Forlanini Hospital, were recruited to the study." | 1.33 | Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. ( Biondi, M; Cairoli, F; Costantini, A; Ferrarese, G; Pasquini, M; Picardi, A; Sternberg, C, 2006) |
| "R-citalopram has been shown to counteract the 5-HT enhancing properties of escitalopram in acute studies in animals." | 1.32 | R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. ( Gruca, P; Papp, M; Sánchez, C, 2003) |
| "In the outcome analysis for depression recurrence, the conventional cutoff scores of the three scales are used." | 1.32 | The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression. ( Andersen, M; Bech, P; Bent-Hansen, J; Klysner, R; Lunde, M; Solstad, K; Tanghøj, P, 2003) |
| "Amitriptyline treatment is not less expensive nor more effective than citalopram or fluoxetine therapies." | 1.31 | Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study. ( Hanus, H; Hosák, L; Straka, L; Tůma, I, 2000) |
| "Priapism is documented to occur in association with treatment with a variety of psychotropic agents." | 1.30 | Citalopram-associated clitoral priapism: a case series. ( Acton, M; Berk, M, 1997) |
| " Chronic administration of cyclic antidepressant drugs (citalopram, clomipramine, imipramine) decreased the immunoreactivity of the up-regulated G alpha i2 protein (31%)." | 1.30 | Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. ( Balant, L; Busquets, X; Escribá, PV; García-Sevilla, JA; Guimón, J; Walzer, C, 1997) |
| "Treatment with citalopram by the intravenous or oral route was most successful in anxious or inhibitory depressions, while atypical forms with hypochondriac or obsedant features responded better to infusions." | 1.29 | [Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression]. ( Buresová, A; Cesková, E; Kamenická, V; Obrovská, V; Svestka, J; Synek, O, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (4.35) | 18.7374 |
| 1990's | 80 (15.12) | 18.2507 |
| 2000's | 205 (38.75) | 29.6817 |
| 2010's | 212 (40.08) | 24.3611 |
| 2020's | 9 (1.70) | 2.80 |
| Authors | Studies |
|---|---|
| Micheli, F | 1 |
| Cavanni, P | 1 |
| Andreotti, D | 1 |
| Arban, R | 1 |
| Benedetti, R | 1 |
| Bertani, B | 1 |
| Bettati, M | 1 |
| Bettelini, L | 1 |
| Bonanomi, G | 1 |
| Braggio, S | 1 |
| Carletti, R | 1 |
| Checchia, A | 1 |
| Corsi, M | 1 |
| Fazzolari, E | 1 |
| Fontana, S | 1 |
| Marchioro, C | 1 |
| Merlo-Pich, E | 1 |
| Negri, M | 1 |
| Oliosi, B | 1 |
| Ratti, E | 1 |
| Read, KD | 1 |
| Roscic, M | 1 |
| Sartori, I | 1 |
| Spada, S | 1 |
| Tedesco, G | 1 |
| Tarsi, L | 1 |
| Terreni, S | 1 |
| Visentini, F | 1 |
| Zocchi, A | 1 |
| Zonzini, L | 1 |
| Di Fabio, R | 1 |
| Lewis, G | 6 |
| Marston, L | 1 |
| Duffy, L | 1 |
| Freemantle, N | 1 |
| Gilbody, S | 1 |
| Hunter, R | 1 |
| Kendrick, T | 1 |
| Kessler, D | 1 |
| Mangin, D | 1 |
| King, M | 1 |
| Lanham, P | 1 |
| Moore, M | 1 |
| Nazareth, I | 1 |
| Wiles, N | 4 |
| Bacon, F | 1 |
| Bird, M | 1 |
| Brabyn, S | 1 |
| Burns, A | 1 |
| Clarke, CS | 1 |
| Hunt, A | 1 |
| Pervin, J | 1 |
| Vinnikova, MA | 1 |
| Severtsev, VV | 1 |
| Komarov, SD | 1 |
| Vdovin, AS | 1 |
| Nirogi, R | 1 |
| Abraham, R | 1 |
| Jayarajan, P | 1 |
| Goura, V | 1 |
| Kallepalli, R | 1 |
| Medapati, RB | 1 |
| Tadiparthi, J | 1 |
| Goyal, VK | 1 |
| Pandey, SK | 1 |
| Subramanian, R | 1 |
| Petlu, S | 1 |
| Thentu, JB | 1 |
| Palacharla, VRC | 1 |
| Gagginapally, SR | 1 |
| Mohammed, AR | 1 |
| Jasti, V | 1 |
| Kim, JM | 11 |
| Stewart, R | 7 |
| Kang, HJ | 10 |
| Kim, SY | 2 |
| Kim, JW | 2 |
| Lee, HJ | 1 |
| Lee, JY | 2 |
| Kim, SW | 11 |
| Shin, IS | 11 |
| Kim, MC | 1 |
| Shin, HY | 2 |
| Hong, YJ | 11 |
| Ahn, Y | 10 |
| Jeong, MH | 11 |
| Yoon, JS | 11 |
| Zastrozhin, MS | 1 |
| Skryabin, V | 1 |
| Rwere, F | 1 |
| Petukhov, AE | 1 |
| Pankratenko, EP | 1 |
| Pozdniakov, SA | 1 |
| Ivanchenko, VA | 1 |
| Noskov, VV | 1 |
| Zaytsev, IA | 1 |
| Vinokurova, NV | 1 |
| Horyaev, DS | 1 |
| Vlasovskih, RV | 1 |
| Bryun, EA | 1 |
| Sychev, DA | 1 |
| Ahmadimanesh, M | 1 |
| Abbaszadegan, MR | 1 |
| Morshedi Rad, D | 1 |
| Moallem, SA | 1 |
| Mohammadpour, AH | 1 |
| Ghahremani, MH | 1 |
| Farid Hosseini, F | 1 |
| Behdani, F | 1 |
| Akhondpour Manteghi, A | 1 |
| Jowsey, P | 1 |
| Shabani Behbahani, F | 1 |
| Moallem, SMH | 1 |
| Etemad, L | 1 |
| Yao, R | 1 |
| Wang, H | 2 |
| Yuan, M | 1 |
| Wang, G | 1 |
| Wu, C | 1 |
| Roy, P | 1 |
| Gupta, B | 3 |
| Tripathi, A | 1 |
| Nischal, A | 1 |
| Dalal, PK | 1 |
| Kar, SK | 1 |
| Puzhko, S | 1 |
| Aboushawareb, SAE | 1 |
| Kudrina, I | 1 |
| Schuster, T | 1 |
| Barnett, TA | 1 |
| Renoux, C | 1 |
| Bartlett, G | 1 |
| Uvais, NA | 1 |
| Hui, A | 1 |
| Bausch, P | 2 |
| Fangmeier, T | 2 |
| Zobel, I | 2 |
| Schoepf, D | 2 |
| Drost, S | 2 |
| Schnell, K | 2 |
| Walter, H | 2 |
| Berger, M | 2 |
| Normann, C | 2 |
| Schramm, E | 2 |
| Chu, CW | 1 |
| Chao, PC | 1 |
| Chang, HA | 1 |
| Liu, YW | 1 |
| Chang, TC | 1 |
| Lin, PY | 1 |
| Chang, CC | 2 |
| Fountoulakis, KN | 1 |
| Rougemont-Bücking, A | 1 |
| Gamma, F | 1 |
| Panksepp, J | 1 |
| Rahikainen, AL | 1 |
| Majaharju, S | 1 |
| Haukka, J | 1 |
| Palo, JU | 1 |
| Sajantila, A | 1 |
| Pałucha-Poniewiera, A | 1 |
| Podkowa, K | 1 |
| Lenda, T | 1 |
| Pilc, A | 1 |
| Mohandas, P | 1 |
| Bewley, A | 1 |
| Taylor, R | 1 |
| Bae, KY | 9 |
| Ahn, YK | 1 |
| Berk, M | 3 |
| Westin, AA | 1 |
| Brekke, M | 1 |
| Molden, E | 2 |
| Skogvoll, E | 1 |
| Spigset, O | 4 |
| Jastrzębska, J | 1 |
| Frankowska, M | 1 |
| Suder, A | 1 |
| Wydra, K | 1 |
| Nowak, E | 1 |
| Filip, M | 1 |
| Przegaliński, E | 2 |
| Sun, Y | 1 |
| Liang, Y | 1 |
| Jiao, Y | 1 |
| Lin, J | 1 |
| Qu, H | 1 |
| Xu, J | 2 |
| Zhao, C | 1 |
| Farzan, F | 1 |
| Atluri, S | 1 |
| Frehlich, M | 1 |
| Dhami, P | 1 |
| Kleffner, K | 1 |
| Price, R | 1 |
| Lam, RW | 3 |
| Frey, BN | 1 |
| Milev, R | 1 |
| Ravindran, A | 1 |
| McAndrews, MP | 1 |
| Wong, W | 1 |
| Blumberger, D | 1 |
| Daskalakis, ZJ | 1 |
| Vila-Rodriguez, F | 1 |
| Alonso, E | 1 |
| Brenner, CA | 1 |
| Liotti, M | 1 |
| Dharsee, M | 1 |
| Arnott, SR | 1 |
| Evans, KR | 1 |
| Rotzinger, S | 1 |
| Kennedy, SH | 1 |
| Rajagopal, R | 1 |
| Jois, SN | 1 |
| Mallikarjuna Majgi, S | 1 |
| Anil Kumar, MN | 1 |
| Shashidhar, HB | 1 |
| Näslund, J | 1 |
| Hieronymus, F | 1 |
| Emilsson, JF | 1 |
| Lisinski, A | 1 |
| Nilsson, S | 1 |
| Eriksson, E | 1 |
| Chon, MW | 1 |
| Lee, J | 1 |
| Chung, S | 1 |
| Kim, Y | 1 |
| Kim, HW | 1 |
| Kwok, CSN | 1 |
| Lim, LEC | 1 |
| Faye, A | 1 |
| Kirpekar, V | 1 |
| Tadke, R | 1 |
| Gawande, S | 1 |
| Bhave, S | 1 |
| Suzuki, H | 1 |
| Hibino, H | 1 |
| Inoue, Y | 1 |
| Mikami, K | 1 |
| Glass, OM | 1 |
| Jukić, MM | 1 |
| Haslemo, T | 1 |
| Ingelman-Sundberg, M | 1 |
| Elzein, FE | 1 |
| Al Sherbini, N | 1 |
| Alotaibi, MM | 1 |
| Al-Hassan, WM | 1 |
| Steyn, SF | 1 |
| Harvey, BH | 2 |
| Brink, CB | 1 |
| Sanchez, C | 4 |
| El Khoury, A | 1 |
| Hassan, M | 1 |
| Wegener, G | 2 |
| Mathé, AA | 3 |
| Gasull-Camós, J | 1 |
| Martínez-Torres, S | 1 |
| Tarrés-Gatius, M | 1 |
| Ozaita, A | 1 |
| Artigas, F | 1 |
| Castañé, A | 1 |
| Laird, KT | 1 |
| Lavretsky, H | 3 |
| St Cyr, N | 1 |
| Siddarth, P | 1 |
| Vengadavaradan, A | 1 |
| Sathyanarayanan, G | 1 |
| Menon, V | 1 |
| Roohi-Azizi, M | 1 |
| Torkaman-Boutorabi, A | 1 |
| Akhondzadeh, S | 1 |
| Nejatisafa, AA | 1 |
| Sadat-Shirazi, MS | 1 |
| Zarrindast, MR | 1 |
| Rubin, R | 1 |
| Willner, P | 2 |
| Gruca, P | 3 |
| Lason, M | 1 |
| Tota-Glowczyk, K | 1 |
| Litwa, E | 2 |
| Niemczyk, M | 1 |
| Papp, M | 4 |
| McGlashan, EM | 1 |
| Nandam, LS | 1 |
| Vidafar, P | 1 |
| Mansfield, DR | 1 |
| Rajaratnam, SMW | 1 |
| Cain, SW | 1 |
| Dai, CX | 1 |
| Hu, CC | 1 |
| Shang, YS | 1 |
| Xie, J | 1 |
| Zhong, Q | 1 |
| Yu, H | 1 |
| Huang, C | 1 |
| Zhong, J | 1 |
| Cheng, Y | 1 |
| Kim, HR | 1 |
| Shin, MG | 1 |
| Hale, MW | 1 |
| Lukkes, JL | 1 |
| Dady, KF | 1 |
| Kelly, KJ | 1 |
| Paul, ED | 1 |
| Smith, DG | 1 |
| Heinze, JD | 1 |
| Raison, CL | 1 |
| Lowry, CA | 1 |
| Thombs, BD | 3 |
| Ziegelstein, RC | 2 |
| Zimmermann, FM | 1 |
| El Farissi, M | 1 |
| Tonino, PAL | 1 |
| Rust, G | 1 |
| Seo, MK | 1 |
| Lee, JG | 1 |
| Park, SW | 1 |
| Smetanka, A | 1 |
| Stara, V | 1 |
| Farsky, I | 1 |
| Tonhajzerova, I | 1 |
| Ondrejka, I | 1 |
| Kokras, N | 2 |
| Papadopoulou, E | 1 |
| Georgiopoulos, G | 1 |
| Dalla, C | 1 |
| Petropoulos, I | 1 |
| Kontogiannis, C | 1 |
| Laina, A | 1 |
| Bampatsias, D | 1 |
| Stellos, K | 1 |
| Kouzoupis, AV | 1 |
| Stamatelopoulos, K | 1 |
| Courlet, P | 1 |
| Guidi, M | 1 |
| Glatard, A | 1 |
| Alves Saldanha, S | 1 |
| Cavassini, M | 1 |
| Buclin, T | 1 |
| Marzolini, C | 1 |
| Eap, CB | 3 |
| Decosterd, LA | 1 |
| Csajka, C | 1 |
| Guo, S | 1 |
| Chen, L | 1 |
| Cheng, S | 1 |
| Xu, H | 2 |
| Hou, R | 1 |
| Ye, G | 1 |
| Liu, Y | 1 |
| Chen, X | 1 |
| Pan, M | 1 |
| Zhu, F | 1 |
| Fu, J | 1 |
| Fu, T | 1 |
| Liu, Q | 1 |
| Gao, Z | 1 |
| Baldwin, DS | 2 |
| Tang, Z | 1 |
| Demyttenaere, K | 2 |
| Corruble, E | 1 |
| Hale, A | 1 |
| Quera-Salva, MA | 1 |
| Picarel-Blanchot, F | 1 |
| Kasper, S | 4 |
| Rotberg, B | 1 |
| Kronenberg, S | 2 |
| Carmel, M | 2 |
| Frisch, A | 2 |
| Brent, D | 2 |
| Zalsman, G | 1 |
| Apter, A | 2 |
| Weizman, A | 2 |
| Zivin, K | 1 |
| Pfeiffer, PN | 1 |
| Bohnert, AS | 1 |
| Ganoczy, D | 1 |
| Blow, FC | 1 |
| Nallamothu, BK | 1 |
| Kales, HC | 1 |
| Hanck, L | 1 |
| Schellekens, AF | 1 |
| Hasnain, M | 1 |
| Howland, RH | 1 |
| Vieweg, WV | 1 |
| Gehlawat, P | 1 |
| Gupta, R | 1 |
| Rajput, R | 1 |
| Gahlan, D | 1 |
| Gehlawat, VK | 1 |
| Opal, MD | 1 |
| Klenotich, SC | 1 |
| Morais, M | 1 |
| Bessa, J | 1 |
| Winkle, J | 1 |
| Doukas, D | 1 |
| Kay, LJ | 1 |
| Sousa, N | 1 |
| Dulawa, SM | 1 |
| Santos-Cubiñá, J | 1 |
| Torres-Rodríguez, A | 1 |
| Castaing-Lespier, PA | 1 |
| Sabaté, N | 1 |
| Torres-Martin, A | 1 |
| Carlo, S | 1 |
| Wielpuetz, C | 1 |
| Kuepper, Y | 1 |
| Grant, P | 1 |
| Munk, AJ | 1 |
| Hennig, J | 1 |
| Beglinger, LJ | 1 |
| Adams, WH | 1 |
| Langbehn, D | 1 |
| Fiedorowicz, JG | 1 |
| Jorge, R | 1 |
| Biglan, K | 1 |
| Caviness, J | 1 |
| Olson, B | 1 |
| Robinson, RG | 3 |
| Kieburtz, K | 1 |
| Paulsen, JS | 1 |
| Kanaeva, LS | 1 |
| Dashkina, GK | 1 |
| Wang, SS | 1 |
| Wang, YG | 1 |
| Chen, HY | 1 |
| Wu, ZP | 1 |
| Xie, HG | 1 |
| Crawford, AA | 1 |
| Lewis, S | 1 |
| Nutt, D | 3 |
| Peters, TJ | 4 |
| Cowen, P | 3 |
| O'Donovan, MC | 3 |
| Basu, B | 1 |
| Gangopadhyay, T | 1 |
| Dutta, N | 1 |
| Mandal, B | 1 |
| De, S | 1 |
| Mondal, S | 1 |
| Gupta, D | 1 |
| Kurhe, Y | 1 |
| Radhakrishnan, M | 1 |
| Kurkjian, N | 1 |
| Kurkjian, C | 1 |
| Pant, S | 1 |
| Tucker, P | 1 |
| Prakash, S | 1 |
| Mandal, P | 1 |
| McRae, K | 1 |
| Rekshan, W | 3 |
| Williams, LM | 3 |
| Cooper, N | 1 |
| Gross, JJ | 1 |
| Ostergaard, SD | 1 |
| Bech, P | 8 |
| Trivedi, MH | 11 |
| Wisniewski, SR | 7 |
| Rush, AJ | 12 |
| Fava, M | 7 |
| Kouros, N | 1 |
| DE Berardis, D | 1 |
| Serroni, N | 1 |
| Marini, S | 1 |
| Fornaro, M | 1 |
| Valchera, A | 1 |
| Martinotti, G | 1 |
| DI Giannantonio, M | 1 |
| Kahn, DA | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Benatti, C | 1 |
| Alboni, S | 1 |
| Blom, JM | 1 |
| Gandolfi, F | 1 |
| Mendlewicz, J | 3 |
| Brunello, N | 1 |
| Tascedda, F | 1 |
| Bruder, GE | 1 |
| Alvarenga, JE | 1 |
| Alschuler, D | 1 |
| Abraham, K | 1 |
| Keilp, JG | 3 |
| Hellerstein, DJ | 1 |
| Stewart, JW | 4 |
| McGrath, PJ | 3 |
| Yuen, GS | 1 |
| Bhutani, S | 1 |
| Lucas, BJ | 1 |
| Gunning, FM | 1 |
| AbdelMalak, B | 1 |
| Seirup, JK | 1 |
| Klimstra, SA | 1 |
| Alexopoulos, GS | 5 |
| Nimber, JS | 1 |
| Aggarwal, A | 3 |
| Staudigl, L | 1 |
| Becker, T | 3 |
| Kösters, M | 1 |
| Zhang, Y | 2 |
| Ma, Y | 1 |
| Koesters, M | 1 |
| Lecardeur, L | 1 |
| Lefebvre, A | 1 |
| Meunier-Cussac, S | 1 |
| Jung, BO | 1 |
| Kim, JH | 1 |
| Kang, G | 1 |
| Kim, JK | 1 |
| Faye, E | 1 |
| Corcos, O | 1 |
| Lancelin, F | 1 |
| Declèves, X | 1 |
| Bergmann, JF | 1 |
| Joly, F | 1 |
| Lloret-Linares, C | 1 |
| Ramos-Zúñiga, R | 1 |
| Pérez-Gómez, HR | 1 |
| Gaytán-Martínez, LA | 1 |
| Vega-Ruiz, B | 1 |
| Soto-Rodríguez, S | 1 |
| Rochín-Mozqueda, A | 1 |
| Day, CV | 1 |
| John Rush, A | 1 |
| Harris, AW | 1 |
| Boyce, PM | 1 |
| Etkin, A | 2 |
| DeBattista, C | 1 |
| Schatzberg, AF | 2 |
| Arnow, BA | 2 |
| Ansermot, N | 1 |
| Chocron, O | 1 |
| Herrera, F | 1 |
| Ho, PS | 1 |
| Yeh, YW | 1 |
| Huang, SY | 1 |
| Liang, CS | 1 |
| Wang, Y | 2 |
| Wang, L | 1 |
| Bai, M | 1 |
| Zhang, X | 1 |
| Zhu, X | 1 |
| Zhang, GF | 1 |
| Liu, WX | 1 |
| Qiu, LL | 1 |
| Guo, J | 1 |
| Wang, XM | 1 |
| Sun, HL | 1 |
| Yang, JJ | 1 |
| Zhou, ZQ | 1 |
| Blasey, C | 1 |
| Palmer, DM | 1 |
| Kulkarni, J | 1 |
| Luther, JF | 4 |
| Asaoka, N | 1 |
| Nagayasu, K | 1 |
| Nishitani, N | 1 |
| Yamashiro, M | 1 |
| Shirakawa, H | 1 |
| Nakagawa, T | 1 |
| Kaneko, S | 1 |
| Munari, L | 1 |
| Provensi, G | 1 |
| Passani, MB | 1 |
| Galeotti, N | 2 |
| Cassano, T | 1 |
| Benetti, F | 1 |
| Corradetti, R | 1 |
| Blandina, P | 1 |
| Li, XL | 2 |
| Yuan, YG | 1 |
| Wu, D | 1 |
| Gong, WG | 1 |
| Geng, LY | 2 |
| Wu, FF | 1 |
| Tang, H | 1 |
| Xu, L | 1 |
| Zhang, ZJ | 3 |
| Llamosas, N | 1 |
| Bruzos-Cidón, C | 1 |
| Rodríguez, JJ | 1 |
| Ugedo, L | 1 |
| Torrecilla, M | 1 |
| Sockalingam, S | 1 |
| Sheehan, K | 1 |
| Feld, JJ | 1 |
| Shah, H | 1 |
| Parthasarathy, S | 1 |
| Shetty, S | 1 |
| Combs, D | 1 |
| Zhu, G | 1 |
| Yin, Y | 1 |
| Xiao, CL | 1 |
| Mao, RJ | 1 |
| Shi, BH | 1 |
| Jie, Y | 1 |
| Wang, ZW | 1 |
| McMahon, FJ | 1 |
| Zhitkova, JV | 1 |
| Pelton, GH | 2 |
| Harper, OL | 1 |
| Roose, SP | 5 |
| Marder, K | 1 |
| D'Antonio, K | 1 |
| Devanand, DP | 3 |
| Valuck, RJ | 1 |
| Libby, AM | 1 |
| Anderson, HD | 1 |
| Allen, RR | 1 |
| Strombom, I | 1 |
| Marangell, LB | 1 |
| Perahia, D | 1 |
| Greeson, JM | 1 |
| Gettes, DR | 3 |
| Spitsin, S | 1 |
| Dubé, B | 3 |
| Benton, TD | 1 |
| Lynch, KG | 2 |
| Douglas, SD | 3 |
| Evans, DL | 3 |
| Gao, J | 1 |
| Lin, M | 1 |
| Zhao, J | 1 |
| Bi, S | 1 |
| Ni, Z | 1 |
| Shang, X | 1 |
| Eskeland, S | 1 |
| Tanum, L | 1 |
| Halvorsen, JA | 1 |
| Phillips, KA | 1 |
| Keshaviah, A | 1 |
| Dougherty, DD | 1 |
| Stout, RL | 1 |
| Menard, W | 1 |
| Wilhelm, S | 1 |
| Olbert, CM | 1 |
| Rasmussen, A | 2 |
| Gala, GJ | 1 |
| Tupler, LA | 1 |
| Hui, JJ | 1 |
| Xi, GJ | 1 |
| Liu, SS | 1 |
| Teng, GJ | 2 |
| Nie, BB | 1 |
| Shan, BC | 1 |
| Yan, J | 1 |
| Dong, L | 1 |
| Reynolds, GP | 1 |
| Shear, MK | 2 |
| Reynolds, CF | 3 |
| Simon, NM | 2 |
| Zisook, S | 5 |
| Mauro, C | 1 |
| Duan, N | 1 |
| Lebowitz, B | 1 |
| Skritskaya, N | 1 |
| Li, QS | 1 |
| Tian, C | 1 |
| Seabrook, GR | 1 |
| Drevets, WC | 1 |
| Narayan, VA | 1 |
| Malki, K | 2 |
| Tosto, MG | 1 |
| Mouriño-Talín, H | 1 |
| Rodríguez-Lorenzo, S | 1 |
| Pain, O | 1 |
| Jumhaboy, I | 1 |
| Liu, T | 1 |
| Parpas, P | 1 |
| Newman, S | 1 |
| Malykh, A | 1 |
| Carboni, L | 2 |
| Uher, R | 13 |
| McGuffin, P | 13 |
| Schalkwyk, LC | 3 |
| Bryson, K | 1 |
| Herbster, M | 1 |
| Ströhle, A | 1 |
| Rieckmann, N | 1 |
| Angermann, CE | 1 |
| Deckert, J | 1 |
| Ertl, G | 1 |
| Sanna, MD | 1 |
| Ghelardini, C | 1 |
| John, A | 1 |
| Marchant, AL | 1 |
| Fone, DL | 1 |
| McGregor, JI | 1 |
| Dennis, MS | 1 |
| Tan, JO | 1 |
| Lloyd, K | 1 |
| Kumar, S | 1 |
| Jha, MK | 1 |
| Minhajuddin, A | 1 |
| Gadad, BS | 1 |
| Greer, T | 1 |
| Grannemann, B | 1 |
| Soyombo, A | 1 |
| Mayes, TL | 1 |
| Martin, AE | 1 |
| Schober, DA | 1 |
| Nikolayev, A | 1 |
| Tolstikov, VV | 1 |
| Anderson, WH | 1 |
| Higgs, RE | 1 |
| Kuo, MS | 1 |
| Laksmanan, A | 1 |
| Catlow, JT | 1 |
| Li, X | 1 |
| Felder, CC | 1 |
| Witkin, JM | 1 |
| Hollander, E | 1 |
| Lorenz, RA | 1 |
| Vandenberg, AM | 1 |
| Canepa, EA | 1 |
| Thase, ME | 5 |
| Kanemaru, K | 1 |
| Hasegawa, S | 1 |
| Nishi, K | 1 |
| Diksic, M | 1 |
| Andreasen, JT | 1 |
| Redrobe, JP | 1 |
| Hoptman, MJ | 1 |
| Gunning-Dixon, FM | 1 |
| Murphy, CF | 1 |
| Ardekani, BA | 1 |
| Hrabe, J | 1 |
| Lim, KO | 1 |
| Etwaroo, GR | 1 |
| Kanellopoulos, D | 1 |
| Lacasse, J | 1 |
| Leo, J | 1 |
| Dettling, M | 1 |
| Opgen-Rhein, C | 1 |
| Anghelescu, I | 1 |
| Schulte-Herbrüggen, O | 1 |
| Röpke, S | 1 |
| Hanash, JA | 1 |
| Hatcher, S | 1 |
| Khan, AY | 1 |
| Morris, DW | 2 |
| Miyahara, S | 1 |
| Nierenberg, AA | 7 |
| Okun, MS | 1 |
| Fernandez, HH | 1 |
| Chakraborty, R | 1 |
| Chatterjee, A | 1 |
| Chaudhury, S | 1 |
| Montes, ML | 1 |
| Fraile, JM | 1 |
| González, JJ | 1 |
| Arribas, JR | 1 |
| Maier, W | 10 |
| Hauser, J | 9 |
| Marusic, A | 3 |
| Schmael, C | 1 |
| Mors, O | 11 |
| Henigsberg, N | 11 |
| Souery, D | 10 |
| Placentino, A | 11 |
| Rietschel, M | 11 |
| Zobel, A | 11 |
| Dmitrzak-Weglarz, M | 1 |
| Petrovic, A | 2 |
| Jorgensen, L | 2 |
| Kalember, P | 5 |
| Giovannini, C | 4 |
| Barreto, M | 3 |
| Elkin, A | 2 |
| Landau, S | 1 |
| Farmer, A | 10 |
| Aitchison, KJ | 11 |
| Tallelli, P | 1 |
| Werring, DJ | 1 |
| Barim, AO | 1 |
| Aydin, S | 1 |
| Colak, R | 1 |
| Dag, E | 1 |
| Deniz, O | 1 |
| Sahin, I | 1 |
| Arndt, S | 2 |
| Lazure, KE | 1 |
| Lydiatt, WM | 1 |
| Denman, D | 1 |
| Burke, WJ | 3 |
| de Diego-Adeliño, J | 1 |
| Portella, MJ | 2 |
| Puigdemont, D | 1 |
| Pérez-Egea, R | 1 |
| Alvarez, E | 1 |
| Pérez, V | 1 |
| Andruskevicius, S | 1 |
| Montgomery, SA | 10 |
| Möller, HJ | 4 |
| Huezo-Diaz, P | 2 |
| Perroud, N | 5 |
| Smith, R | 2 |
| Kozel, D | 3 |
| Dernovsek, MZ | 5 |
| Schulze, TG | 2 |
| Czerski, PM | 3 |
| Larsen, ER | 5 |
| Gray, JM | 2 |
| Lewis, CM | 3 |
| Craig, I | 3 |
| De Fruyt, J | 1 |
| Gusev, EI | 2 |
| Bogolepova, AN | 2 |
| Hoda, F | 1 |
| Warden, D | 2 |
| Lesser, IM | 4 |
| Balasubramani, GK | 1 |
| Shores-Wilson, K | 1 |
| Sharma, RC | 2 |
| Pandey, DK | 1 |
| Yadav, SK | 1 |
| Mahesh, R | 1 |
| Rajkumar, R | 1 |
| Knorr, U | 2 |
| Vinberg, M | 3 |
| Klose, M | 1 |
| Feldt-Rasmussen, U | 1 |
| Hilsted, L | 1 |
| Gade, A | 1 |
| Haastrup, E | 1 |
| Paulson, O | 1 |
| Wetterslev, J | 2 |
| Gluud, C | 2 |
| Gether, U | 2 |
| Kessing, L | 1 |
| Kasckow, J | 1 |
| Lanouette, N | 1 |
| Patterson, T | 1 |
| Fellows, I | 1 |
| Golshan, S | 1 |
| Solorzano, E | 1 |
| Strohmaier, J | 3 |
| Rajewska-Rager, A | 1 |
| Deliyannides, RA | 1 |
| Quitkin, FM | 2 |
| Szczepankiewicz, A | 2 |
| Gunasinghe, C | 1 |
| Gray, J | 1 |
| Campbell, D | 1 |
| Farmer, AE | 2 |
| Marais, L | 1 |
| Hattingh, SM | 1 |
| Stein, DJ | 3 |
| Daniels, WM | 1 |
| Schirman, S | 1 |
| Melhem, N | 1 |
| Pick, N | 1 |
| Gothelf, D | 1 |
| Muthén, B | 1 |
| Jaracz, J | 1 |
| Culang, ME | 2 |
| Sneed, JR | 2 |
| Rutherford, BR | 2 |
| Bruggisser, M | 1 |
| Rätz Bravo, A | 1 |
| Bodmer, M | 1 |
| Martins-de-Souza, D | 1 |
| Harris, LW | 1 |
| Guest, PC | 1 |
| Turck, CW | 1 |
| Bahn, S | 1 |
| McCabe, C | 1 |
| Mishor, Z | 1 |
| Cowen, PJ | 4 |
| Harmer, CJ | 3 |
| Schuhmacher, A | 1 |
| Jessen, F | 1 |
| Höfels, S | 1 |
| von Widdern, O | 1 |
| Metten, M | 1 |
| Pfeiffer, U | 1 |
| Hanses, C | 1 |
| Scheef, L | 1 |
| Block, W | 1 |
| Schild, HH | 1 |
| Schwab, SG | 1 |
| Bella, R | 1 |
| Pennisi, G | 1 |
| Cantone, M | 1 |
| Palermo, F | 1 |
| Pennisi, M | 1 |
| Lanza, G | 1 |
| Zappia, M | 1 |
| Paolucci, S | 1 |
| Boulenger, JP | 1 |
| Hermes, A | 1 |
| Huusom, AK | 2 |
| Weiller, E | 1 |
| Andersen, CL | 1 |
| Videbech, P | 1 |
| Bari, A | 1 |
| Theobald, DE | 1 |
| Caprioli, D | 1 |
| Mar, AC | 1 |
| Aidoo-Micah, A | 1 |
| Dalley, JW | 1 |
| Robbins, TW | 1 |
| Williamson, E | 1 |
| Scahill, L | 1 |
| Sharma, DD | 3 |
| Kumar, R | 2 |
| Ng, MY | 2 |
| Zagar, T | 1 |
| Jerman, B | 2 |
| Cohen-Woods, S | 2 |
| Pirlo, K | 1 |
| Butler, AW | 1 |
| Muglia, P | 1 |
| Barnes, MR | 1 |
| Lathrop, M | 1 |
| Breen, G | 2 |
| Schneeweiss, S | 2 |
| Patrick, AR | 2 |
| Solomon, DH | 2 |
| Dormuth, CR | 1 |
| Miller, M | 2 |
| Mehta, J | 2 |
| Lee, JC | 2 |
| Wang, PS | 2 |
| Dormuth, C | 1 |
| Hollingworth, SA | 1 |
| Burgess, PM | 1 |
| Whiteford, HA | 1 |
| Agius, M | 4 |
| Gardner, J | 3 |
| Liu, K | 3 |
| Zaman, R | 4 |
| Davis, A | 1 |
| Gilhooley, M | 1 |
| Becchi, S | 1 |
| Piubelli, C | 1 |
| Mallei, A | 1 |
| Giambelli, R | 1 |
| Razzoli, M | 1 |
| Popoli, M | 1 |
| Domenici, E | 2 |
| Schnitker, J | 2 |
| Flürenbrock, W | 1 |
| Wagner, G | 1 |
| Koch, K | 1 |
| Schachtzabel, C | 1 |
| Sobanski, T | 1 |
| Reichenbach, JR | 1 |
| Sauer, H | 1 |
| Schlösser, RG | 1 |
| Anderson, IM | 1 |
| Juhasz, G | 1 |
| Thomas, E | 1 |
| Downey, D | 1 |
| McKie, S | 1 |
| Deakin, JF | 2 |
| Elliott, R | 1 |
| Rodríguez Vega, B | 1 |
| Palao, A | 1 |
| Torres, G | 1 |
| Hospital, A | 1 |
| Benito, G | 1 |
| Pérez, E | 1 |
| Dieguez, M | 1 |
| Castelo, B | 1 |
| Bayón, C | 1 |
| Keers, R | 1 |
| Osatuke, K | 1 |
| Reid, M | 1 |
| Stiles, WB | 1 |
| Kasckow, JW | 1 |
| Mohamed, S | 1 |
| Franco, CC | 1 |
| Castro-Prado, J | 1 |
| Rosada, LJ | 1 |
| Sant'Anna, JR | 1 |
| Castro-Prado, MA | 1 |
| Bosker, FJ | 2 |
| Tanke, MA | 1 |
| Jongsma, ME | 1 |
| Cremers, TI | 2 |
| Jagtman, E | 1 |
| Pietersen, CY | 1 |
| van der Hart, MG | 1 |
| Gladkevich, AV | 1 |
| Kema, IP | 1 |
| Westerink, BH | 2 |
| Korf, J | 1 |
| den Boer, JA | 1 |
| Benton, T | 2 |
| Lynch, K | 1 |
| Tustin, NB | 2 |
| Ping Lai, J | 1 |
| Metzger, DS | 1 |
| Blume, J | 1 |
| Dew, MA | 1 |
| Martire, LM | 1 |
| Miller, MD | 1 |
| Cyranowski, JM | 1 |
| Lenze, E | 1 |
| Whyte, EM | 1 |
| Mulsant, BH | 2 |
| Pollock, BG | 3 |
| Karp, JF | 1 |
| Gildengers, A | 1 |
| Szanto, K | 1 |
| Dombrovski, AY | 1 |
| Andreescu, C | 1 |
| Butters, MA | 1 |
| Morse, JQ | 1 |
| Houck, PR | 1 |
| Bensasi, S | 1 |
| Mazumdar, S | 1 |
| Stack, JA | 1 |
| Frank, E | 2 |
| Paya-Cano, J | 1 |
| Binder, E | 1 |
| Sluyter, F | 1 |
| Craig, IW | 2 |
| Sanglier, T | 1 |
| Milea, D | 1 |
| Saragoussi, D | 1 |
| Toumi, M | 1 |
| Cassimjee, N | 1 |
| Fouche, JP | 1 |
| Burnett, M | 1 |
| Lochner, C | 1 |
| Warwick, J | 1 |
| Dupont, P | 1 |
| Cloete, KJ | 1 |
| Carey, PD | 1 |
| Seitz, DP | 1 |
| Gill, SS | 1 |
| Conn, DK | 1 |
| Kuk, AY | 1 |
| Li, J | 1 |
| Mulligan, J | 2 |
| Craddock, N | 1 |
| Ikeda, M | 1 |
| Grozeva, D | 1 |
| Mason, V | 2 |
| Sharp, D | 2 |
| Tallon, D | 2 |
| Thomas, L | 2 |
| Fayssoil, A | 1 |
| Issi, J | 1 |
| Guerbaa, M | 1 |
| Raynaud, JC | 1 |
| Heroguelle, V | 1 |
| Göder, R | 1 |
| Seeck-Hirschner, M | 1 |
| Stingele, K | 1 |
| Huchzermeier, C | 1 |
| Kropp, C | 1 |
| Palaschewski, M | 1 |
| Aldenhoff, J | 1 |
| Koch, J | 1 |
| Mohammed, R | 1 |
| Norton, J | 1 |
| Geraci, SA | 1 |
| Newman, DB | 1 |
| Koch, CA | 2 |
| Singer, A | 1 |
| Schmidt, M | 1 |
| Hauke, W | 1 |
| Stade, K | 1 |
| Warner-Schmidt, JL | 1 |
| Vanover, KE | 1 |
| Chen, EY | 1 |
| Marshall, JJ | 1 |
| Greengard, P | 1 |
| Bobo, WV | 1 |
| Chen, H | 1 |
| Kurian, BT | 1 |
| Husain, MM | 2 |
| Cook, IA | 1 |
| Kornstein, SG | 1 |
| Shelton, RC | 1 |
| Rapaport, MH | 2 |
| Howland, R | 1 |
| Dording, C | 1 |
| Schettler, PJ | 1 |
| Mischoulon, D | 1 |
| Sharma, R | 1 |
| Melas, PA | 1 |
| Rogdaki, M | 1 |
| Lennartsson, A | 1 |
| Björk, K | 1 |
| Qi, H | 1 |
| Witasp, A | 1 |
| Werme, M | 1 |
| Svenningsson, P | 1 |
| Lavebratt, C | 1 |
| Wolkowitz, OM | 1 |
| Wolf, J | 1 |
| Shelly, W | 1 |
| Rosser, R | 1 |
| Burke, HM | 1 |
| Lerner, GK | 1 |
| Reus, VI | 1 |
| Nelson, JC | 2 |
| Epel, ES | 1 |
| Mellon, SH | 1 |
| Browning, M | 1 |
| Grol, M | 1 |
| Ly, V | 1 |
| Goodwin, GM | 2 |
| Holmes, EA | 1 |
| Sotiropoulos, I | 1 |
| Pitychoutis, PM | 1 |
| Almeida, OF | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Kupfer, DJ | 1 |
| Rucci, P | 1 |
| Lotz-Wallace, M | 1 |
| Levenson, J | 1 |
| Fournier, J | 1 |
| Kraemer, HC | 1 |
| Tecco, J | 1 |
| Monreal, J | 1 |
| Staner, L | 1 |
| Zhong, H | 1 |
| Haddjeri, N | 1 |
| Joseph, NT | 1 |
| Myers, HF | 1 |
| Schettino, JR | 1 |
| Olmos, NT | 1 |
| Bingham-Mira, C | 1 |
| Poland, RE | 1 |
| Friedman, ES | 1 |
| Davis, LL | 1 |
| Bschor, T | 1 |
| Ising, M | 1 |
| Erbe, S | 1 |
| Winkelmann, P | 1 |
| Ritter, D | 1 |
| Uhr, M | 1 |
| Lewitzka, U | 1 |
| Brody, BL | 1 |
| Field, LC | 1 |
| Roch-Levecq, AC | 1 |
| Moutier, CY | 1 |
| Edland, SD | 1 |
| Brown, SI | 1 |
| Talarowska, M | 1 |
| Zboralski, K | 2 |
| Chamielec, M | 1 |
| Gałecki, P | 2 |
| Jiang, W | 1 |
| Velazquez, EJ | 1 |
| Samad, Z | 1 |
| Kuchibhatla, M | 1 |
| Martsberger, C | 1 |
| Rogers, J | 1 |
| Williams, R | 1 |
| Kuhn, C | 1 |
| Ortel, TL | 1 |
| Becker, RC | 1 |
| Pristera, N | 1 |
| Krishnan, R | 1 |
| O'Connor, CM | 1 |
| Wiles, NJ | 1 |
| Bould, H | 1 |
| Potokar, J | 1 |
| Nutt, DJ | 2 |
| Abo, R | 1 |
| Hebbring, S | 1 |
| Ji, Y | 1 |
| Zhu, H | 1 |
| Zeng, ZB | 1 |
| Batzler, A | 1 |
| Jenkins, GD | 1 |
| Biernacka, J | 1 |
| Snyder, K | 1 |
| Drews, M | 1 |
| Fiehn, O | 1 |
| Fridley, B | 1 |
| Schaid, D | 1 |
| Kamatani, N | 1 |
| Nakamura, Y | 1 |
| Kubo, M | 1 |
| Mushiroda, T | 1 |
| Kaddurah-Daouk, R | 1 |
| Mrazek, DA | 1 |
| Weinshilboum, RM | 1 |
| Padala, PR | 1 |
| Padala, KP | 1 |
| Monga, V | 1 |
| Ramirez, DA | 1 |
| Sullivan, DH | 1 |
| Colotto, M | 1 |
| Vinci, F | 1 |
| Vo Hong, N | 1 |
| Raimo, O | 1 |
| Castello, A | 1 |
| Carnovale, A | 1 |
| Paciaroni, A | 1 |
| Coletta, P | 1 |
| Mandrioli, R | 1 |
| Mercolini, L | 1 |
| Saracino, MA | 1 |
| Raggi, MA | 1 |
| Vander Wal, JS | 1 |
| Gang, CH | 1 |
| Griffing, GT | 1 |
| Gadde, KM | 1 |
| Laux, G | 1 |
| Friede, M | 1 |
| Müller, WE | 2 |
| Winkel, P | 1 |
| Kessing, LV | 1 |
| Song, HR | 1 |
| Jung, YE | 1 |
| Wang, HR | 1 |
| Woo, YS | 1 |
| Jun, TY | 1 |
| Bahk, WM | 1 |
| Strong, DR | 1 |
| Brown, RA | 1 |
| Sims, M | 1 |
| Herman, DS | 1 |
| Anderson, BJ | 1 |
| Stein, MD | 1 |
| Perlis, RH | 2 |
| D'Erme, AM | 1 |
| Zanieri, F | 1 |
| Campolmi, E | 1 |
| Santosuosso, U | 1 |
| Betti, S | 1 |
| Agnoletti, AF | 1 |
| Cossidente, A | 1 |
| Lotti, T | 1 |
| Dimatelis, JJ | 1 |
| Russell, VA | 1 |
| Powell, TR | 1 |
| Heffernan, AL | 1 |
| Lawrence, T | 1 |
| Price, T | 1 |
| Danese, A | 1 |
| Lewis, C | 1 |
| Tansey, KE | 1 |
| D'Souza, UM | 1 |
| Farrokhi, F | 1 |
| Hosseini, SH | 1 |
| Espahbodi, F | 1 |
| Mirzadeh Goudarzi, SM | 1 |
| Hetrick, SE | 1 |
| McKenzie, JE | 1 |
| Cox, GR | 1 |
| Simmons, MB | 1 |
| Merry, SN | 1 |
| Lai, CH | 1 |
| Shahani, L | 1 |
| Parker, G | 2 |
| Paterson, A | 2 |
| Blanch, B | 2 |
| Hadzi-Pavlovic, D | 1 |
| Sheppard, E | 1 |
| Manicavasagar, V | 1 |
| Synnott, H | 1 |
| Graham, RK | 1 |
| Friend, P | 1 |
| Gilfillan, D | 1 |
| Perich, T | 1 |
| Rostami, Z | 1 |
| Einollahi, B | 1 |
| Diler, RS | 1 |
| Ladouceur, CD | 1 |
| Segreti, A | 1 |
| Almeida, JR | 1 |
| Birmaher, B | 1 |
| Axelson, DA | 1 |
| Phillips, ML | 1 |
| Pan, LA | 1 |
| Licht, RW | 1 |
| van den Brink, RH | 1 |
| van Melle, JP | 2 |
| Honig, A | 2 |
| Schene, AH | 2 |
| Crijns, HJ | 1 |
| Lambert, FP | 1 |
| Ormel, J | 2 |
| Tanghøj, P | 5 |
| Andersen, HF | 2 |
| Overø, K | 2 |
| Mulert, C | 1 |
| Juckel, G | 1 |
| Augustin, H | 1 |
| Hegerl, U | 1 |
| Pandya, R | 1 |
| Patten, S | 1 |
| Baumgartner, JL | 1 |
| Emslie, GJ | 1 |
| Crismon, ML | 1 |
| Salloway, S | 1 |
| Correia, S | 1 |
| Boyle, P | 1 |
| Malloy, P | 1 |
| Schneider, L | 1 |
| Sackheim, H | 1 |
| Roose, S | 1 |
| Krishnan, KR | 2 |
| Trivedi, M | 2 |
| Lu, NZ | 1 |
| Eshleman, AJ | 1 |
| Janowsky, A | 1 |
| Bethea, CL | 1 |
| Soares, CN | 1 |
| Poitras, JR | 1 |
| Prouty, J | 1 |
| Alexander, AB | 1 |
| Shifren, JL | 1 |
| Cohen, LS | 1 |
| Levenson, JL | 1 |
| Hendrick, V | 1 |
| Stowe, ZN | 1 |
| Altshuler, LL | 1 |
| Hwang, S | 1 |
| Lee, E | 1 |
| Haynes, D | 1 |
| Calabrese, JR | 1 |
| Londborg, PD | 1 |
| Shelton, MD | 1 |
| Montastruc, JL | 1 |
| Schmitt, L | 1 |
| Bagheri, H | 1 |
| Litvintsev, SV | 1 |
| Marchenko, AA | 1 |
| Arbuzov, AL | 1 |
| Reznik, AM | 1 |
| Mironychev, GN | 1 |
| Paclt, I | 1 |
| Slavícek, J | 1 |
| Dohnalová, A | 1 |
| Kitzlerová, E | 1 |
| Pisvejcová, K | 1 |
| Lepola, UM | 1 |
| Loft, H | 2 |
| Reines, EH | 1 |
| Benedetti, F | 1 |
| Colombo, C | 1 |
| Pontiggia, A | 1 |
| Bernasconi, A | 1 |
| Florita, M | 1 |
| Smeraldi, E | 3 |
| Marcos, T | 2 |
| Rami, L | 1 |
| Navarro, V | 2 |
| Gastó, C | 2 |
| Salamero, M | 1 |
| McElroy, SL | 1 |
| Hudson, JI | 1 |
| Malhotra, S | 1 |
| Welge, JA | 1 |
| Nelson, EB | 1 |
| Keck, PE | 1 |
| Richards, S | 1 |
| Umbreit, JN | 1 |
| Fanucchi, MP | 1 |
| Giblin, J | 1 |
| Khuri, F | 1 |
| El-Armouche, A | 1 |
| Zolk, O | 1 |
| Eschenhagen, T | 1 |
| Croom, KF | 1 |
| Plosker, GL | 1 |
| Kalayam, B | 1 |
| Bent-Hansen, J | 2 |
| Lunde, M | 2 |
| Klysner, R | 3 |
| Andersen, M | 3 |
| Solstad, K | 1 |
| Rampello, L | 1 |
| Chiechio, S | 1 |
| Nicoletti, G | 1 |
| Alvano, A | 1 |
| Vecchio, I | 1 |
| Raffaele, R | 1 |
| Malaguarnera, M | 1 |
| Najjar, F | 1 |
| Price, LH | 1 |
| Bose, A | 3 |
| Zheng, H | 1 |
| Bruce, ML | 1 |
| Ten Have, TR | 1 |
| Katz, II | 1 |
| Schulberg, HC | 1 |
| Brown, GK | 1 |
| McAvay, GJ | 1 |
| Pearson, JL | 1 |
| Hirschfeld, RM | 2 |
| Vornik, LA | 1 |
| Hemels, ME | 2 |
| Walter, E | 1 |
| Einarson, TR | 2 |
| López-Torres, E | 1 |
| Lucena, MI | 1 |
| Seoane, J | 1 |
| Verge, C | 1 |
| Andrade, RJ | 1 |
| Wagner, KD | 1 |
| Robb, AS | 1 |
| Findling, RL | 1 |
| Jin, J | 1 |
| Gutierrez, MM | 1 |
| Heydorn, WE | 1 |
| Mahlberg, R | 1 |
| Kunz, D | 1 |
| Sasse, J | 1 |
| Kirchheiner, J | 1 |
| Overlack, M | 1 |
| Davids, E | 1 |
| Gastpar, M | 2 |
| Bothmer, J | 1 |
| Pravin, D | 1 |
| Srinath, S | 1 |
| Girimaji, S | 1 |
| Seshadri, SP | 1 |
| Shelley, NC | 1 |
| Joliat, MJ | 1 |
| Brown, EB | 1 |
| Miner, CM | 1 |
| Bielski, RJ | 1 |
| Ventura, D | 2 |
| Pallanti, S | 2 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Prapotnik, M | 1 |
| Di Pauli, J | 1 |
| Vetter, Z | 1 |
| König, P | 2 |
| Conca, A | 2 |
| Waschgler, R | 1 |
| Sackeim, HA | 1 |
| Alexopoulos, G | 1 |
| Katz, IR | 1 |
| Hakkarainen, H | 1 |
| Holzer, L | 1 |
| Paiva, G | 1 |
| Halfon, O | 1 |
| Aragona, M | 1 |
| Bancheri, L | 1 |
| Perinelli, D | 1 |
| Tarsitani, L | 1 |
| Pizzimenti, A | 1 |
| Conte, A | 1 |
| Inghilleri, M | 1 |
| Yuksel, FV | 1 |
| Tuzer, V | 1 |
| Goka, E | 1 |
| Rocca, P | 1 |
| Calvarese, P | 1 |
| Faggiano, F | 1 |
| Marchiaro, L | 1 |
| Mathis, F | 1 |
| Rivoira, E | 1 |
| Taricco, B | 1 |
| Bogetto, F | 1 |
| Florkowski, A | 1 |
| Pietras, T | 1 |
| Kołodziejska, I | 1 |
| Nowakowski, T | 1 |
| Pawełczyk, A | 1 |
| Pedersen, AG | 1 |
| Malin, P | 1 |
| Wengel, SP | 1 |
| Llorca, PM | 1 |
| Azorin, JM | 1 |
| Despiegel, N | 1 |
| Verpillat, P | 2 |
| Wade, AG | 2 |
| Toumi, I | 1 |
| Solomons, K | 1 |
| Gooch, S | 1 |
| Wong, A | 1 |
| Pákáski, M | 1 |
| Bjelik, A | 1 |
| Hugyecz, M | 1 |
| Kása, P | 1 |
| Janka, Z | 1 |
| Kálmán, J | 1 |
| Miehle, K | 1 |
| Paschke, R | 1 |
| Malling, D | 1 |
| Poulsen, MN | 1 |
| Søgaard, B | 1 |
| Falcone, NP | 1 |
| Nappo, A | 1 |
| Neuteboom, B | 1 |
| Kozian, R | 1 |
| Kulp, W | 1 |
| von der Schulenburg, JM | 1 |
| Greiner, W | 1 |
| Kauffman, RP | 1 |
| Castracane, VD | 1 |
| White, DL | 1 |
| Baldock, SD | 1 |
| Owens, R | 1 |
| Insel, TR | 1 |
| Feth, N | 1 |
| Cattapan-Ludewig, K | 1 |
| Jaquenoud Sirot, E | 1 |
| Voon, V | 1 |
| Lang, AE | 1 |
| Spadone, C | 1 |
| Angst, J | 1 |
| Rao, V | 1 |
| Spiro, JR | 1 |
| Rosenberg, PB | 1 |
| Lee, HB | 1 |
| Rosenblatt, A | 1 |
| Lyketsos, CG | 1 |
| Sakkas, P | 1 |
| Psarros, C | 1 |
| Papadimitriou, GN | 1 |
| Theleritis, CG | 1 |
| Soldatos, CR | 1 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Ravna, AW | 1 |
| Thwaites, JH | 1 |
| Hutchinson, C | 1 |
| Collins, C | 1 |
| Zelefsky, JR | 1 |
| Fine, HF | 1 |
| Rubinstein, VJ | 1 |
| Hsu, IS | 1 |
| Finger, PT | 1 |
| Berlanga, C | 1 |
| Flores-Ramos, M | 1 |
| Chenu, F | 1 |
| Guiard, BP | 1 |
| Bourin, M | 1 |
| Gardier, AM | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Costantini, A | 1 |
| Cairoli, F | 1 |
| Ferrarese, G | 1 |
| Picardi, A | 1 |
| Sternberg, C | 1 |
| Doggrell, SA | 1 |
| Wade, A | 2 |
| Simis, S | 1 |
| Nitrini, R | 1 |
| Bogner, HR | 1 |
| Lin, JY | 1 |
| Morales, KH | 1 |
| Ham, BJ | 1 |
| Lee, BC | 1 |
| Paik, JW | 1 |
| Kang, RH | 1 |
| Choi, MJ | 1 |
| Choi, IG | 1 |
| Lee, MS | 1 |
| Bailly, D | 1 |
| Serrano-Blanco, A | 1 |
| Pinto-Meza, A | 1 |
| Suárez, D | 1 |
| Peñarrubia, MT | 1 |
| Haro, JM | 1 |
| Peiró, AM | 1 |
| Margarit, C | 1 |
| Torra, M | 1 |
| Atan, C | 1 |
| Seçkin, U | 1 |
| Bodur, H | 1 |
| Gutiérrez-Alvarez, AM | 1 |
| Rea, K | 1 |
| Wikström, HV | 1 |
| Hogg, S | 1 |
| Mørk, A | 1 |
| Armstrong, EP | 2 |
| Skrepnek, GH | 2 |
| Haim Erder, M | 2 |
| Greist, JH | 1 |
| Mallinckrodt, CH | 1 |
| Prakash, A | 1 |
| Sambunaris, A | 2 |
| Tollefson, GD | 1 |
| Wohlreich, MM | 1 |
| Rantamäki, T | 1 |
| Hendolin, P | 1 |
| Kankaanpää, A | 1 |
| Mijatovic, J | 1 |
| Piepponen, P | 1 |
| Chao, MV | 1 |
| Männistö, PT | 1 |
| Castrén, E | 1 |
| Aframian, DJ | 1 |
| Bajbouj, M | 1 |
| Gallinat, J | 1 |
| Lang, UE | 1 |
| Hellen, F | 1 |
| Vesper, J | 1 |
| Lisanby, SH | 1 |
| Danker-Hopfe, H | 1 |
| Neu, P | 1 |
| Langer, S | 1 |
| Schmauss, M | 1 |
| Leinonen, E | 3 |
| Niemi, H | 1 |
| DeJong, M | 1 |
| Fombonne, E | 1 |
| Hetrick, S | 1 |
| Merry, S | 1 |
| McKenzie, J | 1 |
| Sindahl, P | 1 |
| Proctor, M | 1 |
| Møller, M | 1 |
| Andersen, G | 3 |
| Gjedde, A | 1 |
| McClintock, SM | 1 |
| Davis, L | 1 |
| Wang, SH | 1 |
| Guo, YJ | 1 |
| Chen, BA | 1 |
| de Jonge, P | 1 |
| Kuyper, AM | 1 |
| Tulner, D | 1 |
| Schins, A | 1 |
| Leggio, GM | 1 |
| Micale, V | 1 |
| Drago, F | 1 |
| Cunningham, MG | 1 |
| Donalds, RA | 1 |
| Carlezon, WA | 1 |
| Hong, S | 1 |
| Kim, DS | 1 |
| Kim, DW | 1 |
| Kim, KS | 1 |
| Canuso, CM | 1 |
| Gharabawi, GM | 1 |
| Bossie, CA | 1 |
| Greenspan, A | 1 |
| Turkoz, I | 1 |
| Reynolds, C | 1 |
| Lai, JP | 1 |
| Metzger, D | 1 |
| Thompson, EH | 1 |
| Pollack, MH | 1 |
| Granet, R | 1 |
| Sutter, S | 1 |
| Castro, DB | 1 |
| Gaynes, BN | 1 |
| Gonzalez, J | 1 |
| Alpert, JE | 1 |
| Kraus, MR | 1 |
| Schäfer, A | 1 |
| Schöttker, K | 1 |
| Keicher, C | 1 |
| Weissbrich, B | 1 |
| Hofbauer, I | 1 |
| Scheurlen, M | 1 |
| Li, D | 1 |
| Gandhi, C | 1 |
| Reed, AL | 1 |
| Happe, HK | 1 |
| Petty, F | 1 |
| Bylund, DB | 1 |
| Rocha, FF | 1 |
| Correa, H | 1 |
| Lage, NV | 1 |
| Moorjani, P | 1 |
| Fagerness, J | 1 |
| Purcell, S | 1 |
| Smoller, JW | 1 |
| Popa, D | 1 |
| Léna, C | 1 |
| Alexandre, C | 1 |
| Adrien, J | 1 |
| Bun'kova, KM | 1 |
| Sonnenberg, CM | 1 |
| Deeg, DJ | 1 |
| Comijs, HC | 1 |
| van Tilburg, W | 1 |
| Beekman, AT | 1 |
| Bigos, KL | 1 |
| Aizenstein, HJ | 1 |
| Fisher, PM | 1 |
| Bies, RR | 1 |
| Hariri, AR | 1 |
| Rottach, KG | 1 |
| Schaner, BM | 1 |
| Kirch, MH | 1 |
| Zivotofsky, AZ | 1 |
| Teufel, LM | 1 |
| Gallwitz, T | 1 |
| Messer, T | 1 |
| Starkstein, SE | 1 |
| Mizrahi, R | 1 |
| Power, BD | 1 |
| Pukadan, D | 1 |
| Antony, J | 1 |
| Mohandas, E | 1 |
| Cyriac, M | 1 |
| Smith, G | 1 |
| Elias, A | 1 |
| Dollfus, S | 1 |
| Larmurier-Montagne, A | 1 |
| Razafimandimby, A | 1 |
| Allio, G | 1 |
| Membrey, JM | 1 |
| Delcroix, N | 1 |
| Etard, O | 1 |
| Jorge, RE | 1 |
| Moser, DJ | 1 |
| Acion, L | 1 |
| Solodkin, A | 1 |
| Small, SL | 1 |
| Fonzetti, P | 1 |
| Hegel, M | 1 |
| Ropert, R | 2 |
| Lôo, H | 3 |
| Gay, C | 2 |
| Pedersen, OL | 2 |
| Kragh-Sørensen, P | 3 |
| Bjerre, M | 1 |
| Overø, KF | 5 |
| Gram, LF | 2 |
| Gottlieb, P | 1 |
| Wandall, T | 1 |
| Gastpar, G | 1 |
| Ofsti, E | 3 |
| Baumann, P | 6 |
| Rochat, B | 2 |
| Robert, P | 1 |
| Vestergaard, K | 2 |
| Lauritzen, LU | 1 |
| Scheen, AJ | 1 |
| Lawrence, KM | 1 |
| Falkowski, J | 1 |
| Jacobson, RR | 1 |
| Horton, RW | 1 |
| Pedersen, V | 1 |
| Rasmussen, C | 1 |
| Rioux, P | 1 |
| Rosenberg, C | 2 |
| Damsbo, N | 2 |
| Fuglum, E | 2 |
| Jacobsen, LV | 1 |
| Horsgård, S | 1 |
| Bryois, C | 1 |
| Ferrero, F | 1 |
| Svestka, J | 2 |
| Cesková, E | 1 |
| Kamenická, V | 1 |
| Buresová, A | 1 |
| Obrovská, V | 1 |
| Synek, O | 1 |
| Vinar, O | 1 |
| Koníková, M | 1 |
| Lauritzen, L | 3 |
| Seifritz, E | 2 |
| Holsboer-Trachsler, E | 2 |
| Hemmeter, U | 2 |
| Rasmussen, JG | 3 |
| Haberthur, F | 1 |
| Pöldinger, W | 1 |
| Luo, H | 1 |
| Richardson, JS | 1 |
| Baettig, D | 2 |
| Bondolfi, G | 2 |
| Montaldi, S | 2 |
| Amey, M | 2 |
| Buchholtz-Hansen, PE | 1 |
| Wang, AG | 1 |
| Moryl, E | 1 |
| Leonard, BE | 1 |
| Mattos, P | 1 |
| Dinan, TG | 1 |
| Djärv, L | 1 |
| Muldoon, C | 1 |
| Gottfries, CG | 5 |
| Fischer, P | 2 |
| Linnet, K | 1 |
| Olesen, OV | 1 |
| Patris, M | 1 |
| Bouchard, JM | 2 |
| Bougerol, T | 1 |
| Charbonnier, JF | 1 |
| Chevalier, JF | 1 |
| Clerc, G | 1 |
| Cyran, C | 1 |
| Van Amerongen, P | 1 |
| Lemming, O | 1 |
| Høpfner Petersen, HE | 3 |
| Nil, R | 3 |
| Souche, A | 1 |
| Lambert, S | 1 |
| Uehlinger, C | 1 |
| Kasas, A | 2 |
| Jonzier-Perey, M | 1 |
| Stage, K | 1 |
| Benazzi, F | 2 |
| Lepola, U | 1 |
| Koponen, H | 2 |
| Lucini, V | 1 |
| Lucca, A | 1 |
| Catalano, M | 1 |
| Lauerma, H | 1 |
| Haffmans, PM | 1 |
| Timmerman, L | 3 |
| Hoogduin, CA | 1 |
| Chautems, C | 1 |
| Bertschy, G | 2 |
| Bouwer, CD | 1 |
| Livingston, MG | 1 |
| Clark, A | 1 |
| Vesely, C | 1 |
| Goessler, R | 1 |
| Ragneskog, H | 1 |
| Eriksson, S | 2 |
| Karlsson, I | 3 |
| Pedersen, L | 1 |
| Adielsson, G | 1 |
| Acton, M | 1 |
| Hesselink, JK | 1 |
| Pinder, R | 1 |
| Panagides, J | 1 |
| Stahl, SM | 4 |
| Carieborg, L | 1 |
| Ohman, R | 2 |
| Norström, A | 1 |
| García-Sevilla, JA | 1 |
| Walzer, C | 1 |
| Busquets, X | 1 |
| Escribá, PV | 1 |
| Balant, L | 1 |
| Guimón, J | 1 |
| Raitasuo, S | 1 |
| Virtanen, H | 1 |
| Raitasuo, J | 1 |
| Power, A | 1 |
| Ekselius, L | 3 |
| von Knorring, L | 3 |
| Eberhard, G | 1 |
| Eckert, A | 1 |
| Reiff, J | 1 |
| Jecker, A | 1 |
| Brändli, H | 1 |
| Morand, J | 1 |
| Vuagniaux, O | 1 |
| Ramseier, F | 1 |
| Kyle, CJ | 1 |
| Petersen, HE | 4 |
| Landén, M | 1 |
| Björling, G | 1 |
| Agren, H | 2 |
| Fahlén, T | 1 |
| Taylor, D | 1 |
| Ellison, Z | 1 |
| Ementon Shaw, L | 1 |
| Wickham, H | 1 |
| Murray, R | 1 |
| Nuijten, MJ | 1 |
| Hardens, M | 1 |
| Souêtre, E | 1 |
| Mendels, J | 2 |
| Kiev, A | 1 |
| Fabre, LF | 1 |
| Koran, LM | 1 |
| Thompson, C | 1 |
| Hägg, S | 1 |
| Carleborg, L | 1 |
| Popik, P | 1 |
| Lippa, AS | 1 |
| Beer, B | 2 |
| Cancro, R | 1 |
| Willetts, J | 1 |
| Lippa, A | 1 |
| Skarstein, J | 1 |
| Behnke, K | 1 |
| Helsdingen, JT | 1 |
| Crow, S | 1 |
| Daly, KA | 1 |
| Fatemi, SH | 1 |
| MacGraw, R | 1 |
| Meller, W | 1 |
| Feighner, JP | 2 |
| Franchini, L | 1 |
| Zanardi, R | 1 |
| Gasperini, M | 1 |
| Ashton, AK | 1 |
| Godderis, J | 1 |
| Augusto De Mendonça Lima, C | 1 |
| Nygaard, H | 1 |
| Simányi, M | 1 |
| Taal, M | 1 |
| Eglin, M | 1 |
| Guelfi, JD | 1 |
| Strub, N | 1 |
| Barak, Y | 1 |
| Kimhi, R | 1 |
| Weizman, R | 1 |
| Parker, NG | 1 |
| Brown, CS | 1 |
| Iakovlev, VA | 1 |
| Belinskiĭ, AV | 1 |
| Dorovskikh, IV | 1 |
| Bengtsson, F | 1 |
| Fernando, AT | 1 |
| Schwader, P | 1 |
| Bonomo, V | 1 |
| Fogliani, AM | 1 |
| Stadtland, C | 1 |
| Erfurth, A | 1 |
| Arolt, V | 1 |
| Markowitz, JS | 1 |
| DeVane, CL | 1 |
| Liston, HL | 1 |
| Terao, T | 1 |
| Van der Does, AJ | 1 |
| Keller, MB | 1 |
| Gorman, JM | 2 |
| Baker, SM | 1 |
| Leon, AC | 1 |
| Blier, P | 1 |
| Culpepper, L | 1 |
| Rosenbaum, JF | 1 |
| Dursun, SM | 1 |
| Devarajan, S | 1 |
| Goodnick, PJ | 1 |
| Hochstrasser, B | 1 |
| Isaksen, PM | 1 |
| Mahnert, FA | 1 |
| Rouillon, F | 1 |
| Pedersen, SF | 1 |
| Swart, JC | 1 |
| König, F | 1 |
| von Hippel, C | 1 |
| Petersdorff, T | 1 |
| Neuhöffer-Weiss, M | 1 |
| Wolfersdorf, M | 1 |
| Kaschka, WP | 1 |
| Hosák, L | 1 |
| Tůma, I | 1 |
| Hanus, H | 1 |
| Straka, L | 1 |
| Verhoeven, WM | 1 |
| Veendrik-Meekes, MJ | 1 |
| Jacobs, GA | 1 |
| van den Berg, YW | 1 |
| Tuinier, S | 1 |
| Papakostas, YG | 1 |
| Markianos, M | 1 |
| Zervas, IM | 1 |
| Theodoropoulou, M | 1 |
| Vaidakis, N | 1 |
| Daras, M | 1 |
| Robinson, MJ | 1 |
| Moreau, X | 1 |
| Jeanningros, R | 1 |
| Mazzola-Pomietto, P | 1 |
| Torres, X | 1 |
| Pintor, L | 1 |
| Taylor, BP | 1 |
| Kremer, C | 1 |
| Bostic, JQ | 1 |
| Prince, J | 1 |
| Brown, K | 1 |
| Place, S | 1 |
| Appelberg, BG | 1 |
| Syvälahti, EK | 1 |
| Koskinen, TE | 1 |
| Mehtonen, OP | 1 |
| Muhonen, TT | 1 |
| Naukkarinen, HH | 1 |
| Peschina, W | 1 |
| Fritzsche, H | 1 |
| Beraus, W | 1 |
| Kleiber, BA | 1 |
| Isbister, GK | 1 |
| Dawson, A | 1 |
| Whyte, IM | 1 |
| Lydiard, RB | 1 |
| Bhagwagar, Z | 1 |
| Whale, R | 1 |
| Zimmerman, M | 1 |
| Breen, RB | 1 |
| Posternak, MA | 1 |
| Farah, A | 1 |
| Michael Lemming, O | 1 |
| Bang Hedegaard, K | 1 |
| Gergel, I | 1 |
| Håkanson, R | 1 |
| Hansen, HL | 1 |
| Pleidrup, E | 1 |
| Poulsen, DL | 1 |
| Cialdella, P | 1 |
| Nyth, AL | 2 |
| Lyby, K | 2 |
| Connor, P | 1 |
| Smedegaard-Andersen, L | 1 |
| Gylding-Sabroe, J | 1 |
| Kristensen, M | 1 |
| Refsum, HE | 1 |
| Syversen, S | 1 |
| Leake, A | 1 |
| Fairbairn, AF | 1 |
| McKeith, IG | 1 |
| Ferrier, IN | 1 |
| Bengtsson, BO | 1 |
| Lundmark, J | 1 |
| Wålinder, J | 1 |
| Vanelle, JM | 1 |
| Poirier, MF | 2 |
| Benkelfat, C | 2 |
| Galinowski, A | 1 |
| Sechter, D | 1 |
| Suzini de Luca, H | 1 |
| de Beurs, P | 2 |
| Tan, BK | 2 |
| Leijnse-Ybema, H | 1 |
| Cohen Stuart, MH | 1 |
| Asberg, M | 1 |
| Eriksson, B | 1 |
| Mårtensson, B | 1 |
| Träskman-Bendz, L | 1 |
| Wägner, A | 1 |
| Ostrow, D | 1 |
| Møller, SE | 1 |
| Leijnse-Ybema, HJ | 1 |
| Stuart, MH | 1 |
| Robinson, ML | 1 |
| Gravem, A | 1 |
| Amthor, KF | 1 |
| Astrup, C | 1 |
| Elgen, K | 1 |
| Gjessing, LR | 1 |
| Gunby, B | 1 |
| Pettersen, RD | 1 |
| Kyrdalen, L | 1 |
| Vaadal, J | 1 |
| Dufour, H | 1 |
| Bouchacourt, M | 1 |
| Thermoz, P | 1 |
| Viala, A | 1 |
| Phak Rop, P | 1 |
| Gouezo, F | 1 |
| Durand, A | 1 |
| Delaunay, J | 1 |
| Delisle, JP | 1 |
| Grasset, N | 1 |
| Mermberg, PF | 1 |
| Molczadzki, M | 1 |
| Pagot, R | 1 |
| Richou, H | 1 |
| Robert, G | 1 |
| Léouffre, P | 1 |
| Shaw, DM | 1 |
| Thomas, DR | 1 |
| Briscoe, MH | 1 |
| Watkins, SE | 1 |
| Crimmins, R | 1 |
| Harris, B | 1 |
| Lovett, J | 1 |
| Raj, M | 1 |
| Lloyd, AT | 1 |
| Osborne, C | 1 |
| Haaber, A | 1 |
| Joyce, CR | 1 |
| Beving, H | 1 |
| Bjerkenstedt, L | 3 |
| Malmgren, R | 1 |
| Olsson, P | 1 |
| Unge, G | 1 |
| de Wilde, J | 1 |
| Mertens, C | 1 |
| Flyckt, L | 2 |
| Lingjaerde, O | 1 |
| Christensen, P | 1 |
| Thomsen, HY | 1 |
| Edman, G | 1 |
| Hagenfeldt, L | 1 |
| Sedvall, G | 1 |
| Wiesel, FA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)[NCT05017311] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| Utility of Plasma Drug Level Monitoring and CYP2C19 Genotyping in Dose Personalization of Escitalopram[NCT05210140] | 148 participants (Anticipated) | Observational | 2020-07-16 | Recruiting | |||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| International Study to Predict Optimised Treatment - in Depression[NCT00693849] | Phase 4 | 2,688 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial[NCT00419471] | Phase 4 | 300 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents.[NCT03894696] | 200 participants (Anticipated) | Observational | 2019-08-01 | Not yet recruiting | |||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Web Based Therapist and Patient Tutorials on Prolonged Grief. Study 2[NCT05575817] | 34 participants (Actual) | Interventional | 2022-10-01 | Active, not recruiting | |||
| Web Based Therapist and Patient Tutorials on Prolonged Grief. Study 1[NCT05121792] | 400 participants (Actual) | Interventional | 2021-10-28 | Completed | |||
| Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)[NCT01179568] | Phase 2 | 395 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Pilot Double-Blind Randomized Placebo-Controlled Crossover Study to Investigate Rapid Antidepressant Effects of Leucine[NCT03079297] | Phase 2 | 16 participants (Actual) | Interventional | 2017-03-09 | Terminated (stopped due to Covid-19) | ||
| Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression[NCT03207438] | Phase 4 | 1,790 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Associations Between Gene-Polymorphisms, Endo-Phenotypes for Depression and Antidepressive Treatment (AGENDA)[NCT00386841] | Phase 4 | 80 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE[NCT02625155] | Phase 4 | 14,000 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.[NCT00296712] | Phase 4 | 55 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| The Effect of Seven-Day Atorvastatin Administration on Emotional Processing, Reward Processing, and Inflammation in Healthy Volunteers[NCT03966859] | 50 participants (Actual) | Interventional | 2019-06-19 | Completed | |||
| Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder - Fear of Harm Phenotype[NCT05209217] | 20 participants (Anticipated) | Observational | 2019-06-04 | Recruiting | |||
| Geriatric Depression: Getting Better, Getting Well[NCT00177294] | Phase 4 | 319 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial[NCT02263872] | Phase 4 | 41 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function[NCT02507219] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Ethnic Variations in Antidepressant Response[NCT00047671] | Phase 4 | 400 participants (Anticipated) | Interventional | 2002-06-30 | Completed | ||
| Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847] | Phase 4 | 127 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Escitalopram Treatment of Night Eating Syndrome: a Randomized Controlled Trial[NCT00636649] | 40 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| Antidepressants During Office-Based Buprenorphine[NCT00475878] | Phase 3 | 147 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Applying Mindfulness-Based Cognitive Therapy to Treatment Resistant Depression[NCT00871299] | 173 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
| Prevention of Suicide in Primary Care Elderly: Collaborative Trial[NCT00279682] | Phase 4 | 1,200 participants | Interventional | 1999-05-31 | Completed | ||
| The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders[NCT03122158] | Phase 4 | 60 participants (Anticipated) | Interventional | 2017-04-08 | Active, not recruiting | ||
| "Investigation of Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Hot and Cold Cognitive Systems In Treatment Resistant Depression (TRD)"[NCT03977038] | 25 participants (Actual) | Observational [Patient Registry] | 2020-05-30 | Completed | |||
| Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression[NCT00073411] | Phase 3 | 675 participants | Interventional | 2003-11-30 | Completed | ||
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-01 | Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment) | ||
| Prevention of Post-Stroke Depression - Treatment Strategy[NCT00071643] | 201 participants (Actual) | Interventional | 2002-09-30 | Completed | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| Depression - Can Vitamin D Alleviate Symptoms of Depression Not Cured by Antidepressants as Well as Alleviate Negative Skeletal Effects Caused by Antidepressants?[NCT01932931] | 71 participants (Actual) | Interventional | 2013-10-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
| Intervention | score change from baseline to wk12 (Mean) |
|---|---|
| Citalopram (CIT) | 18 |
| Placebo (PLA; Sugar Pill) | 16 |
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
| Intervention | score change from baseline to wk20 (Mean) |
|---|---|
| Citalopram (CIT) | 20 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 25 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 26 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
| Intervention | score change from baseline to wk12 (Mean) |
|---|---|
| Citalopram (CIT) | 10 |
| Placebo (PLA; Sugar Pill) | 8 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
| Intervention | score change from baseline to wk20 (Mean) |
|---|---|
| Citalopram (CIT) | 10 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 14 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 16 |
Brief rating scale frequently used in clinical trials. For this study, version modified for complicated grief was be used. Response is defined as a score of 1(very much improved) or 2 (much improved) on the scale. The rating was done by an Independent Evaluator. (NCT01179568)
Timeframe: Weeks 12 and 20
| Intervention | percentage of responders (Number) |
|---|---|
| Citalopram (CIT) | 46 |
| Placebo (PLA; Sugar Pill) | 38 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 84 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 83 |
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
"The Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR), self-report is a 16-item measure of depression severity that includes the 9 criterion symptoms for MDD. Items are scored on a 4-point Likert scale, ranging from 0 to 3 (total score range, 0-27). Totals scores of ≤ 5 indicate no depression; 6-10 indicates mild depression; 11-15 indicates moderate depression; 16-20 indicates severe depression; and ≥ 21 indicates very severe depression. For purposes of this report, severe and very severe categories were combined as severe to very severe depression (≥ 16). The QIDS-A self-report has demonstrated acceptable psychometric properties." (NCT03079297)
Timeframe: Baseline to 14 days
| Intervention | score on a scale (Mean) |
|---|---|
| L-leucine | -6 |
| Maltodextrin | -8 |
"Response criteria defined based on QIDS-SR score at baseline and 14 days after treatment initiation.~The Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR), self-report is a 16-item measure of depression severity that includes the 9 criterion symptoms for MDD. Items are scored on a 4-point Likert scale, ranging from 0 to 3 (total score range, 0-27). Totals scores of ≤ 5 indicate no depression; 6-10 indicates mild depression; 11-15 indicates moderate depression; 16-20 indicates severe depression; and ≥ 21 indicates very severe depression. For purposes of this report, severe and very severe categories were combined as severe to very severe depression (≥ 16). The QIDS-A self-report has demonstrated acceptable psychometric properties." (NCT03079297)
Timeframe: Baseline to 14 days
| Intervention | percentage of patients (Number) |
|---|---|
| L-leucine | 0 |
| Maltodextrin | 50 |
"Remission operationalized as QIDS-SR <=5.~The Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR), self-report is a 16-item measure of depression severity that includes the 9 criterion symptoms for MDD. Items are scored on a 4-point Likert scale, ranging from 0 to 3 (total score range, 0-27). Totals scores of ≤ 5 indicate no depression; 6-10 indicates mild depression; 11-15 indicates moderate depression; 16-20 indicates severe depression; and ≥ 21 indicates very severe depression. For purposes of this report, severe and very severe categories were combined as severe to very severe depression (≥ 16). The QIDS-A self-report has demonstrated acceptable psychometric properties." (NCT03079297)
Timeframe: 14 days
| Intervention | percentage of patients (Number) |
|---|---|
| L-leucine | 0 |
| Maltodextrin | 25 |
"Anhedonia will be measured using Snaith-Hamilton Pleasure Scale (SHAPS).~The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item scale that measures anhedonia, the inability to experience pleasure. The items cover the domains of: social interaction, food and drink, sensory experience, and interest/pastimes. A score of 2 or less constitutes a normal score, while an abnormal score is defined as 3 or more. Each item has four possible responses: strongly disagree, disagree, agree, or strongly agree. Either of the disagree responses score one point, and either of the agree responses score 0 points. Thus, the final score ranges from 0 to 14." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Anhedonia 3 days Change | Anhedonia 7 days Change | Anhedonia 14 days Change | |
| L-leucine | -0.21 | 0.79 | -0.07 |
| Maltodextrin | -0.46 | -1.46 | -2.21 |
"Fatigue will be measured with Multidimensional fatigue inventory~The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue. It contains five scales: general fatigue (items 1, 5, 12, 16), mental fatigue (items 7, 11, 13, 19), physical fatigue (items 2, 8, 14, 20), reduced motivation (items 4, 9, 15, 18) and reduced activity (items 3, 6, 10, 17). Items are scored on a 5-point scale on which the participant expressed the degree to which the statement applied to him or her (from agreement yes, that is true to disagreement no, that is not true) in the previous days. Item scores are summed to create a sum score for each scale, ranging between 4 (best condition) and 20 (worst condition). Higher scores indicate more fatigue." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General fatigue 3 days Change | General fatigue 7 days Change | General fatigue 14 days Change | Mental fatigue 3 days Change | Mental fatigue 7 days Change | Mental fatigue 14 days Change | Physical fatigue 3 days Change | Physical fatigue 7 days Change | Physical fatigue 14 days Change | Reduced motivation 3 days Change | Reduced motivation 7 days Change | Reduced motivation 14 days Change | Reduced activity 3 days Change | Reduced activity 7 days Change | Reduced activity 14 days Change | |
| L-leucine | -1.59 | -3.59 | -0.74 | -2.36 | -1.02 | -3.46 | -3.58 | 0.09 | -2.55 | -.032 | -0.71 | -5.51 | -2.80 | -4.14 | -4.47 |
| Maltodextrin | -0.70 | -3.20 | -3.70 | -0.71 | -4.71 | -3.96 | -0.55 | -1.80 | -3.80 | -0.26 | -1.26 | -2.76 | -0.47 | -3.97 | -8.14 |
"Psychosocial function will be measured using Work and Social Adjustment Scale~The Work and Social Adjustment Scale (WSAS) is a 5-item measure for impairment in functioning. Items are scored on an 8-point scale on how much participants' problems impaired their ability to carry out the activity (from Not at all to Very severely). Item scores are summed to create a sum score. The maximum score of the WSAS is 40, lower scores are better. A WSAS score above 20 appears to suggest moderately severe or worse psychopathology. Scores between 10 and 20 are associated with significant functional impairment but less severe clinical symptomatology. Scores below 10 appear to be associated with subclinical populations." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Psychosocial function 3 days Change | Psychosocial function7 days Change | Psychosocial function 14 days Change | |
| L-leucine | 1.49 | -1.18 | -9.38 |
| Maltodextrin | -2.57 | -7.57 | -7.32 |
"Adverse effect burden will be measured with Frequency Intensity and Burden of Side-effect rating scale (FIBSER).~The Frequency, Intensity, Burden of Side Effects Rating (FIBSER) scale was designed by Dr. Stephen Wisniewski for use in the U.S. STAR*D effectiveness study. It is a 3-item scale to assess side effects from antidepressant treatment. To use the FIBSER in measurement-based care, clinicians should consider item 3 (Burden). If the score is 0 to 2 (None to Mild interference with activities), no change in medication is needed. If the score is 3-4 (Moderate to Marked interference with activites), the side effects need to be addressed (i.e., change in dose, side effect antidote, etc). If the score is 5-6 (Severe interference with activities or Unable to Function), the dose needs to be decreased or the medication needs to be switched." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Adverse effect burden 3 days Change | Adverse effect burden function 7 days Change | Adverse effect burden function 14 days Change | |
| L-leucine | 0 | 0 | 0 |
| Maltodextrin | 0 | 0 | -.25 |
Defined as a 50% score reduction from baseline. (NCT03207438)
Timeframe: Day 4 - Week 6
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Day 4 | Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 1 - Insomnia | 6 | 12 | 31 | 44 | 45 |
| Placebo 1 - No Insomnia | 0 | 1 | 1 | 8 | 5 |
| Quetiapine XR 50mg - Insomnia | 8 | 26 | 42 | 59 | 64 |
| Quetiapine XR 50mg - No Insomnia | 0 | 3 | 8 | 5 | 9 |
Calculated without Item 4 (reduced sleep). (NCT03207438)
Timeframe: Day 4 - Week 6
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Day 4 | Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 1 | 6 | 11 | 28 | 49 | 51 |
| Quetiapine XR 50mg | 6 | 22 | 44 | 57 | 66 |
50% score reduction from baseline calculated without Item 4 (reduced sleep). (NCT03207438)
Timeframe: 1 - 6 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 2 - Melancholic Depression | 26 | 45 | 61 | 64 |
| Placebo 2 - Nonmelancholic Depression | 46 | 100 | 136 | 176 |
| Quetiapine XR 150-300mg - Melancholic Depression | 53 | 90 | 124 | 132 |
| Quetiapine XR 150-300mg - Nonmelancholic Depression | 68 | 179 | 231 | 260 |
MADRS is the Montgomery-Asberg Depression Rating Scale. Total scores on this scale range from 0-60. However the response variable is binary coded (0 = No Response, 1 = Response). (NCT03207438)
Timeframe: 1 - 6 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | |
| Placebo 2 - Melancholic Depression | 28 | 41 | 62 | 64 |
| Placebo 2 - Nonmelancholic Depression | 47 | 100 | 136 | 174 |
| Quetiapine XR 150-300mg - Melancholic Depression | 63 | 105 | 124 | 141 |
| Quetiapine XR 150-300mg - Nonmelancholic Depression | 86 | 195 | 251 | 274 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
Three consecutive weekly scores of less than 7 on the Hamilton Rating Scale for Depression (N=17 item). Scores on the Hamilton Rating Scale for Depression(HRSD) range from 0 to 58, with higher scores indicating more severe depression. (NCT00177294)
Timeframe: Measured at Week 6 or 22
| Intervention | Percentage of participants (Number) |
|---|---|
| Escitalopram Plus Interpersonal Psychotherapy (IPT) | 58 |
| Escitalopram Plus Depression Care Management (DCM) | 45 |
Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen (NCT02507219)
Timeframe: 3-6 weeks
| Intervention | percent signal change (Mean) | |
|---|---|---|
| Left amygdala | Right amygdala | |
| Ibuprofen, 200mg | 0.21 | 0.23 |
| Ibuprofen, 600mg | 0.23 | 0.17 |
| Placebo | 0.20 | 0.23 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6
| Intervention | fmol/mg (Mean) |
|---|---|
| Escitalopram | 139.7 |
| Placebo | 160.4 |
The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 7.4 |
| Placebo | 7.0 |
hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 1.6 |
| Placebo | 1.8 |
Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 9.9 |
| Placebo | 10.3 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
| Intervention | percentage of change (Number) |
|---|---|
| Escitalopram | 45.8 |
| Placebo | 52.5 |
"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks
| Intervention | beats/minute (Mean) |
|---|---|
| Escitalopram | 6.34 |
| Placebo | 9.1 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Escitalopram | 11.4 |
| Placebo | 12.2 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Escitalopram | 19.3 |
| Placebo | 23.6 |
Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 21.4 |
| Placebo | 21.8 |
(NCT00574847)
Timeframe: Baseline to week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 71.9 |
| Placebo | 44.4 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 34.2 |
| Placebo | 17.5 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 66.1 |
| Placebo | 83.9 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | nM (Mean) |
|---|---|
| Escitalopram | 4202.4 |
| Placebo | 210.1 |
STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Trait | State | |
| Escitalopram | 31.2 | 27.9 |
| Placebo | 32.0 | 29.5 |
The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety. Scores range from 0 to 63, with higher scores indicative of higher levels of anxiety. (NCT00636649)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | -1.5 |
| Placebo | -1.8 |
The BDI-II is a 21-item self-report questionnaire designed to measure cognitive, somatic, and behavioral aspects of depression. Scores range from 0 to 63, with higher scores indicating a higher level of depressive symptoms. (NCT00636649)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | -2.4 |
| Placebo | -3.5 |
(NCT00636649)
Timeframe: Baseline, 12 Week
| Intervention | mg/dL (Mean) |
|---|---|
| Escitalopram | 3.9 |
| Placebo | 7.6 |
The Perceived Stress Scale (PSS) measures the overall level of stress. This instrument contains 14 items accessing overall appraisals of stress in the past month. Minimum score (best value)=0. Maximum score (worst value)=56. A higher score indicates greater stress. (NCT00636649)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.55 |
| Escitalopram | -2.11 |
(NCT00636649)
Timeframe: Baseline, 12 week
| Intervention | kg (Mean) |
|---|---|
| Escitalopram | -0.43 |
| Placebo | 1.12 |
The Night Eating Questionnaire (NEQ) is a 14-item self-report scale designed to assess the symptoms of NES including nocturnal ingestions, evening hyperphagia, morning anorexia, and mood/sleep. Scores range from 0-56, with higher scores indicative of greater severity. The NEQ has an acceptable internal consistency reliability (.70). A cut-score of 25 has been shown to yield a positive predictive value of .62. (NCT00636649)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | -13.0 |
| Placebo | -10.6 |
The Night Eating Questionnaire (NEQ) is a 14 item self-report scale designed to assess the symptoms of NES including nocturnal ingestions, evening hypcrphagia, morning anorexia, and mood/slccp. Scores range from 0 to 56, with higher scores indicative of greater severity. (NCT00636649)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Escitalopram | 7 |
| Placebo | 6 |
The Night Eating Syndrome History and Inventory (NESHI) is an unpublished, semistructured interview used to confirm a diagnosis of NES. It assesses a typical 24-hour food intake, including a recall of all meals and snacks, and sleeping patterns. Based on the recall of all meals and snacks, the interviewer judged whether ≥25% of the daily caloric intake was eaten after the evening meal and how often nocturnal ingestions occurred. The NEQ items were reviewed and informed by the dietary recall during the interview, and a new total score was tallied. A final score of ≥25 for the NEQ items, as reviewed during the NESHI, was used as the criterion for NES. (NCT00636649)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Escitalopram | 16 |
| Placebo | 12 |
The CGI-I scale is a clinician rating of overall therapeutic effect ranging from 1 (very much improved) to 7 (very much worse) since commencing treatment. (NCT00636649)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Escitalopram | 12 |
| Placebo | 7 |
TASK = task-oriented coping; EMOT = emotion-oriented coping; AVD = avoidance-focused coping; Avoidance-focused coping may be divided into two subtypes: DIS = distraction-oriented coping; SOC = social diversion-oriented coping. CISS is a 48 item self-report measure used to measure responses to stressful situations rated for frequency on a 5 point Likert scales ranging from1, not at all to 5, very much. This measure assesses three coping styles: Task-Oriented, Emotion-Oriented, and two types of Avoidance-Oriented coping (Social Diversion and Distraction). There are 16 items on each of the primary scales (task, emotion, avoidance) and 5 on social diversion and 8 on distraction. Scores are summed for each subscale and then converted to gender-corrected t-scores with a mean of 50 and a standard deviation of 10. T-scores on the CISS range from a low of 25 (1st percentile) to 75 (99th percentile). Higher scores indicate more adaptive levels of coping. (NCT00636649)
Timeframe: Baseline, 12 weeks
| Intervention | t-scores (Mean) | ||||
|---|---|---|---|---|---|
| CISS-TASK | CISS-EMOT | CISS-AVD | CISS-DIS | CISS-SOC | |
| Escitalopram | 1.75 | -1.45 | 2.60 | 1.95 | 2.15 |
| Placebo | 2.35 | 1.25 | 0 | 3.40 | -2.45 |
(NCT00636649)
Timeframe: Baseline,12 weeks
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| HDL | LDL | Triglycerides | total cholesterol | |
| Escitalopram | -2.8 | -3.9 | 27.5 | -4.5 |
| Placebo | -2.2 | 2.8 | -14.0 | -2.3 |
"The TFEQ (also known as the Eating Inventory) measures dimensions of eating behavior including cognitive restraint of eating, disinhibition, and hunger using a combination of dichotomous questions, 4-point likert scales, and one 5-point likert scale. Restraint is comprised of the responses to 21 questions with possible scores ranging from 0 to 21 (Low scores for all scales indicate an uninhibited eating behavior.). Disinhibition is comprised of the responses to 16 questions with possible scores ranging from 0 to 16 (High scores indicate an uninhibited eating behavior strongly depending on external cues). Hunger is comprised of the responses to 14 questions with possible scores ranging from 0 to 14 ( Low scores indicate an eating behavior strongly depending on feelings of hunger.).~RES = Restraint Subscale; DIS = Disinhibition Subscale; HUN = Hunger Subscale" (NCT00636649)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| TFEQ-RES | TFEQ-DIS | TFEQ-HUN | |
| Escitalopram | 1.85 | -1.50 | -1.75 |
| Placebo | 2.95 | -0.85 | -1.60 |
Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms. (NCT00475878)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| 10 mg Escitalopram | 12.31 |
| Placebo | 11.35 |
Drop-out is defined as 7 or more days of missed Buprenorphine doses (NCT00475878)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| 10 mg Escitalopram | 33.3 |
| Placebo | 44.0 |
63 reviews available for citalopram and Depressive Disorder
| Article | Year |
|---|---|
Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Ketamine; Male; Middl | 2020 |
Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Ketamine; Male; Middl | 2020 |
Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder.
Topics: Adult; Antidepressive Agents; Body Weight; Citalopram; Depressive Disorder; Humans; Nortriptyline | 2020 |
Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder.
Topics: Adult; Antidepressive Agents; Body Weight; Citalopram; Depressive Disorder; Humans; Nortriptyline | 2020 |
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Desven | 2020 |
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Desven | 2020 |
Use of tramadol in psychiatric care: A comprehensive review and report of two cases.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder | 2017 |
Use of tramadol in psychiatric care: A comprehensive review and report of two cases.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder | 2017 |
Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Cytokines; Depressive Disorder; Double-Blind Method; Female; Hu | 2018 |
Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Cytokines; Depressive Disorder; Double-Blind Method; Female; Hu | 2018 |
Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2017 |
Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2017 |
Mania following antidepressant discontinuation in depression: two case reports.
Topics: Aged; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Bipolar Diso | 2017 |
Mania following antidepressant discontinuation in depression: two case reports.
Topics: Aged; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Bipolar Diso | 2017 |
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalo | 2019 |
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalo | 2019 |
[If the general practitioner has to decide: what is the evidence for the selection of antidepressants?].
Topics: Acetamides; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Duloxetine Hydroc | 2014 |
[If the general practitioner has to decide: what is the evidence for the selection of antidepressants?].
Topics: Acetamides; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Duloxetine Hydroc | 2014 |
A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; China; Citalopram; Depressive Disorder; Dou | 2014 |
A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; China; Citalopram; Depressive Disorder; Dou | 2014 |
Serum DHEAS levels are associated with the development of depression.
Topics: Adult; Age Factors; Aged; Biomarkers; Case-Control Studies; Citalopram; Dehydroepiandrosterone Sulfa | 2015 |
Serum DHEAS levels are associated with the development of depression.
Topics: Adult; Age Factors; Aged; Biomarkers; Case-Control Studies; Citalopram; Dehydroepiandrosterone Sulfa | 2015 |
Are SNRIs more effective than SSRIs? A review of the current state of the controversy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Depressiv | 2008 |
Are SNRIs more effective than SSRIs? A review of the current state of the controversy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Depressiv | 2008 |
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Majo | 2009 |
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Majo | 2009 |
Quality of life measurement in antidepressant trials. Is there an added value?
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2009 |
Quality of life measurement in antidepressant trials. Is there an added value?
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2009 |
Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Bias; Citalopram; Depressive Disorder; Female; Human | 2010 |
Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Bias; Citalopram; Depressive Disorder; Female; Human | 2010 |
Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.
Topics: Allosteric Regulation; Animals; Antidepressive Agents, Second-Generation; Citalopram; Depressive Dis | 2012 |
Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.
Topics: Allosteric Regulation; Animals; Antidepressive Agents, Second-Generation; Citalopram; Depressive Dis | 2012 |
[Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art].
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Dyslipidemi | 2012 |
[Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art].
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Dyslipidemi | 2012 |
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Topics: Benzofurans; Citalopram; Depressive Disorder; Drug Monitoring; Fluoxetine; Fluvoxamine; Humans; Indo | 2012 |
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Topics: Benzofurans; Citalopram; Depressive Disorder; Drug Monitoring; Fluoxetine; Fluvoxamine; Humans; Indo | 2012 |
Newer generation antidepressants for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Induc | 2012 |
Newer generation antidepressants for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Induc | 2012 |
Escitalopram: efficacy and tolerability in the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Humans | 2002 |
Escitalopram: efficacy and tolerability in the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Humans | 2002 |
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Topics: Antidepressive Agents; Antiparkinson Agents; Bromocriptine; Citalopram; Depressive Disorder; Dopamin | 2003 |
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Topics: Antidepressive Agents; Antiparkinson Agents; Bromocriptine; Citalopram; Depressive Disorder; Dopamin | 2003 |
[Citalopram].
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Panic Di | 2003 |
[Citalopram].
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Panic Di | 2003 |
Escitalopram: a pharmacoeconomic review of its use in depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Depressive Disorder; Dr | 2003 |
Escitalopram: a pharmacoeconomic review of its use in depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Depressive Disorder; Dr | 2003 |
Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Duloxetine Hydrochloride; Humans; Placebos; Ra | 2004 |
Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Duloxetine Hydrochloride; Humans; Placebos; Ra | 2004 |
[Escitalopram: a chiral agent for treatment of depression].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Stereoisomerism | 2004 |
[Escitalopram: a chiral agent for treatment of depression].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Stereoisomerism | 2004 |
Evidence based review of escitalopram in treating major depressive disorder in primary care.
Topics: Adult; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Evidence-Based Medicine; F | 2004 |
Evidence based review of escitalopram in treating major depressive disorder in primary care.
Topics: Adult; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Evidence-Based Medicine; F | 2004 |
Escitalopram and suicidality in adult depression and anxiety.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Databases, Factual; Depress | 2005 |
Escitalopram and suicidality in adult depression and anxiety.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Databases, Factual; Depress | 2005 |
Escitalopram: better treatment for depression is through the looking glass.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials as Topic; D | 2004 |
Escitalopram: better treatment for depression is through the looking glass.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials as Topic; D | 2004 |
Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Double-Blind Metho | 2005 |
Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Double-Blind Metho | 2005 |
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Humans; Randomized Cont | 2006 |
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Humans; Randomized Cont | 2006 |
Managing depressive and anxiety disorders with escitalopram.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive D | 2006 |
Managing depressive and anxiety disorders with escitalopram.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive D | 2006 |
Three-dimensional models of neurotransmitter transporters and their interactions with cocaine and S-citalopram.
Topics: Antidepressive Agents; Citalopram; Cocaine; Depressive Disorder; Models, Molecular; Neurotransmitter | 2006 |
Three-dimensional models of neurotransmitter transporters and their interactions with cocaine and S-citalopram.
Topics: Antidepressive Agents; Citalopram; Cocaine; Depressive Disorder; Models, Molecular; Neurotransmitter | 2006 |
Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Majo | 2006 |
Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Majo | 2006 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Chil | 2006 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Chil | 2006 |
Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Parox | 2007 |
Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Parox | 2007 |
Anxious depression and response to treatment.
Topics: Anxiety Disorders; Citalopram; Comorbidity; Depressive Disorder; Humans; Meta-Analysis as Topic; Psy | 2008 |
Anxious depression and response to treatment.
Topics: Anxiety Disorders; Citalopram; Comorbidity; Depressive Disorder; Humans; Meta-Analysis as Topic; Psy | 2008 |
Antidepressant therapy in post-stroke depression.
Topics: Antidepressive Agents; Citalopram; Controlled Clinical Trials as Topic; Depressive Disorder; Humans; | 2008 |
Antidepressant therapy in post-stroke depression.
Topics: Antidepressive Agents; Citalopram; Controlled Clinical Trials as Topic; Depressive Disorder; Humans; | 2008 |
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Topics: 1-Naphthylamine; Animals; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Fluoxetin | 1995 |
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Topics: 1-Naphthylamine; Animals; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Fluoxetin | 1995 |
Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram.
Topics: Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Meta-Analysis as Topic; R | 1995 |
Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram.
Topics: Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Meta-Analysis as Topic; R | 1995 |
The optimal dosing regimen for citalopram--a meta-analysis of nine placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Clinical Trials as Topic; Depressive Disorde | 1994 |
The optimal dosing regimen for citalopram--a meta-analysis of nine placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Clinical Trials as Topic; Depressive Disorde | 1994 |
A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Humans | 1993 |
A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Humans | 1993 |
New approaches to the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Brain; Bupropion; Citalopram; Cyclohexanols; Depressive Di | 1996 |
New approaches to the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Brain; Bupropion; Citalopram; Cyclohexanols; Depressive Di | 1996 |
Does selectivity matter?
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhibit | 1996 |
Does selectivity matter?
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhibit | 1996 |
Serotonin: current understanding and the way forward.
Topics: Antidepressive Agents; Central Nervous System; Citalopram; Depressive Disorder; Humans; Receptors, S | 1996 |
Serotonin: current understanding and the way forward.
Topics: Antidepressive Agents; Central Nervous System; Citalopram; Depressive Disorder; Humans; Receptors, S | 1996 |
The antidepressant efficacy of citalopram.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depre | 1996 |
The antidepressant efficacy of citalopram.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depre | 1996 |
The safety and tolerability of citalopram.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorde | 1996 |
The safety and tolerability of citalopram.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorde | 1996 |
Scandinavian experience with citalopram in the elderly.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Dementia; Depressive Disorder; Dopamine; Human | 1996 |
Scandinavian experience with citalopram in the elderly.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Dementia; Depressive Disorder; Dopamine; Human | 1996 |
Development of new antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi | 1997 |
Development of new antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi | 1997 |
Recognition and management of depression in the elderly.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Psychiatric Status Rating Scal | 1997 |
Recognition and management of depression in the elderly.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Psychiatric Status Rating Scal | 1997 |
[Medical interactions with antidepressives. Benefits of the specific serotonin reuptake inhibitor citalopram].
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interac | 1998 |
[Medical interactions with antidepressives. Benefits of the specific serotonin reuptake inhibitor citalopram].
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interac | 1998 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxet | 1999 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxet | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Preclinical pharmacology of citalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Citalopram; Depressive Disorder; Drug Eval | 1999 |
Preclinical pharmacology of citalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Citalopram; Depressive Disorder; Drug Eval | 1999 |
Clinical development of citalopram.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents, Second-Generation; Citalopram; Clinical Tri | 1999 |
Clinical development of citalopram.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents, Second-Generation; Citalopram; Clinical Tri | 1999 |
Citalopram in the treatment of depression.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Controlled Clinical Trials as Topic; Cytochrome P-450 | 2000 |
Citalopram in the treatment of depression.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Controlled Clinical Trials as Topic; Cytochrome P-450 | 2000 |
Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Comorb | 2000 |
Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Comorb | 2000 |
Evidence of early onset of antidepressant effect in randomized controlled trials.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; | 2001 |
Evidence of early onset of antidepressant effect in randomized controlled trials.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; | 2001 |
Clinical significance of monitoring early symptom change to predict outcome.
Topics: Algorithms; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Mental Disorders; Pip | 2001 |
Clinical significance of monitoring early symptom change to predict outcome.
Topics: Algorithms; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Mental Disorders; Pip | 2001 |
Using treatment algorithms for the effective management of treatment-resistant depression.
Topics: Algorithms; Antidepressive Agents; Citalopram; Critical Pathways; Decision Support Techniques; Depre | 2001 |
Using treatment algorithms for the effective management of treatment-resistant depression.
Topics: Algorithms; Antidepressive Agents; Citalopram; Critical Pathways; Decision Support Techniques; Depre | 2001 |
Citalopram in depression--meta-analysis of intended and unintended effects.
Topics: Adult; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Dose-Response Relationship | 1992 |
Citalopram in depression--meta-analysis of intended and unintended effects.
Topics: Adult; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Dose-Response Relationship | 1992 |
Treatment of depression in elderly patients with and without dementia disorders.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Dementia, Vascular; Depressive Disorder; Humans; Neur | 1992 |
Treatment of depression in elderly patients with and without dementia disorders.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Dementia, Vascular; Depressive Disorder; Humans; Neur | 1992 |
Therapeutic effects of serotonin uptake inhibitors in depression.
Topics: 5-Hydroxytryptophan; Alanine; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Imip | 1986 |
Therapeutic effects of serotonin uptake inhibitors in depression.
Topics: 5-Hydroxytryptophan; Alanine; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Imip | 1986 |
Clinical experience with serotonin reuptake inhibiting antidepressants.
Topics: Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; | 1987 |
Clinical experience with serotonin reuptake inhibiting antidepressants.
Topics: Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; | 1987 |
183 trials available for citalopram and Depressive Disorder
| Article | Year |
|---|---|
Maintenance or Discontinuation of Antidepressants in Primary Care.
Topics: Adult; Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive Disorder; Double-Blind | 2021 |
Maintenance or Discontinuation of Antidepressants in Primary Care.
Topics: Adult; Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive Disorder; Double-Blind | 2021 |
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective | 2021 |
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective | 2021 |
Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression.
Topics: Adult; Case-Control Studies; Citalopram; Comet Assay; Depressive Disorder; DNA Damage; DNA Glycosyla | 2019 |
Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression.
Topics: Adult; Case-Control Studies; Citalopram; Comet Assay; Depressive Disorder; DNA Damage; DNA Glycosyla | 2019 |
The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: A secondary analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disease; Citalopram; Co | 2017 |
The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: A secondary analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disease; Citalopram; Co | 2017 |
Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial.
Topics: Adult; Citalopram; Combined Modality Therapy; Depression; Depressive Disorder; Double-Blind Method; | 2018 |
Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial.
Topics: Adult; Citalopram; Combined Modality Therapy; Depression; Depressive Disorder; Double-Blind Method; | 2018 |
Resilience predicts remission in antidepressant treatment of geriatric depression.
Topics: Adaptation, Psychological; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Di | 2018 |
Resilience predicts remission in antidepressant treatment of geriatric depression.
Topics: Adaptation, Psychological; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Di | 2018 |
The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose.
Topics: Adult; Antidepressive Agents; Circadian Clocks; Circadian Rhythm; Citalopram; Cross-Over Studies; De | 2018 |
The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose.
Topics: Adult; Antidepressive Agents; Circadian Clocks; Circadian Rhythm; Citalopram; Cross-Over Studies; De | 2018 |
Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B.
Topics: Aged; Chemotherapy, Adjuvant; Citalopram; Cognition; Depression; Depressive Disorder; Female; Ginkgo | 2018 |
Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B.
Topics: Aged; Chemotherapy, Adjuvant; Citalopram; Cognition; Depression; Depressive Disorder; Female; Ginkgo | 2018 |
Methylation of the glucocorticoid receptor gene associated with depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents; Citalopram; CpG Islands; Depression; De | 2019 |
Methylation of the glucocorticoid receptor gene associated with depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents; Citalopram; CpG Islands; Depression; De | 2019 |
Pycnogenol supplementation as an adjunct treatment for antidepressant-induced sexual dysfunction.
Topics: Adult; Antidepressive Agents; Antioxidants; Citalopram; Depressive Disorder; Female; Flavonoids; Hea | 2019 |
Pycnogenol supplementation as an adjunct treatment for antidepressant-induced sexual dysfunction.
Topics: Adult; Antidepressive Agents; Antioxidants; Citalopram; Depressive Disorder; Female; Flavonoids; Hea | 2019 |
Diabetes with comorbid depression: role of SSRI in better glycemic control.
Topics: Administration, Oral; Blood Glucose; Citalopram; Depressive Disorder; Diabetes Mellitus; Female; Gly | 2013 |
Diabetes with comorbid depression: role of SSRI in better glycemic control.
Topics: Administration, Oral; Blood Glucose; Citalopram; Depressive Disorder; Diabetes Mellitus; Female; Gly | 2013 |
Results of the citalopram to enhance cognition in Huntington disease trial.
Topics: Adult; Aged; Citalopram; Cognition; Depressive Disorder; Double-Blind Method; Drug Administration Sc | 2014 |
Results of the citalopram to enhance cognition in Huntington disease trial.
Topics: Adult; Aged; Citalopram; Cognition; Depressive Disorder; Double-Blind Method; Drug Administration Sc | 2014 |
[The formation of clinical and functional remission during the treatment of non-psychotic depression with escitalopram (lenuxin)].
Topics: Adolescent; Adult; Aged; Anxiety; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Aged | 2013 |
[The formation of clinical and functional remission during the treatment of non-psychotic depression with escitalopram (lenuxin)].
Topics: Adolescent; Adult; Aged; Anxiety; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Aged | 2013 |
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dizzine | 2014 |
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dizzine | 2014 |
Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Emot | 2014 |
Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Emot | 2014 |
Neurocognitive predictors of antidepressant clinical response.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Citalopram; Depres | 2014 |
Neurocognitive predictors of antidepressant clinical response.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Citalopram; Depres | 2014 |
Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.
Topics: Acute Coronary Syndrome; Aged; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; | 2015 |
Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.
Topics: Acute Coronary Syndrome; Aged; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; | 2015 |
Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study.
Topics: Acute Coronary Syndrome; Citalopram; Comorbidity; Depressive Disorder; Double-Blind Method; Female; | 2015 |
Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study.
Topics: Acute Coronary Syndrome; Citalopram; Comorbidity; Depressive Disorder; Double-Blind Method; Female; | 2015 |
Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report.
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Citalopram; Cyclohexanols; Depressive Disorder; | 2015 |
Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report.
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Citalopram; Cyclohexanols; Depressive Disorder; | 2015 |
Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Citalopram; | 2015 |
Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Citalopram; | 2015 |
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Topics: Adult; Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Di | 2015 |
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Topics: Adult; Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Di | 2015 |
Predictors of depressive disorder following acute coronary syndrome: Results from K-DEPACS and EsDEPACS.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Comorbidity; Depres | 2015 |
Predictors of depressive disorder following acute coronary syndrome: Results from K-DEPACS and EsDEPACS.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Comorbidity; Depres | 2015 |
Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.
Topics: Acute Coronary Syndrome; Aged; Citalopram; Depressive Disorder; Diagnostic and Statistical Manual of | 2015 |
Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.
Topics: Acute Coronary Syndrome; Aged; Citalopram; Depressive Disorder; Diagnostic and Statistical Manual of | 2015 |
The use of statins for the treatment of depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Cohort Studies; Depressive Disorder; Double-Blind Method; Femal | 2015 |
The use of statins for the treatment of depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Cohort Studies; Depressive Disorder; Double-Blind Method; Femal | 2015 |
BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Ci | 2016 |
BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Ci | 2016 |
Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopram; Depressive Disorder; Fem | 2017 |
Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopram; Depressive Disorder; Fem | 2017 |
Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Body Dysmorphic Disorders; Citalopram; Comorbidity; Depressive Disorder; Double-Blind Method; | 2016 |
Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Body Dysmorphic Disorders; Citalopram; Comorbidity; Depressive Disorder; Double-Blind Method; | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial.
Topics: Adjustment Disorders; Adult; Aged; Citalopram; Combined Modality Therapy; Comorbidity; Depressive Di | 2016 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease; | 2008 |
Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Mal | 2009 |
Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Mal | 2009 |
Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment.
Topics: Acylation; Adult; Antidepressive Agents, Second-Generation; Aryldialkylphosphatase; Carboxylic Ester | 2009 |
Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment.
Topics: Acylation; Adult; Antidepressive Agents, Second-Generation; Aryldialkylphosphatase; Carboxylic Ester | 2009 |
Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell; | 2009 |
Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell; | 2009 |
A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes.
Topics: Adult; Citalopram; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Femal | 2010 |
A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes.
Topics: Adult; Citalopram; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Femal | 2010 |
[Depressive disorders in patients after stroke].
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Depressive D | 2008 |
[Depressive disorders in patients after stroke].
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Depressive D | 2008 |
Moderation of antidepressant response by the serotonin transporter gene.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Tricyclic; | 2009 |
Moderation of antidepressant response by the serotonin transporter gene.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Tricyclic; | 2009 |
Income and attrition in the treatment of depression: a STAR*D report.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Citalopram; Cognition Disorders; Depressive D | 2009 |
Income and attrition in the treatment of depression: a STAR*D report.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Citalopram; Cognition Disorders; Depressive D | 2009 |
Depressive disorders in stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Depressive D | 2009 |
Depressive disorders in stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Depressive D | 2009 |
Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hor | 2009 |
Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hor | 2009 |
Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Citalopram; Depressive Disorder; Female; Humans; M | 2010 |
Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Citalopram; Depressive Disorder; Female; Humans; M | 2010 |
Adverse reactions to antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Ag | 2009 |
Adverse reactions to antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Ag | 2009 |
Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Depress | 2009 |
Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Depress | 2009 |
Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 2009 |
Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 2009 |
Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; | 2010 |
Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; | 2010 |
Trajectories of change in depression severity during treatment with antidepressants.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Europe; Female; Follow-Up Studies; Ge | 2010 |
Trajectories of change in depression severity during treatment with antidepressants.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Europe; Female; Follow-Up Studies; Ge | 2010 |
Change in cognitive functioning following acute antidepressant treatment in late-life depression.
Topics: Aged; Aged, 80 and over; Citalopram; Cognition; Depressive Disorder; Female; Geriatric Assessment; H | 2009 |
Change in cognitive functioning following acute antidepressant treatment in late-life depression.
Topics: Aged; Aged, 80 and over; Citalopram; Cognition; Depressive Disorder; Female; Geriatric Assessment; H | 2009 |
Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anxiety Disorders; Citalopram; Depressive Disorder; Dou | 2010 |
Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anxiety Disorders; Citalopram; Depressive Disorder; Dou | 2010 |
Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive D | 2010 |
Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive D | 2010 |
Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression.
Topics: Aged; Aged, 80 and over; Aging; Citalopram; Depressive Disorder; Executive Function; Female; Geriatr | 2010 |
Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression.
Topics: Aged; Aged, 80 and over; Aging; Citalopram; Depressive Disorder; Executive Function; Female; Geriatr | 2010 |
Combined therapy versus usual care for the treatment of depression in oncologic patients: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Combined Modality The | 2011 |
Combined therapy versus usual care for the treatment of depression in oncologic patients: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Combined Modality The | 2011 |
Changes in body weight during pharmacological treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Body Mass Index; Body Weight; Citalopram; Depressive | 2011 |
Changes in body weight during pharmacological treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Body Mass Index; Body Weight; Citalopram; Depressive | 2011 |
Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia.
Topics: Adaptation, Psychological; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Awareness | 2011 |
Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia.
Topics: Adaptation, Psychological; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Awareness | 2011 |
Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management.
Topics: Aged; Aged, 80 and over; Citalopram; Combined Modality Therapy; Depressive Disorder; Disease Managem | 2010 |
Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management.
Topics: Aged; Aged, 80 and over; Citalopram; Combined Modality Therapy; Depressive Disorder; Disease Managem | 2010 |
Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants.
Topics: Adult; Aged; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Gene Expressio | 2011 |
Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants.
Topics: Adult; Aged; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Gene Expressio | 2011 |
Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care.
Topics: Citalopram; Depressive Disorder; Depressive Disorder, Major; Humans; Precision Medicine; Psychiatric | 2010 |
Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care.
Topics: Citalopram; Depressive Disorder; Depressive Disorder, Major; Humans; Precision Medicine; Psychiatric | 2010 |
Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Homozygote; | 2011 |
Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Homozygote; | 2011 |
Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Depressive Disorder; Female; | 2011 |
Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Depressive Disorder; Female; | 2011 |
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 2011 |
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 2011 |
Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Hyper | 2011 |
Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Hyper | 2011 |
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; | 2011 |
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; | 2011 |
The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Huma | 2011 |
The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Huma | 2011 |
Serum BDNF levels before treatment predict SSRI response in depression.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cross-Over Studies; Dep | 2011 |
Serum BDNF levels before treatment predict SSRI response in depression.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cross-Over Studies; Dep | 2011 |
Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety.
Topics: Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive D | 2011 |
Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety.
Topics: Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive D | 2011 |
Support and undermining in interpersonal relationships are associated with symptom improvement in a trial of antidepressant medication.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Administration Schedule; Female; | 2011 |
Support and undermining in interpersonal relationships are associated with symptom improvement in a trial of antidepressant medication.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Administration Schedule; Female; | 2011 |
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Depressive Dis | 2012 |
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Depressive Dis | 2012 |
Treatment of depression associated with age-related macular degeneration: a double-blind, randomized, controlled study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Cross-Over Studies; D | 2011 |
Treatment of depression associated with age-related macular degeneration: a double-blind, randomized, controlled study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Cross-Over Studies; D | 2011 |
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
Topics: Adult; Cardiovascular Diseases; Citalopram; Depressive Disorder; Exercise Test; Humans; Myocardial I | 2012 |
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
Topics: Adult; Cardiovascular Diseases; Citalopram; Depressive Disorder; Exercise Test; Humans; Myocardial I | 2012 |
Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Citalopram; Depressive Disorder; Female; Huma | 2012 |
Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Citalopram; Depressive Disorder; Female; Huma | 2012 |
Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Fatigue; Female; Follow-Up Studies; H | 2012 |
Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Fatigue; Female; Follow-Up Studies; H | 2012 |
Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial.
Topics: Academic Medical Centers; Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Citalopr | 2012 |
Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial.
Topics: Academic Medical Centers; Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Citalopr | 2012 |
The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.
Topics: Adult; Aggression; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Family | 2012 |
The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.
Topics: Adult; Aggression; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Family | 2012 |
Persistence on a stress-challenge task before initiating buprenorphine treatment was associated with successful transition from opioid use to early abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Buprenorphine; Citalopram; Comorbidity; Depressive | 2012 |
Persistence on a stress-challenge task before initiating buprenorphine treatment was associated with successful transition from opioid use to early abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Buprenorphine; Citalopram; Comorbidity; Depressive | 2012 |
Self-report and clinician-rated measures of depression severity: can one replace the other?
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, Major; Fem | 2012 |
Self-report and clinician-rated measures of depression severity: can one replace the other?
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, Major; Fem | 2012 |
Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response.
Topics: Adult; Aged; Biomarkers; Citalopram; Cytokines; Depressive Disorder; Drug Delivery Systems; Female; | 2013 |
Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response.
Topics: Adult; Aged; Biomarkers; Citalopram; Cytokines; Depressive Disorder; Drug Delivery Systems; Female; | 2013 |
Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2012 |
Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2012 |
Suggested early onset of true action of antidepressant drugs may be artefactual: a heuristic study.
Topics: Affect; Antidepressive Agents, Second-Generation; Artifacts; Citalopram; Cognitive Behavioral Therap | 2013 |
Suggested early onset of true action of antidepressant drugs may be artefactual: a heuristic study.
Topics: Affect; Antidepressive Agents, Second-Generation; Artifacts; Citalopram; Cognitive Behavioral Therap | 2013 |
The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Cognitive Behavioral The | 2013 |
The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Cognitive Behavioral The | 2013 |
Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5).
Topics: Antidepressive Agents; Citalopram; Clomipramine; Denmark; Depressive Disorder; Double-Blind Method; | 2013 |
Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5).
Topics: Antidepressive Agents; Citalopram; Clomipramine; Denmark; Depressive Disorder; Double-Blind Method; | 2013 |
Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Follow-Up Studie | 2002 |
Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Follow-Up Studie | 2002 |
Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Ps | 2002 |
Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Ps | 2002 |
MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression.
Topics: Age of Onset; Aged; Aging; Antidepressive Agents, Second-Generation; Brain; Citalopram; Dementia, Va | 2002 |
MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression.
Topics: Age of Onset; Aged; Aging; Antidepressive Agents, Second-Generation; Brain; Citalopram; Dementia, Va | 2002 |
Citalopram treatment of fluoxetine-intolerant depressed patients.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Drug Tolerance; Female; Fluoxetine; Headache; Humans; | 2003 |
Citalopram treatment of fluoxetine-intolerant depressed patients.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Drug Tolerance; Female; Fluoxetine; Headache; Humans; | 2003 |
Electrocardiographic dose-dependent changes in prophylactic doses of dosulepine, lithium and citalopram.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antide | 2003 |
Electrocardiographic dose-dependent changes in prophylactic doses of dosulepine, lithium and citalopram.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antide | 2003 |
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Dose-Response Rela | 2003 |
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Dose-Response Rela | 2003 |
Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial.
Topics: Circadian Rhythm; Citalopram; Combined Modality Therapy; Depressive Disorder; Female; Humans; Male; | 2003 |
Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial.
Topics: Circadian Rhythm; Citalopram; Combined Modality Therapy; Depressive Disorder; Female; Humans; Male; | 2003 |
Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.
Topics: Adolescent; Adult; Body Mass Index; Bulimia; Citalopram; Depressive Disorder; Double-Blind Method; D | 2003 |
Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.
Topics: Adolescent; Adult; Body Mass Index; Bulimia; Citalopram; Depressive Disorder; Double-Blind Method; D | 2003 |
Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Topics: Adrenergic Uptake Inhibitors; Aged; Analysis of Variance; Case-Control Studies; Citalopram; Depressi | 2004 |
Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Topics: Adrenergic Uptake Inhibitors; Aged; Analysis of Variance; Case-Control Studies; Citalopram; Depressi | 2004 |
Escitalopram continuation treatment prevents relapse of depressive episodes.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Gene | 2004 |
Escitalopram continuation treatment prevents relapse of depressive episodes.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Gene | 2004 |
Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Algorithms; Antidepressive Agents; Citalopram; Combined Modality Therapy; D | 2004 |
Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Algorithms; Antidepressive Agents; Citalopram; Combined Modality Therapy; D | 2004 |
A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents.
Topics: Adolescent; Age Factors; Child; Citalopram; Depressive Disorder; Double-Blind Method; Drug Administr | 2004 |
A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents.
Topics: Adolescent; Age Factors; Child; Citalopram; Depressive Disorder; Double-Blind Method; Drug Administr | 2004 |
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Constipation; Cyclohexanols; Delayed-Ac | 2004 |
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Constipation; Cyclohexanols; Delayed-Ac | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Citalopram; Cyclohexanols; Delayed-Action Preparations; De | 2004 |
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Citalopram; Cyclohexanols; Delayed-Action Preparations; De | 2004 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial.
Topics: Age Factors; Aged; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; F | 2004 |
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial.
Topics: Age Factors; Aged; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; F | 2004 |
Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Analgesics; Central Nervous System; Citalopra | 2005 |
Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Analgesics; Central Nervous System; Citalopra | 2005 |
Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.
Topics: Age Factors; Aged; Citalopram; Cognition Disorders; Depressive Disorder; Female; Follow-Up Studies; | 2005 |
Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.
Topics: Age Factors; Aged; Citalopram; Cognition Disorders; Depressive Disorder; Female; Follow-Up Studies; | 2005 |
[Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients].
Topics: Aged; Citalopram; Cognition; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Neuropsycholo | 2004 |
[Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients].
Topics: Aged; Citalopram; Cognition; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Neuropsycholo | 2004 |
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Cimetidine; Citalopram; Depressive Disorder; Drug Therapy, Com | 2005 |
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Cimetidine; Citalopram; Depressive Disorder; Drug Therapy, Com | 2005 |
Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age.
Topics: Administration, Oral; Adolescent; Adult; Citalopram; Cohort Studies; Depressive Disorder; Drug Admin | 2005 |
Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age.
Topics: Administration, Oral; Adolescent; Adult; Citalopram; Cohort Studies; Depressive Disorder; Drug Admin | 2005 |
Beyond efficacy: the STAR*D trial.
Topics: Animals; Citalopram; Depressive Disorder; Disease Management; Drug Administration Schedule; Health S | 2006 |
Beyond efficacy: the STAR*D trial.
Topics: Animals; Citalopram; Depressive Disorder; Disease Management; Drug Administration Schedule; Health S | 2006 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; C | 2005 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; C | 2005 |
An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalopram; De | 2006 |
An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalopram; De | 2006 |
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Citalopram; Depressive Disorder; Double-Blind Metho | 2006 |
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Citalopram; Depressive Disorder; Double-Blind Metho | 2006 |
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; | 2007 |
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; | 2007 |
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Double-Blind Me | 2007 |
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Double-Blind Me | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Ther | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Ther | 2007 |
Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Citalopram; Depressive Diso | 2007 |
Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Citalopram; Depressive Diso | 2007 |
The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disord | 2007 |
The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disord | 2007 |
Serotonin 5HT1A receptor availability and pathological crying after stroke.
Topics: Aged; Binding, Competitive; Brain; Citalopram; Crying; Depressive Disorder; Down-Regulation; Female; | 2007 |
Serotonin 5HT1A receptor availability and pathological crying after stroke.
Topics: Aged; Binding, Competitive; Brain; Citalopram; Crying; Depressive Disorder; Down-Regulation; Female; | 2007 |
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive | 2007 |
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive | 2007 |
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression.
Topics: Aged; Aged, 80 and over; Citalopram; Depressive Disorder; Double-Blind Method; Drug Therapy, Combina | 2008 |
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression.
Topics: Aged; Aged, 80 and over; Citalopram; Depressive Disorder; Double-Blind Method; Drug Therapy, Combina | 2008 |
Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Biphenyl Compounds; Citalopram; Depressive Disorder; Depr | 2008 |
Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Biphenyl Compounds; Citalopram; Depressive Disorder; Depr | 2008 |
Complicated grief: a case series using escitalopram.
Topics: Adult; Bereavement; Citalopram; Depressive Disorder; Female; Grief; Humans; Pilot Projects; Prospect | 2007 |
Complicated grief: a case series using escitalopram.
Topics: Adult; Bereavement; Citalopram; Depressive Disorder; Female; Grief; Humans; Pilot Projects; Prospect | 2007 |
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder; | 2008 |
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder; | 2008 |
Escitalopram in the acute treatment of depressed patients aged 60 years or older.
Topics: Age Factors; Aged; Analysis of Variance; Citalopram; Depressive Disorder; Double-Blind Method; Drug- | 2008 |
Escitalopram in the acute treatment of depressed patients aged 60 years or older.
Topics: Age Factors; Aged; Analysis of Variance; Citalopram; Depressive Disorder; Double-Blind Method; Drug- | 2008 |
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents; Brain Chemistry; Citalopram; Depressive Dis | 2008 |
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents; Brain Chemistry; Citalopram; Depressive Dis | 2008 |
Acute 5-HT reuptake blockade potentiates human amygdala reactivity.
Topics: Adult; Akathisia, Drug-Induced; Amygdala; Anxiety; Brain Chemistry; Citalopram; Cross-Over Studies; | 2008 |
Acute 5-HT reuptake blockade potentiates human amygdala reactivity.
Topics: Adult; Akathisia, Drug-Induced; Amygdala; Anxiety; Brain Chemistry; Citalopram; Cross-Over Studies; | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male | 1995 |
Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male | 1995 |
[Effective treatment of depression following apoplexy with citalopram].
Topics: Cerebrovascular Disorders; Citalopram; Depressive Disorder; Double-Blind Method; Humans; Prognosis | 1995 |
[Effective treatment of depression following apoplexy with citalopram].
Topics: Cerebrovascular Disorders; Citalopram; Depressive Disorder; Double-Blind Method; Humans; Prognosis | 1995 |
Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Double-B | 1994 |
Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Double-B | 1994 |
[Citalopram in depression (results of an open multicenter study in phase IV of the clinical trial)].
Topics: Adult; Aged; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Aged | 1993 |
[Citalopram in depression (results of an open multicenter study in phase IV of the clinical trial)].
Topics: Adult; Aged; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Aged | 1993 |
Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Citalopram; Cohort Studies; Depression; D | 1994 |
Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Citalopram; Cohort Studies; Depression; D | 1994 |
A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Recurrence; Survival Ana | 1993 |
A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Recurrence; Survival Ana | 1993 |
Mortality in major affective disorder: relationship to subtype of depression. The Danish University Antidepressant Group.
Topics: Adult; Aged; Citalopram; Clomipramine; Denmark; Depressive Disorder; Female; Follow-Up Studies; Huma | 1993 |
Mortality in major affective disorder: relationship to subtype of depression. The Danish University Antidepressant Group.
Topics: Adult; Aged; Citalopram; Clomipramine; Denmark; Depressive Disorder; Female; Follow-Up Studies; Huma | 1993 |
[Citalopram and desmethylcitalopram for psychiatric patients].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; | 1996 |
[Citalopram and desmethylcitalopram for psychiatric patients].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; | 1996 |
Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; | 1996 |
Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; | 1996 |
A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.
Topics: Adult; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; C | 1996 |
A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.
Topics: Adult; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; C | 1996 |
Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Danish University Antidepressant Group.
Topics: Citalopram; Clomipramine; Depressive Disorder; Family Practice; Female; Humans; Imipramine; Male; Ob | 1996 |
Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Danish University Antidepressant Group.
Topics: Citalopram; Clomipramine; Depressive Disorder; Family Practice; Female; Humans; Imipramine; Male; Ob | 1996 |
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Diarrhea; Double-Blind Method; Female | 1996 |
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Diarrhea; Double-Blind Method; Female | 1996 |
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Resistance; Drug Synergism; Drug | 1996 |
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Resistance; Drug Synergism; Drug | 1996 |
Phasic craving for carbohydrate observed with citalopram.
Topics: Adolescent; Adult; Body Weight; Citalopram; Depressive Disorder; Dietary Carbohydrates; Female; Huma | 1996 |
Phasic craving for carbohydrate observed with citalopram.
Topics: Adolescent; Adult; Body Weight; Citalopram; Depressive Disorder; Dietary Carbohydrates; Female; Huma | 1996 |
Curvaceous model of recovery from depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi | 1997 |
Curvaceous model of recovery from depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi | 1997 |
A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Diarrhea; Doub | 1997 |
A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Diarrhea; Doub | 1997 |
A double-blind double-dummy study of citalopram comparing infusion versus oral administration.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorde | 1998 |
A double-blind double-dummy study of citalopram comparing infusion versus oral administration.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorde | 1998 |
Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Female; Hu | 1998 |
Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Female; Hu | 1998 |
Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice.
Topics: Aged; Amitriptyline; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Pri | 1998 |
Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice.
Topics: Aged; Amitriptyline; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Pri | 1998 |
A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Topics: Adult; Aged; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Follow-U | 1998 |
A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Topics: Adult; Aged; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Follow-U | 1998 |
Co-administration of citalopram and clozapine: effect on plasma clozapine levels.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Cloza | 1998 |
Co-administration of citalopram and clozapine: effect on plasma clozapine levels.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Cloza | 1998 |
Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
Topics: Adult; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male | 1999 |
Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
Topics: Adult; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male | 1999 |
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 1999 |
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 1999 |
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
Topics: Administration, Oral; Adult; Ambulatory Care; Citalopram; Depressive Disorder; Drug Administration S | 1999 |
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
Topics: Administration, Oral; Adult; Ambulatory Care; Citalopram; Depressive Disorder; Drug Administration S | 1999 |
Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate.
Topics: Adult; Age of Onset; Ambulatory Care; Citalopram; Cost of Illness; Depressive Disorder; Discriminant | 1999 |
Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate.
Topics: Adult; Age of Onset; Ambulatory Care; Citalopram; Cost of Illness; Depressive Disorder; Discriminant | 1999 |
A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Dementia; Depressive | 2000 |
A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Dementia; Depressive | 2000 |
Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; | 2000 |
Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; | 2000 |
Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopr | 2000 |
Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopr | 2000 |
[A trial of treating depressive states with cipramil].
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depressive Disorder; H | 2000 |
[A trial of treating depressive states with cipramil].
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depressive Disorder; H | 2000 |
Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive | 2000 |
Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive | 2000 |
Citalopram and haloperidol for psychotic depression.
Topics: Adult; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Humans; Male | 2000 |
Citalopram and haloperidol for psychotic depression.
Topics: Adult; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Humans; Male | 2000 |
Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
Topics: Adult; Citalopram; Depressive Disorder; Double-Blind Method; Electrocardiography; Endpoint Determina | 2000 |
Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
Topics: Adult; Citalopram; Depressive Disorder; Double-Blind Method; Electrocardiography; Endpoint Determina | 2000 |
An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Recu | 2000 |
An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Recu | 2000 |
Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexan | 2001 |
Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexan | 2001 |
Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; | 2001 |
Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; | 2001 |
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; B | 2001 |
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; B | 2001 |
Administration of citalopram before ECT: seizure duration and hormone responses.
Topics: Administration, Oral; Aged; Aged, 80 and over; Citalopram; Cross-Over Studies; Depressive Disorder; | 2000 |
Administration of citalopram before ECT: seizure duration and hormone responses.
Topics: Administration, Oral; Aged; Aged, 80 and over; Citalopram; Cross-Over Studies; Depressive Disorder; | 2000 |
Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study.
Topics: Age of Onset; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cita | 2001 |
Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study.
Topics: Age of Onset; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cita | 2001 |
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Topics: Adult; Aged; Ambulatory Care; Buspirone; Citalopram; Depressive Disorder; Double-Blind Method; Drug | 2001 |
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Topics: Adult; Aged; Ambulatory Care; Buspirone; Citalopram; Depressive Disorder; Double-Blind Method; Drug | 2001 |
Citalopram treatment of fluoxetine nonresponders.
Topics: Adult; Ambulatory Care; Citalopram; Depressive Disorder; Drug Administration Schedule; Female; Fluox | 2001 |
Citalopram treatment of fluoxetine nonresponders.
Topics: Adult; Ambulatory Care; Citalopram; Depressive Disorder; Drug Administration Schedule; Female; Fluox | 2001 |
State and trait abnormalities in serotonin function in major depression.
Topics: Acute Disease; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; De | 2002 |
State and trait abnormalities in serotonin function in major depression.
Topics: Acute Disease; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; De | 2002 |
An open-label study of citalopram in the treatment of pathological gambling.
Topics: Adolescent; Adult; Age of Onset; Aged; Citalopram; Comorbidity; Depressive Disorder; Disruptive, Imp | 2002 |
An open-label study of citalopram in the treatment of pathological gambling.
Topics: Adolescent; Adult; Age of Onset; Aged; Citalopram; Comorbidity; Depressive Disorder; Disruptive, Imp | 2002 |
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Double-Blind Method; | 2002 |
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Double-Blind Method; | 2002 |
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Citalopram; Depressive Disorder; Dose-Response Relationshi | 2002 |
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Citalopram; Depressive Disorder; Dose-Response Relationshi | 2002 |
Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; C | 2002 |
Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; C | 2002 |
Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Long | 1992 |
Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Long | 1992 |
Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male | 1992 |
Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male | 1992 |
A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia.
Topics: Aged; Citalopram; Cognition; Dementia; Depressive Disorder; Double-Blind Method; Humans; Placebos | 1992 |
A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia.
Topics: Aged; Citalopram; Cognition; Dementia; Depressive Disorder; Double-Blind Method; Humans; Placebos | 1992 |
Diagnostic and therapeutic value of testing stimulation of thyroid-stimulating hormone by thyrotropin-releasing hormone in 100 depressed patients.
Topics: Adult; Aged; Bipolar Disorder; Citalopram; Depressive Disorder; Female; Humans; Male; Maprotiline; M | 1990 |
Diagnostic and therapeutic value of testing stimulation of thyroid-stimulating hormone by thyrotropin-releasing hormone in 100 depressed patients.
Topics: Adult; Aged; Bipolar Disorder; Citalopram; Depressive Disorder; Female; Humans; Male; Maprotiline; M | 1990 |
A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients.
Topics: Adult; Aged; Anthracenes; Blood Platelets; Citalopram; Clinical Trials as Topic; Depressive Disorder | 1987 |
A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients.
Topics: Adult; Aged; Anthracenes; Blood Platelets; Citalopram; Clinical Trials as Topic; Depressive Disorder | 1987 |
Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group.
Topics: Adolescent; Adult; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Clomipramine; Depres | 1986 |
Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group.
Topics: Adolescent; Adult; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Clomipramine; Depres | 1986 |
Clinical experience with serotonin reuptake inhibiting antidepressants.
Topics: Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; | 1987 |
Clinical experience with serotonin reuptake inhibiting antidepressants.
Topics: Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; | 1987 |
The new generation antidepressants: promising innovations or disappointments?
Topics: Alprazolam; Antidepressive Agents; Benzodiazepines; Bupropion; Citalopram; Clinical Trials as Topic; | 1985 |
The new generation antidepressants: promising innovations or disappointments?
Topics: Alprazolam; Antidepressive Agents; Benzodiazepines; Bupropion; Citalopram; Clinical Trials as Topic; | 1985 |
Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study.
Topics: Adult; Aged; Amino Acids; Anthracenes; Antidepressive Agents; Citalopram; Depressive Disorder; Femal | 1986 |
Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study.
Topics: Adult; Aged; Amino Acids; Anthracenes; Antidepressive Agents; Citalopram; Depressive Disorder; Femal | 1986 |
A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients.
Topics: Adult; Aged; Amitriptyline; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1987 |
A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients.
Topics: Adult; Aged; Amitriptyline; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1987 |
Citalopram--a highly selective 5-HT uptake inhibitor--in the treatment of depressed patients.
Topics: Adult; Aged; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Mal | 1987 |
Citalopram--a highly selective 5-HT uptake inhibitor--in the treatment of depressed patients.
Topics: Adult; Aged; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Mal | 1987 |
Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients.
Topics: Adult; Aged; Anthracenes; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blind Me | 1987 |
Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients.
Topics: Adult; Aged; Anthracenes; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blind Me | 1987 |
Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression.
Topics: Adult; Aged; Anthracenes; Citalopram; Depressive Disorder; Dexamethasone; Female; Humans; Male; Mapr | 1987 |
Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression.
Topics: Adult; Aged; Anthracenes; Citalopram; Depressive Disorder; Dexamethasone; Female; Humans; Male; Mapr | 1987 |
A comparison of the antidepressant action of citalopram and amitriptyline.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Citalopram; Clinical Trials as Topic; | 1986 |
A comparison of the antidepressant action of citalopram and amitriptyline.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Citalopram; Clinical Trials as Topic; | 1986 |
Experiments on clinical observation and judgement in the assessment of depression: profiled videotapes and Judgement Analysis.
Topics: Adult; Citalopram; Clinical Trials as Topic; Clomipramine; Depressive Disorder; Double-Blind Method; | 1986 |
Experiments on clinical observation and judgement in the assessment of depression: profiled videotapes and Judgement Analysis.
Topics: Adult; Citalopram; Clinical Trials as Topic; Clomipramine; Depressive Disorder; Double-Blind Method; | 1986 |
Citalopram versus mianserin. A controlled, double-blind trial in depressed patients.
Topics: Adolescent; Adult; Aged; Citalopram; Clinical Trials as Topic; Depressive Disorder; Dibenzazepines; | 1985 |
Citalopram versus mianserin. A controlled, double-blind trial in depressed patients.
Topics: Adolescent; Adult; Aged; Citalopram; Clinical Trials as Topic; Depressive Disorder; Dibenzazepines; | 1985 |
Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.
Topics: Adult; Aged; Blood Platelets; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blin | 1985 |
Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.
Topics: Adult; Aged; Blood Platelets; Citalopram; Clinical Trials as Topic; Depressive Disorder; Double-Blin | 1985 |
Orthostatic side effects of clomipramine and citalopram during treatment for depression.
Topics: Adult; Citalopram; Clomipramine; Depressive Disorder; Female; Humans; Hypotension, Orthostatic; Male | 1985 |
Orthostatic side effects of clomipramine and citalopram during treatment for depression.
Topics: Adult; Citalopram; Clomipramine; Depressive Disorder; Female; Humans; Hypotension, Orthostatic; Male | 1985 |
Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Amino Acids; Antidepressive Agents; Biogenic Amines; | 1985 |
Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Amino Acids; Antidepressive Agents; Biogenic Amines; | 1985 |
284 other studies available for citalopram and Depressive Disorder
| Article | Year |
|---|---|
6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.
Topics: Animals; Antidepressive Agents; Azabicyclo Compounds; Brain; Depressive Disorder; Dopamine; Heptanes | 2010 |
6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.
Topics: Animals; Antidepressive Agents; Azabicyclo Compounds; Brain; Depressive Disorder; Dopamine; Heptanes | 2010 |
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive | 2022 |
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive | 2022 |
Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study-ADDENDUM.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Humans | 2021 |
Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study-ADDENDUM.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Humans | 2021 |
Influence of
Topics: Citalopram; Cytochrome P-450 CYP2C19; Depressive Disorder; Escitalopram; Humans; Polymorphism, Genet | 2022 |
Influence of
Topics: Citalopram; Cytochrome P-450 CYP2C19; Depressive Disorder; Escitalopram; Humans; Polymorphism, Genet | 2022 |
Sexual functioning in females with depression in remission receiving escitalopram.
Topics: Adolescent; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; India; Mi | 2019 |
Sexual functioning in females with depression in remission receiving escitalopram.
Topics: Adolescent; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; India; Mi | 2019 |
Psychological Impact of the COVID-19 Pandemic Among the Elderly: A Case Series From India.
Topics: Acetamides; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Betacoronavirus; Ci | 2020 |
Psychological Impact of the COVID-19 Pandemic Among the Elderly: A Case Series From India.
Topics: Acetamides; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Betacoronavirus; Ci | 2020 |
Escitalopram induced thrombocytopenia reversed after shifting to bupropion in a depressive patient.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Humans; | 2017 |
Escitalopram induced thrombocytopenia reversed after shifting to bupropion in a depressive patient.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Humans; | 2017 |
Is Really Crocus Sativus as Effective as Citalopram in the Treatment of Depression?
Topics: Citalopram; Crocus; Depression; Depressive Disorder; Humans; Phytotherapy; Plant Extracts | 2018 |
Is Really Crocus Sativus as Effective as Citalopram in the Treatment of Depression?
Topics: Citalopram; Crocus; Depression; Depressive Disorder; Humans; Phytotherapy; Plant Extracts | 2018 |
Serotonergic 5HTTLPR/rs25531 s-allele homozygosity associates with violent suicides in male citalopram users.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Case-Control S | 2017 |
Serotonergic 5HTTLPR/rs25531 s-allele homozygosity associates with violent suicides in male citalopram users.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Case-Control S | 2017 |
The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test.
Topics: alpha-Methyltyrosine; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Disease Model | 2017 |
The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test.
Topics: alpha-Methyltyrosine; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Disease Model | 2017 |
Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Antipsychotic | 2018 |
Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Antipsychotic | 2018 |
Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.
Topics: Adult; Antidepressive Agents; Citalopram; Databases, Factual; Depressive Disorder; Drug Monitoring; | 2017 |
Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.
Topics: Adult; Antidepressive Agents; Citalopram; Databases, Factual; Depressive Disorder; Drug Monitoring; | 2017 |
Effects of escitalopram and imipramine on cocaine reinforcement and drug-seeking behaviors in a rat model of depression.
Topics: Animals; Citalopram; Cocaine; Cocaine-Related Disorders; Cues; Depressive Disorder; Disease Models, | 2017 |
Effects of escitalopram and imipramine on cocaine reinforcement and drug-seeking behaviors in a rat model of depression.
Topics: Animals; Citalopram; Cocaine; Cocaine-Related Disorders; Cues; Depressive Disorder; Disease Models, | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depre | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depre | 2017 |
Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression.
Topics: Access to Information; Antidepressive Agents; Aripiprazole; Brain Mapping; Canada; Citalopram; Data | 2017 |
Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression.
Topics: Access to Information; Antidepressive Agents; Aripiprazole; Brain Mapping; Canada; Citalopram; Data | 2017 |
Prescription Pattern of Antidepressants for Children and Adolescents in Korea Based on Nationwide Data.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Child; Citalopram; | 2017 |
Prescription Pattern of Antidepressants for Children and Adolescents in Korea Based on Nationwide Data.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Child; Citalopram; | 2017 |
Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Patients with Chronic Depression: Results from a Naturalistic Long-Term Follow-Up.
Topics: Citalopram; Cognitive Behavioral Therapy; Depressive Disorder; Female; Follow-Up Studies; Humans; Ma | 2017 |
Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Patients with Chronic Depression: Results from a Naturalistic Long-Term Follow-Up.
Topics: Citalopram; Cognitive Behavioral Therapy; Depressive Disorder; Female; Follow-Up Studies; Humans; Ma | 2017 |
Obsession of pregnancy: Does it exist?
Topics: Attitude to Health; Citalopram; Clomipramine; Clonazepam; Cognitive Behavioral Therapy; Depressive D | 2017 |
Obsession of pregnancy: Does it exist?
Topics: Attitude to Health; Citalopram; Clomipramine; Clonazepam; Cognitive Behavioral Therapy; Depressive D | 2017 |
The benefits of the concomitant use of antidepressants and acetyl-l-carnitine in the treatment of moderate depression.
Topics: Acetylcarnitine; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Therapy, Combin | 2019 |
The benefits of the concomitant use of antidepressants and acetyl-l-carnitine in the treatment of moderate depression.
Topics: Acetylcarnitine; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Therapy, Combin | 2019 |
Finding Meaning during Times of Anguish in Later Life.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Bereavement; Citalopram; Depressive Dis | 2018 |
Finding Meaning during Times of Anguish in Later Life.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Bereavement; Citalopram; Depressive Dis | 2018 |
Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Topics: Adult; Aged; Citalopram; Cytochrome P-450 CYP2C19; Depressive Disorder; Drug Monitoring; Drug Substi | 2018 |
Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Topics: Adult; Aged; Citalopram; Cytochrome P-450 CYP2C19; Depressive Disorder; Drug Monitoring; Drug Substi | 2018 |
Brucellosis accompanied by haemophagocytic lymphohistiocytosis and multiple splenic abscesses in a patient with depression.
Topics: Abscess; Adult; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Brucellosis; Citalo | 2018 |
Brucellosis accompanied by haemophagocytic lymphohistiocytosis and multiple splenic abscesses in a patient with depression.
Topics: Abscess; Adult; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Brucellosis; Citalo | 2018 |
Immediate and long-term antidepressive-like effects of pre-pubertal escitalopram and omega-3 supplementation combination in young adult stress-sensitive rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Dietary Supplements; Disease Models | 2018 |
Immediate and long-term antidepressive-like effects of pre-pubertal escitalopram and omega-3 supplementation combination in young adult stress-sensitive rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Dietary Supplements; Disease Models | 2018 |
Sex-dependent behavior, neuropeptide profile and antidepressant response in rat model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Brain Edema; Citalopram; Depressive Disord | 2018 |
Sex-dependent behavior, neuropeptide profile and antidepressant response in rat model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Brain Edema; Citalopram; Depressive Disord | 2018 |
Serotonergic mechanisms involved in antidepressant-like responses evoked by GLT-1 blockade in rat infralimbic cortex.
Topics: Animals; Antidepressive Agents; Cerebral Cortex; Citalopram; Depressive Disorder; Dorsal Raphe Nucle | 2018 |
Serotonergic mechanisms involved in antidepressant-like responses evoked by GLT-1 blockade in rat infralimbic cortex.
Topics: Animals; Antidepressive Agents; Cerebral Cortex; Citalopram; Depressive Disorder; Dorsal Raphe Nucle | 2018 |
Course of recurrent depression in monozygotic twins - A case report.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Diseases in Twins; Female; Humans; Middle Ag | 2018 |
Course of recurrent depression in monozygotic twins - A case report.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Diseases in Twins; Female; Humans; Middle Ag | 2018 |
Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice.
Topics: Animals; Antidepressive Agents; Chemotherapy, Adjuvant; Citalopram; Cytidine Diphosphate Choline; De | 2018 |
Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice.
Topics: Animals; Antidepressive Agents; Chemotherapy, Adjuvant; Citalopram; Cytidine Diphosphate Choline; De | 2018 |
Exploring the Relationship Between Depression and Dementia.
Topics: Adult; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Dementia; Depres | 2018 |
Exploring the Relationship Between Depression and Dementia.
Topics: Adult; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Dementia; Depres | 2018 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Benzamides; Cerebral Cortex; Chronic Disease; Citalopram; Cyclic AMP | 2019 |
FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Benzamides; Cerebral Cortex; Chronic Disease; Citalopram; Cyclic AMP | 2019 |
Interactions between whole-body heating and citalopram on body temperature, antidepressant-like behaviour, and neurochemistry in adolescent male rats.
Topics: Animals; Antidepressive Agents; Body Temperature; Citalopram; Combined Modality Therapy; Depressive | 2019 |
Interactions between whole-body heating and citalopram on body temperature, antidepressant-like behaviour, and neurochemistry in adolescent male rats.
Topics: Animals; Antidepressive Agents; Body Temperature; Citalopram; Combined Modality Therapy; Depressive | 2019 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Effects of escitalopram and ibuprofen on a depression-like phenotype induced by chronic stress in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cor | 2019 |
Effects of escitalopram and ibuprofen on a depression-like phenotype induced by chronic stress in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cor | 2019 |
The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study.
Topics: Adult; Antidepressive Agents; Blood Pressure; Citalopram; Depressive Disorder; Endothelium, Vascular | 2019 |
The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study.
Topics: Adult; Antidepressive Agents; Blood Pressure; Citalopram; Depressive Disorder; Endothelium, Vascular | 2019 |
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Topics: Adult; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Biological Variation, Population; | 2019 |
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Topics: Adult; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Biological Variation, Population; | 2019 |
Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; C-Reactive Prot | 2019 |
Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; C-Reactive Prot | 2019 |
Modifying effects of depression on the association between BDNF methylation and prognosis of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Brain-Derived Neurot | 2019 |
Modifying effects of depression on the association between BDNF methylation and prognosis of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Brain-Derived Neurot | 2019 |
Antidepressants and QTc prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Antidepressants and QTc prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressiv | 2013 |
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressiv | 2013 |
Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Depressive Disorder; Female; Humans; Male; Polymor | 2013 |
Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Depressive Disorder; Female; Humans; Male; Polymor | 2013 |
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Female; Heart | 2013 |
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Female; Heart | 2013 |
[Hallucinogen persisting perception disorder after ecstasy use].
Topics: Anxiety Disorders; Citalopram; Depressive Disorder; Hallucinations; Hallucinogens; Humans; Male; N-M | 2013 |
[Hallucinogen persisting perception disorder after ecstasy use].
Topics: Anxiety Disorders; Citalopram; Depressive Disorder; Hallucinations; Hallucinogens; Humans; Male; N-M | 2013 |
Escitalopram and QTc prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Escitalopram and QTc prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Author response.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Author response.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Citalopram; Cycl | 2014 |
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Citalopram; Cycl | 2014 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
Variations in central serotonergic activity - relevance of the 5-HTTLPR, life events and their interaction.
Topics: Adolescent; Adult; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Female; Genetic | 2015 |
Variations in central serotonergic activity - relevance of the 5-HTTLPR, life events and their interaction.
Topics: Adolescent; Adult; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Female; Genetic | 2015 |
Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hormone; Cyto | 2013 |
Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hormone; Cyto | 2013 |
A case of akathisia induced by escitalopram: case report & review of literature.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Breast Neoplasms; Citalopram; | 2014 |
A case of akathisia induced by escitalopram: case report & review of literature.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Breast Neoplasms; Citalopram; | 2014 |
Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight | 2014 |
Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight | 2014 |
Psycho-oncology: a brief history and case study.
Topics: Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell; Citalopram; Clonazepam; Depressi | 2013 |
Psycho-oncology: a brief history and case study.
Topics: Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell; Citalopram; Clonazepam; Depressi | 2013 |
Drug trials in psychiatry: methodological issues.
Topics: Alcoholism; Chlordiazepoxide; Citalopram; Depressive Disorder; Diabetes Mellitus; Female; Humans; Hy | 2014 |
Drug trials in psychiatry: methodological issues.
Topics: Alcoholism; Chlordiazepoxide; Citalopram; Depressive Disorder; Diabetes Mellitus; Female; Humans; Hy | 2014 |
Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Majo | 2014 |
Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Majo | 2014 |
Warning of risk to foetus for mothers using SSRIs.
Topics: Abnormalities, Drug-Induced; Citalopram; Depressive Disorder; Female; Humans; Pregnancy; Pregnancy C | 2013 |
Warning of risk to foetus for mothers using SSRIs.
Topics: Abnormalities, Drug-Induced; Citalopram; Depressive Disorder; Female; Humans; Pregnancy; Pregnancy C | 2013 |
Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction.
Topics: Adult; Bipolar Disorder; Citalopram; Depressive Disorder; Female; Humans; Psychiatric Status Rating | 2014 |
Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction.
Topics: Adult; Bipolar Disorder; Citalopram; Depressive Disorder; Female; Humans; Psychiatric Status Rating | 2014 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Weight; Chronic Disease; Citalopram | 2014 |
Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Weight; Chronic Disease; Citalopram | 2014 |
Apathy in late-life depression: common, persistent, and disabling.
Topics: Aged; Antidepressive Agents, Second-Generation; Apathy; Citalopram; Depressive Disorder; Depressive | 2015 |
Apathy in late-life depression: common, persistent, and disabling.
Topics: Aged; Antidepressive Agents, Second-Generation; Apathy; Citalopram; Depressive Disorder; Depressive | 2015 |
Acute extrapyramidal syndrome induced by escitalopram: a case report.
Topics: Acute Disease; Adult; Basal Ganglia Diseases; Citalopram; Depressive Disorder; Female; Humans; Selec | 2014 |
Acute extrapyramidal syndrome induced by escitalopram: a case report.
Topics: Acute Disease; Adult; Basal Ganglia Diseases; Citalopram; Depressive Disorder; Female; Humans; Selec | 2014 |
Rhabdomyolysis after escitalopram treatment in a young adult with melancholic depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Male; Rhabdomyoly | 2015 |
Rhabdomyolysis after escitalopram treatment in a young adult with melancholic depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Male; Rhabdomyoly | 2015 |
Antidepressant agents in short bowel syndrome.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Ag | 2014 |
Antidepressant agents in short bowel syndrome.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Ag | 2014 |
[Temporal lobe epilepsy and active neurocysticercosis: two representative case reports].
Topics: Albendazole; Anomia; Anthelmintics; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Citalopram | 2015 |
[Temporal lobe epilepsy and active neurocysticercosis: two representative case reports].
Topics: Albendazole; Anomia; Anthelmintics; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Citalopram | 2015 |
Severe manic episode associated with tramadol in a patient with recurrent depressive disorder.
Topics: Analgesics, Opioid; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents | 2015 |
Severe manic episode associated with tramadol in a patient with recurrent depressive disorder.
Topics: Analgesics, Opioid; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents | 2015 |
A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Cytokines; Depressive Disorder; Depr | 2015 |
A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Cytokines; Depressive Disorder; Depr | 2015 |
Dopamine Receptor D2 and Associated microRNAs Are Involved in Stress Susceptibility and Resistance to Escitalopram Treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Corpus Striatum; Dep | 2015 |
Dopamine Receptor D2 and Associated microRNAs Are Involved in Stress Susceptibility and Resistance to Escitalopram Treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Corpus Striatum; Dep | 2015 |
Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, A | 2015 |
Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, A | 2015 |
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.
Topics: Animals; Antidepressive Agents; Benzodiazepines; Bicuculline; Citalopram; Depressive Disorder; Disea | 2015 |
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.
Topics: Animals; Antidepressive Agents; Benzodiazepines; Bicuculline; Citalopram; Depressive Disorder; Disea | 2015 |
Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antidepressive Agents; Brain; Citalopram; Cyclic AM | 2015 |
Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antidepressive Agents; Brain; Citalopram; Cyclic AM | 2015 |
Changed Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats.
Topics: Animals; Antidepressive Agents; Blotting, Western; Body Weight; Brain; Chronic Disease; Citalopram; | 2015 |
Changed Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats.
Topics: Animals; Antidepressive Agents; Blotting, Western; Body Weight; Brain; Chronic Disease; Citalopram; | 2015 |
Deletion of GIRK2 Subunit of GIRK Channels Alters the 5-HT1A Receptor-Mediated Signaling and Results in a Depression-Resistant Behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Antidepressive Agents, Second-Ge | 2015 |
Deletion of GIRK2 Subunit of GIRK Channels Alters the 5-HT1A Receptor-Mediated Signaling and Results in a Depression-Resistant Behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Antidepressive Agents, Second-Ge | 2015 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; De | 2015 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; De | 2015 |
Mend the Mind and Mind the "MCC".
Topics: Acute Coronary Syndrome; Citalopram; Depressive Disorder; Female; Humans; Male; Sleep Wake Disorders | 2015 |
Mend the Mind and Mind the "MCC".
Topics: Acute Coronary Syndrome; Citalopram; Depressive Disorder; Female; Humans; Male; Sleep Wake Disorders | 2015 |
Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?
Topics: Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, | 2015 |
Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?
Topics: Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, | 2015 |
[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Citalopram; Cogniti | 2015 |
[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Citalopram; Cogniti | 2015 |
Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Depressive Disord | 2016 |
Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Depressive Disord | 2016 |
Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Comorbidity; Databases, Factual; | 2016 |
Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Comorbidity; Databases, Factual; | 2016 |
The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.
Topics: Adolescent; Adult; CD4 Antigens; Citalopram; Depressive Disorder; Down-Regulation; Female; HIV Infec | 2016 |
The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.
Topics: Adolescent; Adult; CD4 Antigens; Citalopram; Depressive Disorder; Down-Regulation; Female; HIV Infec | 2016 |
Delayed pressure urticaria treated with the selective serotonin reuptake inhibitor escitalopram.
Topics: Adult; Citalopram; Depressive Disorder; Female; Humans; Selective Serotonin Reuptake Inhibitors; Tre | 2016 |
Delayed pressure urticaria treated with the selective serotonin reuptake inhibitor escitalopram.
Topics: Adult; Citalopram; Depressive Disorder; Female; Humans; Selective Serotonin Reuptake Inhibitors; Tre | 2016 |
Treatment outcome variation between depression symptom combinations in the STAR*D study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; | 2016 |
Treatment outcome variation between depression symptom combinations in the STAR*D study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; | 2016 |
Citalopram, escitalopram: no more effective than other SSRIs, but more toxic.
Topics: Citalopram; Depressive Disorder; Humans; Long QT Syndrome; Seizures; Selective Serotonin Reuptake In | 2016 |
Citalopram, escitalopram: no more effective than other SSRIs, but more toxic.
Topics: Citalopram; Depressive Disorder; Humans; Long QT Syndrome; Seizures; Selective Serotonin Reuptake In | 2016 |
Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment.
Topics: Affect; Animals; Antidepressive Agents, Second-Generation; Brain; Brain Mapping; Cerebrovascular Cir | 2016 |
Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment.
Topics: Affect; Animals; Antidepressive Agents, Second-Generation; Brain; Brain Mapping; Cerebrovascular Cir | 2016 |
[Continuing therapy also in summer].
Topics: Citalopram; Depressive Disorder; Drug Administration Schedule; Female; Humans; Long-Term Care; Male; | 2016 |
[Continuing therapy also in summer].
Topics: Citalopram; Depressive Disorder; Drug Administration Schedule; Female; Humans; Long-Term Care; Male; | 2016 |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
Topics: Adult; Antidepressive Agents; Bupropion; Chromosomes, Human, Pair 4; Circadian Rhythm; Citalopram; D | 2016 |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
Topics: Adult; Antidepressive Agents; Bupropion; Chromosomes, Human, Pair 4; Circadian Rhythm; Citalopram; D | 2016 |
Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.
Topics: Animals; Antidepressive Agents; Citalopram; Cyclic AMP Response Element-Binding Protein; Depression; | 2017 |
Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.
Topics: Animals; Antidepressive Agents; Citalopram; Cyclic AMP Response Element-Binding Protein; Depression; | 2017 |
Escitalopram and Outcomes Among Patients With Depression and Heart Failure.
Topics: Citalopram; Depression; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Heart | 2016 |
Escitalopram and Outcomes Among Patients With Depression and Heart Failure.
Topics: Citalopram; Depression; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Heart | 2016 |
Escitalopram and Outcomes Among Patients With Depression and Heart Failure-Reply.
Topics: Citalopram; Depression; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Heart | 2016 |
Escitalopram and Outcomes Among Patients With Depression and Heart Failure-Reply.
Topics: Citalopram; Depression; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Heart | 2016 |
Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression.
Topics: Acute Disease; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; CA3 Region, Hippocampal; Ch | 2017 |
Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression.
Topics: Acute Disease; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; CA3 Region, Hippocampal; Ch | 2017 |
Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study.
Topics: Adolescent; Antidepressive Agents; Anxiety; Child; Citalopram; Cohort Studies; Databases, Factual; D | 2016 |
Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study.
Topics: Adolescent; Antidepressive Agents; Anxiety; Child; Citalopram; Cohort Studies; Databases, Factual; D | 2016 |
Sobering news about post-stroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Double-Blind Method; Humans; Stroke | 2017 |
Sobering news about post-stroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Double-Blind Method; Humans; Stroke | 2017 |
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, Co | 2017 |
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, Co | 2017 |
Differential treatment response, neuroinflammation, and psychosis associated with chromosome deletion.
Topics: Brain; Chromosome Deletion; Citalopram; Depressive Disorder; Humans; Inflammation Mediators; Obsessi | 2008 |
Differential treatment response, neuroinflammation, and psychosis associated with chromosome deletion.
Topics: Brain; Chromosome Deletion; Citalopram; Depressive Disorder; Humans; Inflammation Mediators; Obsessi | 2008 |
Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child, Preschool; Citalopram; Depressive Diso | 2008 |
Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child, Preschool; Citalopram; Depressive Diso | 2008 |
Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depressive Di | 2008 |
Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depressive Di | 2008 |
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2009 |
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2009 |
Blood pressure and white matter integrity in geriatric depression.
Topics: Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Blood Pressure; Brai | 2009 |
Blood pressure and white matter integrity in geriatric depression.
Topics: Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Blood Pressure; Brai | 2009 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Th | 2008 |
The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Th | 2008 |
Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Desipramine; Female; Humans; Male | 2009 |
Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Desipramine; Female; Humans; Male | 2009 |
Withdrawal symptoms of trifluoperazine.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depressive Disorde | 2008 |
Withdrawal symptoms of trifluoperazine.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depressive Disorde | 2008 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopr | 2009 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopr | 2009 |
Pharmacological augmentation of motor recovery after stroke: antidepressants for non-depressed patients?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2009 |
Pharmacological augmentation of motor recovery after stroke: antidepressants for non-depressed patients?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2009 |
Incomplete financial disclosure in a study of escitalopram and problem-solving therapy for prevention of poststroke depression.
Topics: Citalopram; Depressive Disorder; Disclosure; Humans; Psychotherapy; Selective Serotonin Reuptake Inh | 2009 |
Incomplete financial disclosure in a study of escitalopram and problem-solving therapy for prevention of poststroke depression.
Topics: Citalopram; Depressive Disorder; Disclosure; Humans; Psychotherapy; Selective Serotonin Reuptake Inh | 2009 |
Parameters of the spectral analysis of the heart rate variability in treating depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Circadian Rhythm; Citalopram; Dep | 2009 |
Parameters of the spectral analysis of the heart rate variability in treating depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Circadian Rhythm; Citalopram; Dep | 2009 |
Genetic predictors of response to antidepressants in the GENDEP project.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Linkage Disequilibrium; Norep | 2009 |
Genetic predictors of response to antidepressants in the GENDEP project.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Linkage Disequilibrium; Norep | 2009 |
Hypomania induced by escitalopram: 2 case reports.
Topics: Adult; Aged; Bipolar Disorder; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; | 2009 |
Hypomania induced by escitalopram: 2 case reports.
Topics: Adult; Aged; Bipolar Disorder; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; | 2009 |
Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain Injuries; Citalopram; Co | 2009 |
Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain Injuries; Citalopram; Co | 2009 |
A proteomic analysis of the ventral hippocampus of rats subjected to maternal separation and escitalopram treatment.
Topics: Animals; Causality; Citalopram; Depressive Disorder; Disease Models, Animal; Energy Metabolism; Fema | 2009 |
A proteomic analysis of the ventral hippocampus of rats subjected to maternal separation and escitalopram treatment.
Topics: Animals; Causality; Citalopram; Depressive Disorder; Disease Models, Animal; Energy Metabolism; Fema | 2009 |
[Medication associated long QT syndrome].
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Citalopram; D | 2009 |
[Medication associated long QT syndrome].
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Citalopram; D | 2009 |
The role of proteomics in depression research.
Topics: Animals; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder; Disease Models, Animal; | 2010 |
The role of proteomics in depression research.
Topics: Animals; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder; Disease Models, Animal; | 2010 |
DNA sequence variants of the FKBP5 gene are associated with unipolar depression.
Topics: Adolescent; Adult; Alleles; Base Sequence; Case-Control Studies; Citalopram; Depressive Disorder; Fe | 2010 |
DNA sequence variants of the FKBP5 gene are associated with unipolar depression.
Topics: Adolescent; Adult; Alleles; Base Sequence; Case-Control Studies; Citalopram; Depressive Disorder; Fe | 2010 |
Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease.
Topics: Activities of Daily Living; Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopr | 2010 |
Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease.
Topics: Activities of Daily Living; Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Citalopr | 2010 |
[Discontinuation of antidepressant serotonergic antidepressant].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder; Diagnosis, | 2010 |
[Discontinuation of antidepressant serotonergic antidepressant].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder; Diagnosis, | 2010 |
Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats.
Topics: Animals; Avoidance Learning; Behavior, Animal; Biofeedback, Psychology; Citalopram; Cognition Disord | 2010 |
Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats.
Topics: Animals; Avoidance Learning; Behavior, Animal; Biofeedback, Psychology; Citalopram; Cognition Disord | 2010 |
Use of antidepressants in children: is it time for a comparative effectiveness trial?
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Female; Fluoxetine; Human | 2010 |
Use of antidepressants in children: is it time for a comparative effectiveness trial?
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Female; Fluoxetine; Human | 2010 |
Probable epistaxis associated with escitalopram.
Topics: Adult; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Epistaxis; Humans; Male | 2010 |
Probable epistaxis associated with escitalopram.
Topics: Adult; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Epistaxis; Humans; Male | 2010 |
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; De | 2010 |
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; De | 2010 |
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Cohort Studies; Cross-Sectional Studies; Depre | 2010 |
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Cohort Studies; Cross-Sectional Studies; Depre | 2010 |
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Topics: Adult; Aged; Antidepressive Agents; British Columbia; Cause of Death; Citalopram; Cohort Studies; De | 2010 |
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Topics: Adult; Aged; Antidepressive Agents; British Columbia; Cause of Death; Citalopram; Cohort Studies; De | 2010 |
Affective and anxiety disorders: prevalence, treatment and antidepressant medication use.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; A | 2010 |
Affective and anxiety disorders: prevalence, treatment and antidepressant medication use.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; A | 2010 |
An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Comorbidity; Cyclohexanol | 2010 |
An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Comorbidity; Cyclohexanol | 2010 |
An audit to compare discharge rates and suicidality between antidepressant monotherapies prescribed for unipolar depression.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Cyclohexanols; Depressive | 2010 |
An audit to compare discharge rates and suicidality between antidepressant monotherapies prescribed for unipolar depression.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Cyclohexanols; Depressive | 2010 |
Suicide risk and choice of antidepressant.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Community Mental Heal | 2010 |
Suicide risk and choice of antidepressant.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Community Mental Heal | 2010 |
Early-life stress and antidepressants modulate peripheral biomarkers in a gene-environment rat model of depression.
Topics: Animals; Biomarkers; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Citalopram; Corticostero | 2010 |
Early-life stress and antidepressants modulate peripheral biomarkers in a gene-environment rat model of depression.
Topics: Animals; Biomarkers; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Citalopram; Corticostero | 2010 |
Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Citalopram; Dementia; Depression; Depressive Disorder; De | 2010 |
Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Citalopram; Dementia; Depression; Depressive Disorder; De | 2010 |
Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Brain; Citalopram; Cognition; | 2010 |
Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Brain; Citalopram; Cognition; | 2010 |
The effect of acute citalopram on face emotion processing in remitted depression: a pharmacoMRI study.
Topics: Adult; Amygdala; Brain; Cerebral Cortex; Citalopram; Depressive Disorder; Emotions; Facial Expressio | 2011 |
The effect of acute citalopram on face emotion processing in remitted depression: a pharmacoMRI study.
Topics: Adult; Amygdala; Brain; Cerebral Cortex; Citalopram; Depressive Disorder; Emotions; Facial Expressio | 2011 |
Mitotic recombination: a genotoxic effect of the antidepressant citalopram in Aspergillus nidulans.
Topics: Antidepressive Agents, Second-Generation; Aspergillus nidulans; Carcinogens; Citalopram; Crossing Ov | 2010 |
Mitotic recombination: a genotoxic effect of the antidepressant citalopram in Aspergillus nidulans.
Topics: Antidepressive Agents, Second-Generation; Aspergillus nidulans; Carcinogens; Citalopram; Crossing Ov | 2010 |
Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: role of serotonin synthesis.
Topics: Animals; Behavior, Animal; Brain Chemistry; Citalopram; Depressive Disorder; Male; Rats; Rats, Wista | 2010 |
Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: role of serotonin synthesis.
Topics: Animals; Behavior, Animal; Brain Chemistry; Citalopram; Depressive Disorder; Male; Rats; Rats, Wista | 2010 |
Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD8-Positive T-Lymphocytes; Cell Line; Cells, Cultured; C | 2010 |
Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD8-Positive T-Lymphocytes; Cell Line; Cells, Cultured; C | 2010 |
Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Health Care Costs; Humans; Ma | 2012 |
Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Health Care Costs; Humans; Ma | 2012 |
Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team.
Topics: Antidepressive Agents; Citalopram; Community Mental Health Services; Cyclohexanols; Depressive Disor | 2010 |
Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team.
Topics: Antidepressive Agents; Citalopram; Community Mental Health Services; Cyclohexanols; Depressive Disor | 2010 |
Changes in regional brain volumes in social anxiety disorder following 12 weeks of treatment with escitalopram.
Topics: Adolescent; Adult; Aged; Anxiety; Anxiety Disorders; Brain; Citalopram; Depressive Disorder; Diagnos | 2010 |
Changes in regional brain volumes in social anxiety disorder following 12 weeks of treatment with escitalopram.
Topics: Adolescent; Adult; Aged; Anxiety; Anxiety Disorders; Brain; Citalopram; Depressive Disorder; Diagnos | 2010 |
Torsade de pointes induced by citalopram and amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Depressive D | 2011 |
Torsade de pointes induced by citalopram and amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Depressive D | 2011 |
Prolonged QTc interval due to escitalopram overdose.
Topics: Adult; Citalopram; Depressive Disorder; Drug Overdose; Electrocardiography; Female; Humans; Long QT | 2010 |
Prolonged QTc interval due to escitalopram overdose.
Topics: Adult; Citalopram; Depressive Disorder; Drug Overdose; Electrocardiography; Female; Humans; Long QT | 2010 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.
Topics: Animals; Annexin A2; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressi | 2011 |
Escitalopram and ischemic stroke: causal or chance association?
Topics: Adult; Antidepressive Agents; Brain Ischemia; Citalopram; Depressive Disorder; Humans; Male; Stroke | 2011 |
Escitalopram and ischemic stroke: causal or chance association?
Topics: Adult; Antidepressive Agents; Brain Ischemia; Citalopram; Depressive Disorder; Humans; Male; Stroke | 2011 |
Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression.
Topics: Animals; Annexin A2; Citalopram; Depressive Disorder; Disease Models, Animal; DNA (Cytosine-5-)-Meth | 2012 |
Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression.
Topics: Animals; Annexin A2; Citalopram; Depressive Disorder; Disease Models, Animal; DNA (Cytosine-5-)-Meth | 2012 |
Citalopram-mediated anxiolysis and differing neurobiological responses in both sexes of a genetic model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disor | 2011 |
Citalopram-mediated anxiolysis and differing neurobiological responses in both sexes of a genetic model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disor | 2011 |
Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Confidence Intervals; Data Interpretati | 2012 |
Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Confidence Intervals; Data Interpretati | 2012 |
Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients: an open multicenter study in Belgium and Luxembourg.
Topics: Aged; Aging; Analysis of Variance; Antidepressive Agents, Second-Generation; Belgium; Blood Pressure | 2011 |
Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients: an open multicenter study in Belgium and Luxembourg.
Topics: Aged; Aging; Analysis of Variance; Antidepressive Agents, Second-Generation; Belgium; Blood Pressure | 2011 |
Impact of citalopram on the HPA system. A study of the combined DEX/CRH test in 30 unipolar depressed patients.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Antidepressive Agents, Second-Generation; Area | 2012 |
Impact of citalopram on the HPA system. A study of the combined DEX/CRH test in 30 unipolar depressed patients.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Antidepressive Agents, Second-Generation; Area | 2012 |
The MMPI-2 neurotic triad subscales and depression levels after pharmacological treatment in patients with depressive disorders - clinical study.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Hypochond | 2011 |
The MMPI-2 neurotic triad subscales and depression levels after pharmacological treatment in patients with depressive disorders - clinical study.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Hypochond | 2011 |
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.
Topics: Citalopram; Depressive Disorder; Genome-Wide Association Study; Glycine; Glycine Dehydrogenase; Hapl | 2012 |
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.
Topics: Citalopram; Depressive Disorder; Genome-Wide Association Study; Glycine; Glycine Dehydrogenase; Hapl | 2012 |
[Treatment research of intermediate severity depression: what is useful for the routine patient?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Cl | 2012 |
[Treatment research of intermediate severity depression: what is useful for the routine patient?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Cl | 2012 |
Reversal of SSRI-associated apathy syndrome by discontinuation of therapy.
Topics: Aged; Antidepressive Agents; Apathy; Citalopram; Depressive Disorder; Fluoxetine; Humans; Male; Midd | 2012 |
Reversal of SSRI-associated apathy syndrome by discontinuation of therapy.
Topics: Aged; Antidepressive Agents; Apathy; Citalopram; Depressive Disorder; Fluoxetine; Humans; Male; Midd | 2012 |
When prevention is a bad idea: problems with the DECARD trial and the premise behind it.
Topics: Acute Coronary Syndrome; Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Randomized | 2012 |
When prevention is a bad idea: problems with the DECARD trial and the premise behind it.
Topics: Acute Coronary Syndrome; Antidepressive Agents; Citalopram; Depressive Disorder; Humans; Randomized | 2012 |
Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Data Interpretation, Sta | 2013 |
Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Data Interpretation, Sta | 2013 |
Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Bupropion; Citalopram; Cyclohexano | 2012 |
Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Bupropion; Citalopram; Cyclohexano | 2012 |
Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; De | 2014 |
Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; De | 2014 |
Behavioral changes after maternal separation are reversed by chronic constant light treatment.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Dep | 2012 |
Behavioral changes after maternal separation are reversed by chronic constant light treatment.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Dep | 2012 |
Clarification of the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment (REMIT) trial protocol.
Topics: Cardiovascular Diseases; Citalopram; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhib | 2012 |
Clarification of the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment (REMIT) trial protocol.
Topics: Cardiovascular Diseases; Citalopram; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhib | 2012 |
Depression among dialysis patients: barriers to good care.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2012 |
Depression among dialysis patients: barriers to good care.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2012 |
Escitalopram-related visual and auditory hallucination in a non-dementia patient with depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Hallucinations; Hum | 2012 |
Escitalopram-related visual and auditory hallucination in a non-dementia patient with depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Hallucinations; Hum | 2012 |
Tramadol precipitating serotonin syndrome in a patient on antidepressants.
Topics: Analgesics, Opioid; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder; Drug Therapy, | 2012 |
Tramadol precipitating serotonin syndrome in a patient on antidepressants.
Topics: Analgesics, Opioid; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder; Drug Therapy, | 2012 |
Re: citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2013 |
Re: citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2013 |
Neural correlates of treatment response in depressed bipolar adolescents during emotion processing.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Diso | 2013 |
Neural correlates of treatment response in depressed bipolar adolescents during emotion processing.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Diso | 2013 |
Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression.
Topics: Adult; Auditory Perception; Citalopram; Depressive Disorder; Electroencephalography; Female; Humans; | 2002 |
Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression.
Topics: Adult; Auditory Perception; Citalopram; Depressive Disorder; Electroencephalography; Female; Humans; | 2002 |
Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Topics: Adjuvants, Immunologic; Adult; Citalopram; Depressive Disorder; Female; Humans; Interferon beta-1a; | 2002 |
Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Topics: Adjuvants, Immunologic; Adult; Citalopram; Depressive Disorder; Female; Humans; Interferon beta-1a; | 2002 |
Citalopram in children and adolescents with depression or anxiety.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopram; Comorbidity; Depre | 2002 |
Citalopram in children and adolescents with depression or anxiety.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopram; Comorbidity; Depre | 2002 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques.
Topics: Animals; Basal Ganglia; Carrier Proteins; Citalopram; Depressive Disorder; Estrogens; Female; Hormon | 2003 |
Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques.
Topics: Animals; Basal Ganglia; Carrier Proteins; Citalopram; Depressive Disorder; Estrogens; Female; Hormon | 2003 |
Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms.
Topics: Adult; Antidepressive Agents; Citalopram; Climacteric; Depressive Disorder; Drug Therapy, Combinatio | 2003 |
Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms.
Topics: Adult; Antidepressive Agents; Citalopram; Climacteric; Depressive Disorder; Drug Therapy, Combinatio | 2003 |
Burning mouth syndrome as a side effect of SSRIs.
Topics: Burning Mouth Syndrome; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; F | 2003 |
Burning mouth syndrome as a side effect of SSRIs.
Topics: Burning Mouth Syndrome; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; F | 2003 |
Placental passage of antidepressant medications.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Fem | 2003 |
Placental passage of antidepressant medications.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Fem | 2003 |
[Cipramil treatment of neurotic depression].
Topics: Adult; Citalopram; Depressive Disorder; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors | 2003 |
[Cipramil treatment of neurotic depression].
Topics: Adult; Citalopram; Depressive Disorder; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors | 2003 |
Residual cognitive impairment in late-life depression after a 12-month period follow-up.
Topics: Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2003 |
Residual cognitive impairment in late-life depression after a 12-month period follow-up.
Topics: Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2003 |
R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Topics: Animals; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; | 2003 |
R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Topics: Animals; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; | 2003 |
Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Citalopram; Depressive Disord | 2003 |
Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Citalopram; Depressive Disord | 2003 |
A preliminary study of left frontal region error negativity and symptom improvement in geriatric depression.
Topics: Aged; Attention; Citalopram; Conflict, Psychological; Depressive Disorder; Electroencephalography; F | 2003 |
A preliminary study of left frontal region error negativity and symptom improvement in geriatric depression.
Topics: Aged; Attention; Citalopram; Conflict, Psychological; Depressive Disorder; Electroencephalography; F | 2003 |
The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder | 2003 |
The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder | 2003 |
Citalopram and dystonia.
Topics: Adolescent; Citalopram; Depressive Disorder; Dystonia; Humans; Male; Selective Serotonin Reuptake In | 2004 |
Citalopram and dystonia.
Topics: Adolescent; Citalopram; Depressive Disorder; Dystonia; Humans; Male; Selective Serotonin Reuptake In | 2004 |
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.
Topics: Absenteeism; Austria; Citalopram; Cost-Benefit Analysis; Decision Theory; Depressive Disorder; Healt | 2004 |
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.
Topics: Absenteeism; Austria; Citalopram; Cost-Benefit Analysis; Decision Theory; Depressive Disorder; Healt | 2004 |
Hepatotoxicity related to citalopram.
Topics: Adult; Chemical and Drug Induced Liver Injury; Citalopram; Depressive Disorder; Humans; Liver; Liver | 2004 |
Hepatotoxicity related to citalopram.
Topics: Adult; Chemical and Drug Induced Liver Injury; Citalopram; Depressive Disorder; Humans; Liver; Liver | 2004 |
Serotonin syndrome with tramadol and citalopram.
Topics: Aged; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Narcotics; Pain; S | 2004 |
Serotonin syndrome with tramadol and citalopram.
Topics: Aged; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Narcotics; Pain; S | 2004 |
Citalopram and mania.
Topics: Adolescent; Bipolar Disorder; Child; Citalopram; Depressive Disorder; Humans; Male; Selective Seroto | 2004 |
Citalopram and mania.
Topics: Adolescent; Bipolar Disorder; Child; Citalopram; Depressive Disorder; Humans; Male; Selective Seroto | 2004 |
Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine.
Topics: Citalopram; Depressive Disorder; Drug Administration Schedule; Fatigue; Fluoxetine; Humans; Paroxeti | 2004 |
Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine.
Topics: Citalopram; Depressive Disorder; Drug Administration Schedule; Fatigue; Fluoxetine; Humans; Paroxeti | 2004 |
Antidepressant-associated mania with escitalopram.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Citalopram; Depressive Disorder; Humans; Male; Selective S | 2004 |
Antidepressant-associated mania with escitalopram.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Citalopram; Depressive Disorder; Humans; Male; Selective S | 2004 |
Quetiapine-induced weight gain and escitalopram.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Depressive Disorder; Dibenzothiazepines; Drug Synergis | 2005 |
Quetiapine-induced weight gain and escitalopram.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Depressive Disorder; Dibenzothiazepines; Drug Synergis | 2005 |
Escitalopram intoxication.
Topics: Adult; Antidepressive Agents, Second-Generation; Charcoal; Citalopram; Depressive Disorder; Female; | 2005 |
Escitalopram intoxication.
Topics: Adult; Antidepressive Agents, Second-Generation; Charcoal; Citalopram; Depressive Disorder; Female; | 2005 |
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Depressi | 2005 |
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Depressi | 2005 |
Toxicity with selective serotonin reuptake inhibitors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Citalopram; Depressive Disorder; Female; Fluvoxamine; | 2005 |
Toxicity with selective serotonin reuptake inhibitors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Citalopram; Depressive Disorder; Female; Fluvoxamine; | 2005 |
Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antidepressive Ag | 2005 |
Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antidepressive Ag | 2005 |
Citalopram therapy as a risk factor for symptomatic hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): a case report.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Hyp | 2005 |
Citalopram therapy as a risk factor for symptomatic hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): a case report.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Hyp | 2005 |
Interferon beta-1a overdose in a multiple sclerosis patient.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder; Drug Overdose; Emergencie | 2005 |
Interferon beta-1a overdose in a multiple sclerosis patient.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder; Drug Overdose; Emergencie | 2005 |
[The serotonin syndrome].
Topics: Aged; Antipsychotic Agents; Citalopram; Depressive Disorder; Dibenzothiepins; Dose-Response Relation | 2005 |
[The serotonin syndrome].
Topics: Aged; Antipsychotic Agents; Citalopram; Depressive Disorder; Dibenzothiepins; Dose-Response Relation | 2005 |
Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cycloh | 2005 |
Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cycloh | 2005 |
Electric sensations: neglected symptom of escitalopram discontinuation.
Topics: Citalopram; Confusion; Depressive Disorder; Electric Stimulation; Female; Humans; Paresthesia; Photi | 2006 |
Electric sensations: neglected symptom of escitalopram discontinuation.
Topics: Citalopram; Confusion; Depressive Disorder; Electric Stimulation; Female; Humans; Paresthesia; Photi | 2006 |
Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Clorazepate Dipotassium; | 2006 |
Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Clorazepate Dipotassium; | 2006 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Neurotoxic reaction to citalopram.
Topics: Aged; Basal Ganglia Diseases; Citalopram; Depressive Disorder; Dystonia; Female; Humans; Parkinson D | 2006 |
Neurotoxic reaction to citalopram.
Topics: Aged; Basal Ganglia Diseases; Citalopram; Depressive Disorder; Dystonia; Female; Humans; Parkinson D | 2006 |
Escitalopram-induced uveal effusions and bilateral angle closure glaucoma.
Topics: Acute Disease; Adult; Anterior Eye Segment; Citalopram; Depressive Disorder; Exudates and Transudate | 2006 |
Escitalopram-induced uveal effusions and bilateral angle closure glaucoma.
Topics: Acute Disease; Adult; Anterior Eye Segment; Citalopram; Depressive Disorder; Exudates and Transudate | 2006 |
Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Depr | 2006 |
Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Depr | 2006 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
After the failure of citalopram for depression, what next?
Topics: Citalopram; Depressive Disorder; Humans; Placebos; Remission Induction; Treatment Failure; Uncertain | 2006 |
After the failure of citalopram for depression, what next?
Topics: Citalopram; Depressive Disorder; Humans; Placebos; Remission Induction; Treatment Failure; Uncertain | 2006 |
Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; | 2006 |
Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; | 2006 |
Patterns of early adherence to the antidepressant citalopram among older primary care patients: the prospect study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; | 2006 |
Patterns of early adherence to the antidepressant citalopram among older primary care patients: the prospect study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; | 2006 |
Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population.
Topics: Adult; Alleles; Antidepressive Agents; Citalopram; Depressive Disorder; DNA; Female; Genotype; Human | 2007 |
Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population.
Topics: Adult; Alleles; Antidepressive Agents; Citalopram; Depressive Disorder; DNA; Female; Genotype; Human | 2007 |
Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Topics: Adolescent; Adult; Aged; Catchment Area, Health; Citalopram; Cost-Benefit Analysis; Depressive Disor | 2006 |
Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Topics: Adolescent; Adult; Aged; Catchment Area, Health; Citalopram; Cost-Benefit Analysis; Depressive Disor | 2006 |
Citalopram-induced Raynaud's phenomenon.
Topics: Adult; Analgesics; Citalopram; Depressive Disorder; Female; Humans; Neuralgia; Raynaud Disease; Sele | 2007 |
Citalopram-induced Raynaud's phenomenon.
Topics: Adult; Analgesics; Citalopram; Depressive Disorder; Female; Humans; Neuralgia; Raynaud Disease; Sele | 2007 |
Hysterical paralysis.
Topics: Adult; Age Factors; Citalopram; Conversion Disorder; Depressive Disorder; Diagnosis, Differential; D | 2007 |
Hysterical paralysis.
Topics: Adult; Age Factors; Citalopram; Conversion Disorder; Depressive Disorder; Diagnosis, Differential; D | 2007 |
Do your patients suffer from excessive yawning?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Dose-Response Relationshi | 2007 |
Do your patients suffer from excessive yawning?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Dose-Response Relationshi | 2007 |
Attention to side effects enhances medical adherence.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Citalopram; Depre | 2007 |
Attention to side effects enhances medical adherence.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Citalopram; Depre | 2007 |
Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies.
Topics: Animals; Brain; Brain Chemistry; Citalopram; Depressive Disorder; Drug Administration Routes; Drug S | 2007 |
Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies.
Topics: Animals; Brain; Brain Chemistry; Citalopram; Depressive Disorder; Drug Administration Routes; Drug S | 2007 |
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Depres | 2007 |
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Depres | 2007 |
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Binding Sites; Brain; Brain Chemistry; | 2007 |
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Binding Sites; Brain; Brain Chemistry; | 2007 |
Oral adverse effects for escitalopram (Cipralex).
Topics: Adult; Citalopram; Depressive Disorder; Female; Humans; Lichenoid Eruptions; Lip Diseases; Mouth Dis | 2007 |
Oral adverse effects for escitalopram (Cipralex).
Topics: Adult; Citalopram; Depressive Disorder; Female; Humans; Lichenoid Eruptions; Lip Diseases; Mouth Dis | 2007 |
[Prospective study using a modified Montgomery-Asberg Depression Scale].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cohort Studies; Depressive Disorder; Follow-Up | 2007 |
[Prospective study using a modified Montgomery-Asberg Depression Scale].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cohort Studies; Depressive Disorder; Follow-Up | 2007 |
Citalopram to treat depression in pediatric oncology.
Topics: Adolescent; Central Nervous System Neoplasms; Child; Citalopram; Craniopharyngioma; Depressive Disor | 2007 |
Citalopram to treat depression in pediatric oncology.
Topics: Adolescent; Central Nervous System Neoplasms; Child; Citalopram; Craniopharyngioma; Depressive Disor | 2007 |
Pain in depression: STAR*D study findings.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; M | 2007 |
Pain in depression: STAR*D study findings.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; M | 2007 |
[Establishment of rat model of post-stroke depression and the effects of citalopram on behavior thereof].
Topics: Animals; Behavior, Animal; Brain Ischemia; Citalopram; Depressive Disorder; Disease Models, Animal; | 2007 |
[Establishment of rat model of post-stroke depression and the effects of citalopram on behavior thereof].
Topics: Animals; Behavior, Animal; Brain Ischemia; Citalopram; Depressive Disorder; Disease Models, Animal; | 2007 |
Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST).
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2008 |
Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST).
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2008 |
Antidepressant effect of stem cell-derived monoaminergic grafts.
Topics: Animals; Antidepressive Agents, Second-Generation; Aromatic-L-Amino-Acid Decarboxylases; Biogenic Mo | 2007 |
Antidepressant effect of stem cell-derived monoaminergic grafts.
Topics: Animals; Antidepressive Agents, Second-Generation; Aromatic-L-Amino-Acid Decarboxylases; Biogenic Mo | 2007 |
Can chemotherapy induce reactions of recollection?
Topics: Antidepressive Agents; Antineoplastic Agents; Breast Neoplasms; Citalopram; Depressive Disorder; Fem | 2007 |
Can chemotherapy induce reactions of recollection?
Topics: Antidepressive Agents; Antineoplastic Agents; Breast Neoplasms; Citalopram; Depressive Disorder; Fem | 2007 |
Ethnicity/race and outcome in the treatment of depression: results from STAR*D.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug A | 2007 |
Ethnicity/race and outcome in the treatment of depression: results from STAR*D.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug A | 2007 |
Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.
Topics: Adolescent; Age Factors; Animals; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Des | 2008 |
Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.
Topics: Adolescent; Age Factors; Animals; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Des | 2008 |
Behavioral disinhibition without persistent mood elevation after high dose citalopram treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Depressive Disorder; | 2007 |
Behavioral disinhibition without persistent mood elevation after high dose citalopram treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Depressive Disorder; | 2007 |
Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Animals, Newborn; Antidepress | 2008 |
Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Animals, Newborn; Antidepress | 2008 |
[Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression].
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive A | 2008 |
[Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression].
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive A | 2008 |
Trends in antidepressant use in the older population: results from the LASA-study over a period of 10 years.
Topics: Adult; Age Distribution; Age Factors; Aged; Antidepressive Agents; Citalopram; Cognition Disorders; | 2008 |
Trends in antidepressant use in the older population: results from the LASA-study over a period of 10 years.
Topics: Adult; Age Distribution; Age Factors; Aged; Antidepressive Agents; Citalopram; Cognition Disorders; | 2008 |
Restless legs syndrome as side effect of second generation antidepressants.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, M | 2008 |
Restless legs syndrome as side effect of second generation antidepressants.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, M | 2008 |
Use of escitalopram in psychogenic excoriation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Compulsive Behavior; Depressive Disorde | 2008 |
Use of escitalopram in psychogenic excoriation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Compulsive Behavior; Depressive Disorde | 2008 |
Treatment of auditory hallucinations by combining high-frequency repetitive transcranial magnetic stimulation and functional magnetic resonance imaging.
Topics: Antidepressive Agents; Antipsychotic Agents; Citalopram; Combined Modality Therapy; Comorbidity; Dep | 2008 |
Treatment of auditory hallucinations by combining high-frequency repetitive transcranial magnetic stimulation and functional magnetic resonance imaging.
Topics: Antidepressive Agents; Antipsychotic Agents; Citalopram; Combined Modality Therapy; Comorbidity; Dep | 2008 |
[Open preliminary study of new antidepressive compound: citalopram].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Citalopram; Depressive Disorder; D | 1984 |
[Open preliminary study of new antidepressive compound: citalopram].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Citalopram; Depressive Disorder; D | 1984 |
Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long-term effect--a phase II study.
Topics: Adult; Citalopram; Depressive Disorder; Drug Evaluation; Electroconvulsive Therapy; Female; Humans; | 1982 |
Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long-term effect--a phase II study.
Topics: Adult; Citalopram; Depressive Disorder; Drug Evaluation; Electroconvulsive Therapy; Female; Humans; | 1982 |
Initial, clinical trial of a new, specific 5-HT reuptake inhibitor, citalopram (Lu 10-171).
Topics: Adult; Aged; Benzofurans; Citalopram; Depressive Disorder; Drug Evaluation; Female; Humans; Male; Mi | 1980 |
Initial, clinical trial of a new, specific 5-HT reuptake inhibitor, citalopram (Lu 10-171).
Topics: Adult; Aged; Benzofurans; Citalopram; Depressive Disorder; Drug Evaluation; Female; Humans; Male; Mi | 1980 |
Preliminary studies with citalopram (LU 10-171), a specific 5-HT-reuptake inhibitor, as antidepressant.
Topics: Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Middle Aged; Propyl | 1982 |
Preliminary studies with citalopram (LU 10-171), a specific 5-HT-reuptake inhibitor, as antidepressant.
Topics: Aged; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Middle Aged; Propyl | 1982 |
Citalopram--a specific 5-HT-reuptake inhibitor--as an antidepressant drug: a phase II multicentre trail.
Topics: Adult; Age Factors; Aged; Citalopram; Depressive Disorder; Drug Evaluation; Female; Humans; Male; Mi | 1982 |
Citalopram--a specific 5-HT-reuptake inhibitor--as an antidepressant drug: a phase II multicentre trail.
Topics: Adult; Age Factors; Aged; Citalopram; Depressive Disorder; Drug Evaluation; Female; Humans; Male; Mi | 1982 |
[Drug of the month. Citalopram (Cipramil)].
Topics: Citalopram; Depressive Disorder; Humans | 1995 |
[Drug of the month. Citalopram (Cipramil)].
Topics: Citalopram; Depressive Disorder; Humans | 1995 |
Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.
Topics: Adult; Biomarkers; Blood Platelets; Cell Membrane; Citalopram; Depressive Disorder; Desipramine; Fem | 1993 |
Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.
Topics: Adult; Biomarkers; Blood Platelets; Cell Membrane; Citalopram; Depressive Disorder; Desipramine; Fem | 1993 |
Mania induced by citalopram.
Topics: Bipolar Disorder; Citalopram; Depressive Disorder; Humans; Male; Middle Aged | 1994 |
Mania induced by citalopram.
Topics: Bipolar Disorder; Citalopram; Depressive Disorder; Humans; Male; Middle Aged | 1994 |
[Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression].
Topics: Citalopram; Depressive Disorder; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Tablets | 1993 |
[Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression].
Topics: Citalopram; Depressive Disorder; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Tablets | 1993 |
Increased trimipramine plasma levels during fluvoxamine comedication.
Topics: Aged; Citalopram; Depressive Disorder; Dextromethorphan; Drug Interactions; Female; Fluvoxamine; Hum | 1994 |
Increased trimipramine plasma levels during fluvoxamine comedication.
Topics: Aged; Citalopram; Depressive Disorder; Dextromethorphan; Drug Interactions; Female; Fluvoxamine; Hum | 1994 |
Unrecognized pregnancy during citalopram treatment.
Topics: Abortion, Induced; Adult; Citalopram; Depressive Disorder; Female; Fetus; Humans; Maternal-Fetal Exc | 1993 |
Unrecognized pregnancy during citalopram treatment.
Topics: Abortion, Induced; Adult; Citalopram; Depressive Disorder; Female; Fetus; Humans; Maternal-Fetal Exc | 1993 |
Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, | 1993 |
Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, | 1993 |
The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Citalopram; Depressive Disorder; Disease Models, An | 1995 |
The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Citalopram; Depressive Disorder; Disease Models, An | 1995 |
Citalopram, depression and pseudo dementia: a neuropsychological case study.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Diagnosis, Differential; Factitious Di | 1995 |
Citalopram, depression and pseudo dementia: a neuropsychological case study.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Diagnosis, Differential; Factitious Di | 1995 |
Serotonin syndrome in the elderly after antidepressive monotherapy.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Benzamid | 1995 |
Serotonin syndrome in the elderly after antidepressive monotherapy.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Benzamid | 1995 |
A "therapeutic window" with citalopram in a case of depression.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male | 1996 |
A "therapeutic window" with citalopram in a case of depression.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Male | 1996 |
Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Carbamazepine; Citalopram; Depressive Disorder; Drug | 1996 |
Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Carbamazepine; Citalopram; Depressive Disorder; Drug | 1996 |
Three new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depre | 1996 |
Three new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depre | 1996 |
Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors.
Topics: Amino Acids; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxa | 1996 |
Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors.
Topics: Amino Acids; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxa | 1996 |
Successful treatment of citalopram-induced anorgasmia by cyproheptadine.
Topics: Antidepressive Agents; Citalopram; Cyproheptadine; Depressive Disorder; Dose-Response Relationship, | 1996 |
Successful treatment of citalopram-induced anorgasmia by cyproheptadine.
Topics: Antidepressive Agents; Citalopram; Cyproheptadine; Depressive Disorder; Dose-Response Relationship, | 1996 |
Mania associated with serotonin selective reuptake inhibitors.
Topics: Bipolar Disorder; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Paroxet | 1997 |
Mania associated with serotonin selective reuptake inhibitors.
Topics: Bipolar Disorder; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Paroxet | 1997 |
Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Antidepressive Agents; Anxiety Disorders; Citalopram; C | 1996 |
Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Antidepressive Agents; Anxiety Disorders; Citalopram; C | 1996 |
Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 1997 |
Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 1997 |
Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
Topics: Aged; Buspirone; Citalopram; Depressive Disorder; Drug Interactions; Female; Humans; Hyponatremia; M | 1997 |
Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
Topics: Aged; Buspirone; Citalopram; Depressive Disorder; Drug Interactions; Female; Humans; Hyponatremia; M | 1997 |
Citalopram-associated clitoral priapism: a case series.
Topics: Adult; Antidepressive Agents; Citalopram; Clitoris; Depressive Disorder; Dose-Response Relationship, | 1997 |
Citalopram-associated clitoral priapism: a case series.
Topics: Adult; Antidepressive Agents; Citalopram; Clitoris; Depressive Disorder; Dose-Response Relationship, | 1997 |
Excretion of citalopram in breast milk.
Topics: Adult; Antidepressive Agents; Breast Feeding; Citalopram; Depressive Disorder; Female; Humans; Infan | 1997 |
Excretion of citalopram in breast milk.
Topics: Adult; Antidepressive Agents; Breast Feeding; Citalopram; Depressive Disorder; Female; Humans; Infan | 1997 |
Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment.
Topics: Adult; Antidepressive Agents; Blood Platelets; Citalopram; Clomipramine; Depressive Disorder; Dose-R | 1997 |
Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment.
Topics: Adult; Antidepressive Agents; Blood Platelets; Citalopram; Clomipramine; Depressive Disorder; Dose-R | 1997 |
Anorexia nervosa, major depression, and obsessive-compulsive disorder in a Down's syndrome patient.
Topics: Adult; Anorexia Nervosa; Antidepressive Agents; Citalopram; Depressive Disorder; Down Syndrome; Huma | 1998 |
Anorexia nervosa, major depression, and obsessive-compulsive disorder in a Down's syndrome patient.
Topics: Adult; Anorexia Nervosa; Antidepressive Agents; Citalopram; Depressive Disorder; Down Syndrome; Huma | 1998 |
Drug treatment of depression. Citalopram in overdose may result in serious morbidity and death.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Drug Overdose; Humans; Selective Serotonin R | 1998 |
Drug treatment of depression. Citalopram in overdose may result in serious morbidity and death.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Drug Overdose; Humans; Selective Serotonin R | 1998 |
Citalopram approved for treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug Approval; Humans; Se | 1998 |
Citalopram approved for treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug Approval; Humans; Se | 1998 |
A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Cost-Benefit Ana | 1995 |
A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Cost-Benefit Ana | 1995 |
Citalopram and sexual side effects of selective serotonin reuptake inhibitors.
Topics: Aged; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptak | 1999 |
Citalopram and sexual side effects of selective serotonin reuptake inhibitors.
Topics: Aged; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptak | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fl | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fl | 1999 |
Introduction. Overview of citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 1999 |
Introduction. Overview of citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 1999 |
Citalopram: a rapid-onset selective serotonin reuptake inhibitor?
Topics: Adult; Citalopram; Depressive Disorder; Female; Humans; Selective Serotonin Reuptake Inhibitors | 1999 |
Citalopram: a rapid-onset selective serotonin reuptake inhibitor?
Topics: Adult; Citalopram; Depressive Disorder; Female; Humans; Selective Serotonin Reuptake Inhibitors | 1999 |
Lack of desipramine toxicity with citalopram.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P | 2000 |
Lack of desipramine toxicity with citalopram.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P | 2000 |
A case of citalopram withdrawal.
Topics: Citalopram; Depressive Disorder; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; | 2000 |
A case of citalopram withdrawal.
Topics: Citalopram; Depressive Disorder; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; | 2000 |
De novo onset of Parkinson's disease after antidepressant treatment with citalopram.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Magnetic Resonance Ima | 2000 |
De novo onset of Parkinson's disease after antidepressant treatment with citalopram.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Magnetic Resonance Ima | 2000 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combina | 2001 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combina | 2001 |
The mood-lowering effect of tryptophan depletion: possible explanation for discrepant findings.
Topics: Affect; Brain; Citalopram; Depressive Disorder; Humans; Monoamine Oxidase Inhibitors; Psychiatric St | 2001 |
The mood-lowering effect of tryptophan depletion: possible explanation for discrepant findings.
Topics: Affect; Brain; Citalopram; Depressive Disorder; Humans; Monoamine Oxidase Inhibitors; Psychiatric St | 2001 |
An ideal trial to test differential onset of antidepressant effect.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Paroxetine | 2001 |
An ideal trial to test differential onset of antidepressant effect.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Paroxetine | 2001 |
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Citalopram; Depressi | 2000 |
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Citalopram; Depressi | 2000 |
Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Citalopram; Czech Republic; Depressiv | 2000 |
Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Citalopram; Czech Republic; Depressiv | 2000 |
Citalopram in mentally retarded patients with depression: a long-term clinical investigation.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Follow-Up Studies; Humans; In | 2001 |
Citalopram in mentally retarded patients with depression: a long-term clinical investigation.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Follow-Up Studies; Humans; In | 2001 |
Are newer antidepressants really "better tolerated"?
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Contusions; Depressive Disorder; Female | 2001 |
Are newer antidepressants really "better tolerated"?
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Contusions; Depressive Disorder; Female | 2001 |
Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Tricyclic; Body Weight; Brai | 2001 |
Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Tricyclic; Body Weight; Brai | 2001 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statisti | 2001 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statisti | 2001 |
A retrospective study of citalopram in adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Human | 2001 |
A retrospective study of citalopram in adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Human | 2001 |
Low frequency rTMS as an add-on antidepressive strategy: heterogeneous impact on 99mTc-HMPAO and 18 F-FDG uptake as measured simultaneously with the double isotope SPECT technique. Pilot study.
Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Citalopram; Depressive Disorder; Female; Fluorod | 2001 |
Low frequency rTMS as an add-on antidepressive strategy: heterogeneous impact on 99mTc-HMPAO and 18 F-FDG uptake as measured simultaneously with the double isotope SPECT technique. Pilot study.
Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Citalopram; Depressive Disorder; Female; Fluorod | 2001 |
Citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome?
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Diagnosis, Differential; Drug Overdose; Huma | 2001 |
Citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome?
Topics: Antidepressive Agents; Citalopram; Depressive Disorder; Diagnosis, Differential; Drug Overdose; Huma | 2001 |
Organic hypomania secondary to sibutramine-citalopram interaction.
Topics: Adult; Appetite Depressants; Bipolar Disorder; Citalopram; Cyclobutanes; Depressive Disorder; Drug I | 2002 |
Organic hypomania secondary to sibutramine-citalopram interaction.
Topics: Adult; Appetite Depressants; Bipolar Disorder; Citalopram; Cyclobutanes; Depressive Disorder; Drug I | 2002 |
Interferon-induced depression treated with citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug Therapy, Combination | 2002 |
Interferon-induced depression treated with citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug Therapy, Combination | 2002 |
The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2002 |
The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2002 |
Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates.
Topics: Adult; Aged; Bipolar Disorder; Brain; Brain Mapping; Citalopram; Depressive Disorder; Dominance, Cer | 1991 |
Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates.
Topics: Adult; Aged; Bipolar Disorder; Brain; Brain Mapping; Citalopram; Depressive Disorder; Dominance, Cer | 1991 |
No crossover reactions to citalopram or paroxetine among patients hypersensitive to zimeldine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Combined Modality Therapy; Depressive Di | 1991 |
No crossover reactions to citalopram or paroxetine among patients hypersensitive to zimeldine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Combined Modality Therapy; Depressive Di | 1991 |
Treatment of depression using citalopram with less side-effects.
Topics: Amitriptyline; Citalopram; Depressive Disorder; Double-Blind Method; Humans; Propylamines | 1988 |
Treatment of depression using citalopram with less side-effects.
Topics: Amitriptyline; Citalopram; Depressive Disorder; Double-Blind Method; Humans; Propylamines | 1988 |
The effects of citalopram (Lu 10-171) on the serotonin (5-HT) uptake kinetics in platelets from endogenously depressed patients.
Topics: Adult; Biological Transport; Blood Platelets; Citalopram; Depressive Disorder; Female; Humans; Kinet | 1985 |
The effects of citalopram (Lu 10-171) on the serotonin (5-HT) uptake kinetics in platelets from endogenously depressed patients.
Topics: Adult; Biological Transport; Blood Platelets; Citalopram; Depressive Disorder; Female; Humans; Kinet | 1985 |